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1. Skin
1.1. Skin, a flexible and protective tissue.
Skin is a unique tissue in many ways. It forms the last barrier from the inside out and the
first barrier from the outside in. It is this barrier function that forces the skin, and
especially the epidermis, to meet high criteria in both physical and biological properties.
It regulates the body temperature and protects the skin from water loss. It protects the
body from the damaging effects of penetrating chemicals or radiation. And in the case of
loss of barrier function, for instance by wounding, it closes the ruptured barrier as quic-
kly as possible and in the meantime forms a first line of defence against micro-organisms
and viruses that have crossed the epidermal barrier before wound closing. The skin has to
form a reliable protective barrier under normal conditions and must be capable of quick
tissue regeneration and initial host protection if necessary. The physiological reliability
and flexibility that is described above is the result of a highly co-ordinated process of cel-
lular proliferation and differentiation that can be adapted to changing circumstances and
that is accurately regulated in a very complex manner. All these properties make the regu-
lation of keratinocyte growth and differentiation a very interesting subject for study from
a biological point of view. Moreover information on the possibility to influence the regu-
latory mechanisms could ultimately lead to new therapeutic targets in the treatment of
epithelial disorders concerning epidermal growth and differentiation.
1.2. The structure of skin
Human skin consists of an outer epithelial layer, the epidermis, and an inner connective
tissue layer, the dermis. These two layers are physically separated by a basement mem-
brane. The dermis assumes the important functions of thermoregulation and supports the
vascular network to supply the avascular epidermis with nutrients. The dermis contains
mostly fibroblasts that are responsible for secreting collagen, elastin and proteoglycans
that give the support and elasticity of the skin. Also present are immune cells that are
involved in defence against foreign invaders passing through the epidermis [1,2].
The epidermis is the outermost layer of the skin and provides the first barrier of pro-
tection. The epidermis consists mainly of cells called keratinocytes. The epidermis is sub-
divided into four layers or strata, the stratum basale (SB), the stratum spinosum (SS), the
stratum granulosum (SGR) and the stratum corneum (SC) through which a keratinocyte
gradually migrates from the dermal epidermal junction to the surface. The stratum basale
(SB (also called stratum germinativum)) provides the germinal cells necessary for the
regeneration of the layers of the epidermis. After a mitotic division a newly formed cell is
pushed toward the surface and a process of terminal differentiation begins as the cell
migrates to the surface. The cells that divide in the stratum germinativum soon begin to
accumulate many desmosomes on their outer surface which provide the characteristic
‘prickles’ of the stratum spinosum (SS), which is often called the prickle-cell layer. The
progressive maturation of a keratinocyte is characterised by the accumulation of keratin,
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called keratinisation. The cells of the stratum granulosum (SGR) accumulate dense baso-
philic keratohyalin granules. These granules contain lipids, which along with the desmo-
somal connections, help to form a waterproof barrier that functions to prevent fluid loss
from the body [1,2].
As a cell accumulates keratohyalin granules, it is thought that rupture of lysosomal
membranes release lysosomal enzymes that eventually cause cell death. The dead and
dying cells filled with mature keratin form the stratum corneum (SC). The deeper cells of
the stratum corneum retain their desmosomal junctions, but as they are pushed to the sur-
face by newly forming cells of the stratum basale, the dead cells gradually break apart and
are lost, a process called desquamation [1,2].
2. Epidermal growth and differentiation
2.1. Epidermal differentiation
The keratinocytes in the stratum corneum (corneocytes) have lost their nuclei and other
recognisable cell organelles and comprise 65% insoluble cysteine-rich fibrous proteins cal-
led cytokeratins (CKs). There is a very characteristic expression pattern of CKs in the epi-
dermis. The basal cells are characterised by the expression of CK5 and CK14. As the dif-
ferentiating keratinocytes migrate upward in the epidermis they start to express the
cytokeratins CK1 and CK10. The expression of these CKs (CK1 and CK10) is specific for
normal epidermal differentiation. In the stratum granulosum, release of filaggrin from the
keratohyalin granules induces the aggregation of CKs forming macrofibers. In addition
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Figure 1. The structure of human skin consisting of the dermis covered by the epidermis. In the magnification
of the epidermis the different layers of cells (strata) that are formed by the terminal differentiation of the kerati-
nocytes are clearly visible and indicated.
epidermal differentiation involves the synthesis of a highly insoluble cornified envelope
whose cross-linking is catalysed by Transglutaminases 1 and 2 using the precursor protein
involucrin as a first scaffold. In addition to formation of keratin macrofilaments and the
cornified envelope, changes also occur during terminal differentiation in the synthesis of
intercellular lipids, membrane glycoproteins and intercellular adhesion molecules (inte-
grins). This complex terminal differentiation process leads to the continuous formation
and renewal of a tight barrier layer [1,2].
In situations of hostile environmental changes, like e.g. loss of barrier function or epi-
dermal damage due to genotoxic compounds or ionising radiation, the epidermal kerati-
nocytes are capable of switching to a second pathway of differentiation [3,4,5]. This pathway
of differentiation takes place in the context of hyperproliferation where almost all basal
keratinocytes are mitotic. This epidermal phenotype is generally referred to as regenerati-
ve maturation [6,7], also called the activated keratinocyte phenotype [8,9]. In a number of epi-
dermal pathological conditions, like e.g. psoriasis [10] and skin tumours [11], this keratinocy-
te phenotype can also be found where it has no obvious physiological function and in
most cases is directly responsible for the outer characteristics of many skin diseases. The
alternative differentiation pathway is characterised by the upregulation of the expression
of proteins that are normally involved in the formation of the corneocyte like involucrin
and transglutaminase. The most obvious difference and main characteristic of the regene-
rative maturation phenotype, is the de novo synthesis of a number of proteins that are
absent in normal skin but are highly expressed during this pathway of regenerative matu-
ration. Among these proteins are the cytokeratins CK6, CK16 and CK17 [3,12,13] and the
proteinase inhibitor SKALP [14,15] (which is an acronym for SKin derived Anti-Leuko-
Proteinase). The expression of these proteins is tightly associated with the epidermal phe-
notype of regenerative differentiation. Although it is not likely that any of these proteins
have an actual function in the initiation or regulation of the differentiation switch itself,
these proteins can form the key to unravelling the mechanisms underlying the transition
between the different epidermal differentiation pathways. It is our belief that any infor-
mation on the regulatory pathways, regulatory (co)factors that are involved in, and the
environmental conditions that are prerequisite for the initiation and regulation of the
expression of these proteins, should be informative on the regulation of the total pheno-
type. Knowledge on the regulatory pathways underlying the epidermal phenotypes may
lead to tools that can be used for targeted manipulation of these phenotypes. Ultimately
this ability can provide us with new therapeutic targets and tools for the treatment of skin
disorders where the activated skin phenotype is responsible for cosmetic and clinical pro-
blems.
2.2. Epidermal proliferation
With respect to their proliferative characteristics tissues can be divided in three groups. In
nerve and skeletal muscle there is no cell division. In other tissues like e.g. liver cell divi-
sion can occur in response to injury, a process called conditional renewal. And finally in
tissues like skin and mucosa (stratified squamous epithelia) and the gastrointestinal tract
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(simple epithelia) there is a permanently renewing population of differentiating cells with
a very short life span originating from a relatively small number of dividing ‘stem’ cells.
Skin is a classical example of a tissue with these kind of proliferative characteristics. The
rate of cell shedding at the surface of this tissue must exactly match the rate of cell divi-
sion in the basal layer in order to maintain normal skin thickness, although disturbed
ratios of cell division and cell loss occur in pathological states.
The basis of cell proliferation is the cell cycle. The cell cycle can be divided into four
separate stages, G1- (and G0-), S-, G2- and M-phase. The G1 (Gap 1) phase is characteri-
sed by gene expression and protein synthesis. This gap phase enables the cell to grow, to
produce and gather all the necessary proteins and co-factors needed for the next phase and
to replicate cell organelles. The cell may pause at the end of its G1 phase for some time
before initiating DNA synthesis in the S phase. This time is known as the restriction or
start point. If the cell remains at this point for a long period of time without replicating
its DNA, it is said to be in the G0 phase. The S (Synthesis) phase is characterised by the
replication of the cell’s DNA. After DNA replication is completed the cell enters the third
cell cycle stage, the G2 (Gap 2) phase. During the G2 phase the cell prepares itself for the
actual division by e.g. synthesising necessary proteins and condensing the chromosomal
DNA. Finally the cell enters the fourth and final phase of the cell cycle: the M (Mitosis)
phase. During the M phase the actual cell division takes place. This division can be sepa-
rated into two separate events, the division of the cell’s chromosomes (the actual mitosis,
also called karyokinesis) and the division of the cell’s cytoplasm in two daughter cells (cal-
led cytokinesis). At this stage the cell cycle is completed and the cell has two choices, eit-
her to enter the cycle again or become a resting cell in G0 (called cell quiescence). At this
stage of the cell cycle the cell can also choose to escape the cell cycle and start to terminally
differentiate (see figure 2). In normal skin a basal keratinocyte divides about once every
13 days spending the majority of its time in the G1/G0 phase of the cell cycle.
Maturation/differentiation and shedding of a newly formed keratinocyte lasts about 26
days. In contrast, the cell cycle of a psoriatic keratinocyte is shortened to about 1.5 days
and the maturation/differentiation and shedding phase to about 4 days [1,16].
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Figure 2. Schematic represen-
tation of the cell cycle.
Indicated are the different
phases of this cycle
(G0/G1/S/G2/M). After the
actual mitosis the cell can
continue in the G1 phase,
become quiescent in G0 or
start to differentiate. From G0
the cell can reënter the cell
cycle in G1 at a given time.
2.3. Apoptosis
Apoptosis or programmed cell death is a physiological form of cell death that plays a pivo-
tal role in tissue (re)formation during embryogenesis and metamorphosis but also occurs
in adult tissue during regenerative processes. Cell death occurs throughout the life span of
the organism and represents the ultimate differentiative decision made by cells. It is char-
acterised by specific morphological changes such as DNA fragmentation, membrane bleb-
bing, cellular shrinkage and disassembly in membrane-enclosed vesicles (apoptotic
bodies). Many hormones, cytokines and growth factors are known to act as general and/or
tissue-specific survival factors preventing the onset of apoptosis. In addition, many hor-
mones and growth factors are also capable of inducing or facilitating programmed cell
death under physiological or pathological conditions, or both (for reviews see [17,18]).
Apoptosis has become a hot topic of research during the last few years. Insight into the
process of cell death will not only contribute to the understanding of basic developmen-
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Figure 3. Schematical over-
view of the eukaryotic stress
response pathway leading to
the activation of the Mitogen
Activated Protein Kinases
(MAPKs). Through different
stages of protein phosphory-
lation extracellular signals like
(pro)inflammatory cytokines,
growth factors or cellular
stress are transduced through
the cell, finally leading to the
alteration of the cell's gene
expression profile through
activation of transcription
factors in the nucleus.
tal issues, but will also facilitate the development of therapeutic interventions that could
alter the course of disease. Since all cells have the apoptosis machinery required to com-
mit suicide encoded in their genome, the ability to initiate it in a lineage-specific, non-
inflammatory manner would allow for instance the irradiation of specific (skin)cancers.
Alternatively, inhibition of cell death pathways could rescue valuable but condemned cells,
such as HIV infected CD4+ T cells or dopaminergic neurons in Parkinson’s disease.
Caspases are members of a family of cysteine proteases that orchestrate the intracellular
biochemical events that enable cells to kill themselves by apoptosis. Caspases are highly
specific and efficient proteases with an unusual and absolute requirement for cleavage
after aspartic acid [19], a specificity shared only by the cytotoxic lymphocyte serine protei-
nase Granzyme B. A tetrapeptide sequence and additional tertiary structures are involved
in substrate recognition. Activated caspases cleave a restricted set of proteins rather than
causing indiscriminate protein digestion. The affected proteins are usually cleaved, in a co-
ordinated manner, at one site only resulting in loss or change of function. The overall pic-
ture of how caspases lead the apoptotic process is not fully understood. From a number of
structural and regulatory proteins it is known that they undergo endoproteolytic cleavage
by various caspases. An example of the proteolysis of a regulatory protein is the cleavage
of the inhibitor of ‘caspase activated deoxyribonuclease’ (CAD) called ICAD by caspase-3.
In non-apoptotic cells CAD is held inactive in the cytoplasm by ICAD. During apoptosis
ICAD is inactivated, leaving CAD free to function as a nuclease leading to DNA fragmen-
tation [20,21]. An example of a structural element that is a target for caspase cleavage are the
lamins, the structural component of the nuclear lamina. During apoptosis lamins are
cleaved at a single site by caspases, causing the nuclear lamina to collapse. Other known
caspase substrate examples are the cleavage of Bcl-2 proteins , protein kinase C delta [24-26],
the retinoblastoma protein [27,28] and a number of proteins involved in RNA splicing [29],
cytoskeletal organisation [30,31] and DNA repair [32]. Although the exact involvement of these
kinds of cleavages in the process of cell death is not completely clear it is obvious that the
cellular homeostasis is disabled and that cellular disassembly is facilitated.
The caspase cascade can generally be activated in two different ways, either through
receptor ligand interactions at the surface of the predestined cell or by intracellular sig-
nals. These intracellular signals involve cytochrome c release from mitochondria. In the
cytosol, cytochrome c combines with APAF-1 (Apoptotic Protease Activating Factor) in
the presence of ATP to activate caspase-9 that, in turn, activates effector caspases such as
caspase-3. Bcl-2 and related proteins control cytochrome c release from the mitochondria.
Plasma membrane receptors such as Fas (CD95, APO-1), characterised by a so-called
‘death domain’ in their cytoplasmic part, can activate the caspase cascade after ligand
binding through adaptator molecules such as FADD (Fas-Associated protein with a Death
Domain). This route leads to the activation of caspase 8 and subsequently to the activa-
tion of the effector caspases.
With respect to skin there are some parallels between the normal terminal differen-
tiation pathway of keratinocytes in the epidermis and the process of programmed cell
death, apoptosis. In both cases the cells are initiated to die in an organised fashion and in
both cases there is an orderly removal of the cells nuclei and organelles. Although in nor-
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mal epidermis only few apoptotic cells (as determined by TUNEL-staining) can be detec-
ted, there have been reports that at least a part of the general apoptosis machinery, i.e.
members of the caspase family, is activated during the normal terminal differentiation
process in keratinocytes [33]. The activated caspases are thought to play a possible role in
the normal loss of the keratinocytes nuclei at the end of the differentiation process,
perhaps together with proteins involved in the formation of the cornified envelope [34].
Disturbance of this process may lead to parakeratosis that is seen in many pathological
skin conditions [35]. It should however be emphasised that terminal differentiation and
apoptosis are obviously two distinct processes, one leading to the formation of a wanted
cell and the other leading to the removal of an unwanted cell.
In skin, apoptosis plays also a very important role in reacting to environmental changes
resulting in cellular stress. UV light is the major extrinsic factor affecting the keratinocyte
and it is well established that UV exposure can lead to premature skin ageing (photo-
ageing) and has carcinogenic effects. UV irradiation damages proteins, lipids, DNA [36] and
leads to the activation of signal transduction pathways involved in the cellular stress
response. Depending on the nature and the quantity of cellular damage, the cell either
decides to repair damage, survive and react or adapt to the environmental changes or,
when cellular damage is too large, decides to sacrifice itself by undergoing apoptosis. This
pathway of UV induced epidermal apoptosis leads to the formation of the well-known
‘sunburn’ cells that are TUNEL positive. In this manner apoptosis plays a role in the
prevention of malignant cell formation. There are however examples in which apoptosis
itself is directly the cause of a pathological skin condition like e.g. in the case of ‘toxic
epidermal necrolysis’ (TEN), a Fas ligand mediated massive onset of epidermal apoptosis
induced by the use of certain drugs .
3. Regulation of epidermal growth and differentiation
Cellular proliferation and differentiation in the epidermis are fine-tuned in order to main-
tain epidermal integrity and epidermal homeostasis. Because the epidermis is subjected to
a variety of environmental hazards, this integrity and homeostasis is constantly being
threatened. The epidermis possesses a broad array of regulatory systems to respond to
these threats. Through signalling molecules, receptor ligand interactions and cytoplasmic
changes, intracellular signal transduction pathways are activated. These pathways are
responsible for the amplification and mediation of the initial signal to the nucleus. In the
nucleus, the cell can change its transcription factor repertoire and, by doing so, change its
transcription pattern. In that way the cell can respond to extracellular influences by either
adapting to the ‘new’ environment through the synthesis of new proteins that can act in
cellular defence strategies and adapt the proliferation and differentiation patterns of the
cell or, in case of severe cell damage, the cell can go into apoptosis. In the next few para-
graphs I will give a brief overview of the regulatory mechanisms that are known to exist
in keratinocytes and the regulatory factors that are involved in these routes.
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3.1 Regulation through extracellular factors
3.1.1 Extracellular factors regulating epidermal proliferation
Regulation of stem cell proliferation is an important topic since the rate of stem cell pro-
liferation determines the rate at which the differentiating cells enter the upper epidermal
layers. Many factors have been identified that influence the proliferative rate of keratino-
cytes and most of these factors also have effects on keratinocyte differentiation as well.
Most of the studies on these factors have been done in in vitro model systems and the
actual situation in skin is still not completely understood. Growth factors like Epidermal
Growth Factor (EGF), transforming Growth Factor alpha (TGF-α) (both sharing the EGF
receptor) and Insulin like Growth Factor (IGF) have shown to enhance both keratinocyte
proliferation [39,40] and migration [41,42]. In psoriatic skin the IGF and the EGF system is
altered compared to the situation in normal epidermis, there is an overexpression of EGF-
receptors (EGFR) [43] and IGF-receptors (IGFR) [44]. Treatment with antipsoriatic agents
downregulate the number of IGFR [44] and EGFR [43] in keratinocytes. In addition it has
been shown that EGF is directly involved in regulating the expression of CK6 and CK16
[45,46] in hyperproliferative keratinocytes, suggesting a possible role for these two signalling
complexes in the psoriatic keratinocyte phenotype. Another growth factor relevant for
keratinocyte proliferation is Keratinocyte growth factor (KGF). KGF is like EGF, TGF-α
and IGF a potent epithelial cell mitogen. However, studies indicate that in contrast to EGF,
KGF plays a role in inducing normal keratinocyte differentiation [47]. The increase in the
expression of KGF and its receptor (KGFR) in psoriatic skin correlates with the pool of
proliferative keratinocytes in the affected epidermis of prosiasis patients. This observation
together with the fact that the expression of the KGFR is downregulated upon treatment
with ultraviolet-B light (UVB, an established anti-psoriatic treatment) suggests a role of
the KGF pathway in the typical hyperproliferative keratinocytes in the basal and lower
suprabasal layers in the psoriatic epidermis [48].
Besides growth factors also inflammation mediators, like Interleukin-1 (IL-1 [49,50]),
Interleukin-4 (IL-4 [51]) and Interleukin-6 (IL-6 [52,53]) display stimulatory effects on
keratinocyte proliferation. There have also been reports on other signalling molecules that
stimulate keratinocyte proliferation like nitric oxide (NO [54]), Granulocyte/macrophage
colony stimulating factor (GM-CSF [55,56]) and Substance P (SP [57]). In contrast to these
factors that specifically induce or stimulate keratinocyte proliferation there are factors 
that have opposite effects and suppress or block proliferation in keratinocytes. The most
extensively studied factor is Transforming Growth Factor beta (TGF-β). Many studies
have shown the repression of keratinocyte proliferation by TGF-β in vitro. The presumed
mechanism involves the regulation of the retinoblastoma gene product (pRB) function by
TGF-β [58,59]. This is supported by the fact that events that compromise the function of the
pRB protein (e.g. the presence of viral proteins with pRB binding domains) uncouple
TGF-β regulation of proliferation [60]. There are several indications that other factors that
have repressive effects on keratinocyte proliferation as well as on other cell types, like e.g.
tumour necrosis factor alpha (TNF-α [61,62]), interferon gamma (IFN-γ [61]) and 1,25-
dihydroxyvitamine D3 [63] also mediate these effects through pRB [63-66]. The tumour
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suppressor gene product pRB seems to play a central role in the repression of keratinocyte
proliferation and there are indications that proliferation repression by a number of factors
through pRB could be a mechanism for the initiation of keratinocyte terminal differen-
tiation [67-70]. The studies mentioned here, in which factors were identified that influence
keratinocyte proliferation, were done in a variety of different model systems. It is there-
fore unclear whether these effects coexist, whether they interact meaningfully and what
their relative roles are.
3.1.2 Extracellular factors regulating epidermal differentiation
As indicated in the previous paragraph it is very difficult to uncouple the regulation of
keratinocyte differentiation from the regulation of proliferation. The cessation of kera-
tinocyte proliferation is a prerequisite for the initiation of normal terminal differentiation.
It is therefore obvious that factors that repress keratinocyte proliferation could be the first
signal for terminal differentiation whereas factors that stimulate proliferation indirectly
prohibit the initiation of differentiation. In contrast a recent study from Pariamo et. al
describes the opposite event, where ectopic expression of proteins like CK10 and CK16
that are normally exclusively expressed by differentiating cells drastically influence cellu-
lar proliferation [71]. It is likely that there are many factors that influence both the prolife-
ration and differentiation in such a way that it eventually tips the ‘cellular scale’ in favour
of differentiation and the cell dedicates itself to this terminal maturation route. Factors
that act in such way, both on repression of proliferation and the induction of differentia-
tion are IFN-γ [72,73] and 1,25-dihydroxvitamin D3 [75].
A very extensively studied inducer of keratinocyte differentiation is calcium. In normal
epidermis there is a gradient of calcium. Calcium concentrations in the outer, more
differentiated layers are higher than in the more basaly located epidermal cell layers [76].
This suggested role for calcium in the keratinocyte differentiation process was confirmed
by several in vitro studies. These studies showed that in the presence of low levels of
calcium (<0.1 mM), low expression levels of differentiation markers could be found.
However when the concentration of calcium in the culture medium was elevated to 1.5-2
mM, differentiation is markedly increased as measured by the expression of marker
proteins [77-79]. Recent reports describe a calcium receptor on the keratinocyte that can be
expressed in two different forms due to alternative splicing. The shortest form lacks a part
of the extracellular domain and is inactive. Speculations are made that the ratio of expres-
sion of these two receptors on a cell can determine the calcium sensitivity of that cell and
thereby regulate the differentiation response to calcium [80,81]. Another very important
mechanism by which differentiation is regulated is through contact with the basement
membrane and extracellular matrix. Several studies have indicated that loss of integrin
mediated attachment of keratinocytes to several proteins in the basement membrane,
leads to cell-cycle withdrawal and commits the cells irreversibly to terminal differen-
tiation [82-86]. In addition also the composition of the extracellular matrix can determine the
cell’s fate with respect to terminal differentiation. Studies have shown that exposure of
differentiating keratinocytes to fibronectin leads to inhibition of differentiation specific
gene expression [82] and sustained keratinocyte proliferation [87].
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3.2. Regulation through signal transduction routes
3.2.1. Signal transduction routes in skin
Intracellular signal transduction pathways are the tools by which cells can link events that
take place at the level of the plasma membrane to downstream events that take place at the
cytoplasmic or nuclear level. After initial receptor-ligand binding or cytosolic changes,
intracellular protein cascades conduct the signal through the cell to the nucleus where
transcription factors are activated. Through the alteration of the cell’s transcription factor
repertoire, appropriately altered gene expression is established. These signal transduction
pathways are responsible for the transmission, amplification and diversification of the
initial signal and are therefore fundamental to the life and death of cells.
As in other cell types, many signal transduction routes are known to be functional in
keratinocytes. These signal transduction routes can roughly be divided in a few distinct
groups with respect to their substrate specificity. The protein tyrosine kinases like the EGF
receptor, the IGF receptor, the Focal Adhesion Kinase (FAK) and the Janus kinases (JAKs)
have been described in keratinocytes. As mentioned earlier the EGF-receptor and the IGF-
receptor but also the FAK are involved in regulating keratinocyte proliferation and migra-
tion [39-42,88]. The JAKs are well known for their role in the activation of a group of trans-
cription factors called the Signal Transducers and Activators of Transcription (STATs) [89,90]
that is known to be involved in the regulation of CK17 expression by keratinocytes [91].
A second group of protein kinases are the serine/threonine kinases like amongst many
others, the protein kinase C (PKC), the cyclic AMP dependent protein kinase A (PKA) and
the Mitogen Activated Protein Kinases (MAPKs). PKC has been reported to be involved in
repression of keratinocyte proliferation [92,93] and regulation of the expression of late kera-
tinocyte differentiation markers induced by calcium [94,95]. The role of PKA in skin remains
obscure but is linked with cAMP dependent regulations of keratinocyte proliferation and
differentiation [96]. The MAPKs is a group of kinases that is activated upon cellular stress
and proinflammatory cytokines and will be described in more detail later.
Another group of signal transduction molecules is the phospolipases. The phos-
pholipases are enzymes that hydrolyse various bonds in the head group of phospholipids
and are important for the degradation of damaged or aged cell membranes. Phospholipase
A2 is involved in the release of arachidonic acid from membranes and its subsequent con-
version into leukotrienes and prostaglandins. This route has shown to be deregulated in
hyperproliferative skin and prostaglandin E2 induces proliferation in keratinocytes [97,98].
A second phospholipase called phospholipase D (PLD) catalyses the hydrolysis of mem-
brane phospholipids to produce phosphatidic acid which can further be converted into
diacylglycerol (DAG) that can act as a second messenger. A third phospholipase is phosp-
holipase C (PLC), which function in keratinocytes is unclear. However an isoform of PLC
with a substrate specificity for sphingomyelin called sphingomyelinase (SMase) has been
implicated in a great number of regulatory processes in keratinocytes. SMase can hydro-
lyse spingomyelin into ceramide and phosphorylcholine after which ceramide can serve as
a second messenger. Ceramides could be involved in the regulation of keratinocyte dif-
ferentiation, proliferation and apoptosis [99-101]. With respect to changes in differentiation
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phenotypes induced by extracellular signals like wounding, UV-B irradiation, epidermal
water loss and inflammation, the MAPK signal transduction pathway is extremely impor-
tant. For that reason I will describe the MAPK routes into further detail in the next few
paragraphs.
3.2.2. The Mitogen Activated Protein Kinase cascade (MAPK)
One of the best-studied signal transduction pathways is the Mitogen Activated Protein
Kinase cascade (the MAPK cascade). A MAP kinase cascade is universally composed of
three protein kinases acting in series. From the nucleus up: a MAP kinase (MAPK) that is
activated upon phosphorylation by a MAPK kinase (MAPKK) which in turn is activated
upon phosphorylation by a MAPKK kinase (MAPKKK). These MAPKKKs are activated
through interaction with small GTP binding proteins that belong to the Ras superfamily.
The MAPKs can carry the information to the nucleus by virtue of their ability to undergo
nuclear translocation upon activation. The MAPKs have two main characteristics. First
they are activated by dual phosphorylation of a Threonine and a Tyrosine amino acid resi-
due. Second they are proline directed Serine/Threonine protein kinases with a minimum
consensus target of Ser/Thr-Pro. The MAPKs consists of three main family members, the
extracellular regulated kinases (ERKs), the c-jun N-terminal kinases (JNKs) and p38 kina-
ses each of which is activated by its own MAPKK and further upstream cascade. For a
schematical overview see figure 3.
3.2.1. The extracellular regulated MAP kinases (ERKs)
The activation of the ERKs is by far the best understood mammalian MAP kinase path-
way and leads to the activation of the ERK family members ERK1 (p44) and/or ERK2
(p42) [102,103]. The MAPKKS MEK1 or MEK2 activates the MAPKs ERK1/ERK2. MEK1 and
MEK2 can activate both ERK1 and ERK2; there seems to be no strict substrate specificity.
In their turn the MAPKKs MEK1 and MEK2 are activated by c-Raf, a MAPKKK that 
is activated by the GTP bound form of Ras. This Ras activity is initiated through the
activation of receptor tyrosine kinases like for instance the EGF receptor or the PDGF
receptor which are two well established mechanisms for the activation of ERK1 and 
ERK2 [104]. Obviously these receptor tyrosine kinases can become active upon binding of
the ligand to its receptor but there are also ligand-independent mechanisms known. For
example the EGF receptor that can become active through voltage dependent calcium
channels resulting in activation of Ras leading to increased ERK kinase activity [105].
A second mechanism of calcium dependent Ras activation is mediated by the calcium
sensitive Ras guanine nucleotide-release factor (Ras-GRF) that is expressed in brain
neurons [106]. Once activated the ERKs can phosphorylate a number of cytoplasmic pro-
teins including phospholipase A2 [107] and interestingly c-Raf-1 and MEK1 suggesting that
they may regulate their own signalling pathway [108]. Activated ERK1 and ERK2 have the
ability to translocate to the nucleus where they can phosphorylate and thereby activate a
number of transcription factors including c-myc [109,110], Elk-1 [111,112] and STAT proteins [113].
In skin an involvement of the ERKs in signalling processes was shown in melanocytes [114]
and dermal fibroblasts [115]. In human keratinocytes it is well known that exposure to UVB
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leads to the activation of the ERKs through phosphorylation of the EGF receptor [116,117].
There is increasing evidence that this UV induced ERK activity plays a role in the erythe-
ma and oedema seen after UV irradiation through the biosynthesis of prostaglandin [118].
In addition to these effects of UV irradiation on ERK activation, it was demonstrated that
cell adhesion could also activate the ERKs. Integrin dependent cell adhesion leads to the
activation of a Focal Adhesion Kinase (FAK) and ultimately activates Ras leading to the
activation of ERK1 and ERK2 [119,120]. This can have important implications for cell growth
and differentiation by the extracellular matrix with respect to keratinocyte or fibroblast
migration in processes like wound healing and re-epithelialisation.
3.2.2. The c-jun N-terminal MAP kinases
The c-Jun N-terminal Kinases (JNKs, also known as Stress Activated Protein Kinases
(SAPKs)) is a MAP kinase family group that was first identified as a kinase activity that
bound and phosphorylated the transcription factor c-jun on Ser-73 and Ser-63 within its
NH2-terminal activation domain 
[121]. Subsequently several human JNK isoforms have
been cloned and are known as JNK1, JNK2 and JNK3. The transcripts of each of these
genes are alternatively spliced to create mRNAs that encode 46 kDa and 55 kDa JNK iso-
forms. These JNKs are activated upon dual phosphorylation by the MAPKKs MKK4 and
MKK7, whereas MKK4 can activate both the MAP kinases p38 and JNK, MKK7 can exclu-
sively activate JNKs. The MAPK kinases MKK4 and MKK7 can become active upon
phosphorylation by the MAPKK kinases, MEKK1 [122,123], MUK [123] and Tpl-2 [124]. These
MAPKK kinases are initially activated by GTP binding proteins of the Rho family (e.g.
Rac-1 and Cdc42 [125,126]). The JNKs are activated by exposure of cells to environmental
stress (ionising radiation, heat shock, oxidative stress, osmotic shock) or by treatment with
pro-inflammatory cytokines. Targets of the JNKs include the transcription factors 
c-jun [127], Elk-1 [128] and ATF-2 [129] (Activating Transcription Factor 2). The transcription
factors c-jun and ATF-2 both belong to a group of proteins that can form AP1 complexes
as homo- or heterodimers with other proteins. The JNKs are therefore the major regula-
tory factor in the formation of active AP1 complexes in mammalian cells in response to
cellular stress. In keratinocytes JNK activity is induced upon UV-B irradiation and photo-
dynamic therapy [130-132] resulting ultimately in elevated levels of AP-1. These elevated levels
of AP-1 have been implicated in the induction of abnormal epidermal gene expression and
photoageing [133,134].
3.2.3. The p38 MAP kinases
Finally the third group of MAPKs is the p38 family consisting of five members i.e. p38α,
p38β1, p38β2, p38γ and p38δ [135-137]. The p38s are the mammalian homologues of the yeast
stress activated protein kinase HOG1 [138] and were initially identified in mammalian cells
as a kinase that was activated by hyperosmolarity and endotoxic (LPS) shock [139], and was
essential for cytokine production by monocytes [140]. Additional studies have shown that
p38 MAP kinases can be activated by a number of other environmental stimuli as well, e.g.
UV radiation and proinflammatory cytokines [141-143]. Two p38 MAP kinase activating
kinases have been cloned, i.e. the MAPKKs MKK3 and MKK6 [144,145]. The MAPKK MKK4
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is also capable of activating p38 as well as JNK MAP kinases. Although there have been
several reports on potential MAPKKKs that activate MKK3 or MKK6, like e.g. MLK3 [146],
MTK1 [147], ASK1 [148] and TAK1 [149] it remains largely unclear how this activation is media-
ted in vivo. Upon activation, p38 MAP kinases can activate a number of substrates. It has
been shown that p38 can in its turn activate two kinases termed Mitogen Activated Protein
Kinase Activated Protein Kinase 2 and 3 (MAPKAP-K2 and MAPKAP-K3) [150,151]. The phy-
siological substrates of these MAPKAP kinases are small heat shock protein 27 [152,153] and
transcription factors like CREB (cAMP response element binding protein) and the serum
response factor (SRF) [154]. A recent report describes the involvement of MAPKAP-K2 in
the transport of activated p38 from the nucleus to the cytosol as a regulator of cellular
localisation of p38 [155]. Other downstream substrates for p38 MAP kinases are transcrip-
tion factors like CHOP [156], ATF-2 and Elk-1 [157]. In keratinocytes p38 is activated upon UV
irradiation [141,158] and is implicated in the regulation of matrix metalloproteinase expres-
sion [159,160].
3.3 Regulation through transcription factors 
Many keratinocyte specific genes discovered so far were found to be regulated at the trans-
criptional level. The fact that many of these genes are expressed in a co-ordinated and stra-
tum-specific manner might predict a common, stratum-specific expression regulation
mechanism. Studies done so far did not reveal such a common regulation pattern at the
transcriptional level but a rather individual strategy where genes are individually regula-
ted by at least one regulatory agent. In addition, comparison between the promoter
regions of epidermal genes did not reveal large regions of high homology. Transcription
factors regulating epidermal genes tend to be of the ‘generic’ type and it is possible that
epidermal or stratum specific gene expression is achieved through the action of a network
of factors with low individual epithelial specificity. Nevertheless the intensive analysis of
epidermal gene regulation has resulted in the identification of factors regulating the
various differentiated epidermal states.
3.3.1. Transcription regulation in the basal layer
Keratins 5 and 14 are expressed in the basal layer of most stratified epithelia including the
epidermis. A number of studies have identified a set of transcription factors that may be
important in CK5 gene regulation including Activator Protein 1 (AP1), Activator Protein
2 (AP2) and Sp1 [161,162]. The promoter region of CK5 seems to consist of two major regions,
one responsible for differentiation specific gene expression and the other for tissue speci-
fic gene expression [163]. In the promoter of the bovine CK5 gene, an AP1 site seems to
confer tissue specific CK5 expression, however footprinting analysis of this region in CK5
expressing and non-expressing cells produced identical results [164]. The promoter of acidic
CK14, the molecular partner of CK5, also contains a consensus element for AP2, this
sequence element is important for gene activity but is not sufficient for tissue specific gene
expression [165].
In addition to general transcription factors like AP1, AP2 and Sp1, there are also
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transcription factors that are mainly used by keratinocytes. Basonuclin is an example of a
transcription factor originally identified in basal keratinocytes and thought to be
keratinocyte specific, but it has been detected in other cell types as well and is correlated
with proliferative activity [166]. Studies have indicated that keratinocyte differentiation 
is preceded by the removal of basonuclin from the nucleus to the cytoplasm [166,167].
In addition it has been shown that the transcription factor NFκB has a repressive effect on
the promoter activity of both the K5 and the K14 promoter [159] and, moreover has growth
inhibitory effects [168]. NFκB family includes proteins p65 (RelA), p50, p52 and c/rel,
which homo- and heterodimerise amongst themselves [169-171]. Activation of these proteins
is not dependent on new protein synthesis but they are stored in the cytoplasm where they
are held inactive bound to an inhibitory protein, IκB. It is known that NFκB complexes
can interact with other transcription factors like C/EBP and AP1 and regulate trans-
cription  These data suggest that removal of basonuclin and activation of NFκB could be
part of the transition from basal gene expression and cell proliferation towards terminal 
differentiation.
3.3.2. Transcription regulation in normally differentiating keratinocytes
Calcium, an element capable of inducing keratinocyte differentiation can directly stimu-
late the expression of several differentiation related genes such as CK1 [174], loricrin [79],
involucrin [78,175] and transglutaminase [175]. The 3’ end of the CK1 gene contains a region,
comprising an AP1 site and two hormone response elements that regulates this calcium
responsiveness [176]. The induction of differentiation by calcium is accompanied by an
increase in AP1 activity in the nuclei of keratinocytes [177], and many genes associated with
terminal differentiation possess functional AP1 consensus sites in their promoter regions
[178] including involucrin [179-181], transglutaminase [182], CK1 [183] and loricrin [184,185]. However
it must be taken into account that there are indications that these AP1 consensus sites
might play a role both in activation and repression of gene activity, depending on the
composition of the AP1 transcription factor complex. AP1 transcription factor complexes
function as homo- or heterodimers of jun (c-jun, junB or junD), fos (Fra-1, Fra-2, c-fos
or fosB) and Activating Transcription Factor (ATF). The actual effect of AP1 binding to its
consensus sequence might be dependent on the composition of the AP1 complex [186,187,178].
This could also play a role in differential stimulation of genes by AP1 in the basal and
suprabasal layers of the epidermis. In addition to AP1 also other general transcription
factors have been found to play a role in keratinocyte or differentiation specific regulation
of gene expression. In addition to AP1, transcription factors like AP2, Sp1 and POU
domain proteins also play a dominant role in the transcription regulation of many genes
expressed during the differentiation process of the keratinocyte including involucrin [188],
transglutaminase-1 [189] and transglutaminase-3 [190]. Whereas it was mentioned that NFκB
was thought to play a role in the induction of epidermal differentiation, there are no
studies that identify NFκB as a regulator of differentiation markers. However several
studies in mice in which the NFκB pathway was disrupted indicate that lack of NFκB
activity results in loss of epidermal homeostasis indicating its importance in maintaining
this homeostatic situation [191-193].
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3.3.3. Transcription regulation in activated keratinocytes
Environmental signals such as growth factors, cytokines and irritants can modulate the
activation of nuclear transcription factors, thus regulating gene expression. This regulation
is very important in skin where a large variety of signals appear, especially in disease states
or in wound healing, to stimulate new gene expression in keratinocytes. Several studies
have indicated that the expressed genes that are characteristic for activated keratinocytes [12],
i.e. CK6, CK16 and CK17 are regulated at the transcriptional level by distinct regulatory
mechanisms [194]. As during normal differentiation, transcription factor complexes like AP1,
AP2 and Sp1, are also involved in the regulation of gene expression in activated keratino-
cytes [13,194,195]. However there are regulatory processes that are restricted to the activated
keratinocyte phenotype as well. An example is the regulation of CK17, a keratin associated
with several skin diseases, skin tumours and skin irritation [196,-198]. The expression of the
CK17 gene can be induced by the exposure of keratinocytes to IFN-γ and this expression is
regulated at the transcriptional level by the activation and translocation of the transcrip-
tion factor STAT1/91 (Signal Transducer and Activator of Transcription) to the nucleus of
the keratinocytes. Through binding of STAT-1 to Gamma Interferon Activation Sites (GAS)
in the CK17 promoter, CK17 gene expression is induced [91,199-201]. Another transcription
factor that is known to be activated by cellular stress like inflammation and radiation is
NFκB. The study by Ma et al that was mentioned two paragraphs ago showed that in addi-
tion to a repressive effect on the CK5 and CK14 promoter, the CK6 promoter is strongly
activated by NFκB [159]. However studies using bandshift or promoter deletion mutant never
confirmed the regulatory role of NFκB in abnormal epidermal gene expression.
4. Models for studying epidermal growth and differentiation
In the past years many models for the investigation of epidermal growth and differentia-
tion have been described and used. Being on the outside of every organism, skin is one of
the few organs that can be studied in vivo in a non-invasive manner. In addition one can
easily obtain biopsies that can be studied biochemically, immunohistochemmically or that
can be used for further cell biological characterisation. In the next two paragraphs a num-
ber of in vivo and in vitro models that are commonly used for the analysis of both normal
and abnormal epidermal differentiation will be described.
4.1 In vivo models for studying epidermal growth and differentiation
Obviously a great advantage of in vivo models in comparison with keratinocyte mono-
cultures is the fact that it closely resembles the in situ situation. Especially interactions
between the different cell types in skin and the interaction of skin cells with the organism’s
immune system are important advantages of in vivo models. Data obtained from these
models are bound to be relevant for the actual situation in normal skin, in contrast to data
from in vitro models that should be interpreted with more caution with respect to the
actual in situ situation.
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A well-known standardised human model for epidermal injury is the repeated applica-
tion of adhesive tape to the skin in order to remove the stratum corneum called ‘tape
stripping’. This tape stripping results in hyperproliferation of the affected skin accompa-
nied by inflammation and abnormal differentiation [202-204]. Other models are the appli-
cation of detergents and other skin irritants to normal skin [205,206], the study of the
spreading margin of a psoriatic plaque [207-209], controlled wounding of skin [210,211] and UV
irradiation of normal human skin [212,213]. From an ethical point of view these human
models are limited in their application with respect to experimental procedures. Therefore
in addition to these human models, animal counterparts for every model mentioned
above are also known and are used for epidermal research [214-216]. The disadvantage of these
animal models is the fact that the skin of most animals is quite different from human skin
with respect to thickness and anatomy. For that reason a number of xenotransplantation
models have been developed in which normal or pathological skin is transplanted on
(mostly) mice [217-220]. There are however disadvantages on all these in vivo models. They 
do not form an unlimited source of material and they can not be exactly controlled. This
has been one of the reasons for the development of a number of in vitro models for kera-
tinocyte growth and differentiation.
4.2 In vitro models for studying epidermal growth and differentiation
Scientists have been culturing keratinocytes for over 100 years. In 1897 C.A. Ljunggren
reported that excised pieces of skin remained viable when cultured in ascites fluid at room
temperature, and that the skin could subsequently be grafted onto wounds [221]. During the
first half of the twentieth century, as in vitro culture techniques were developed, experi-
ments were carried out on explants of skin and the epidermal sheets that migrated out
from them (for review see [222]). Later cultures were established from desegregated kerati-
nocytes, but high seeding densities were required and subculture was rarely successful
(reviewed in [223]). A major breakthrough came in 1975, when Rheinwald and Green repor-
ted that epidermal keratinocytes could be cultured at clonal density if maintained in the
presence of a feeder layer of lethally irradiated 3T3 mouse embryo cells [224]. Large num-
bers of cells can be grown from small biopsies; it has many applications and is still wide-
ly used. In the years after the introduction of the method by Rheinwald and Green a lot of
work has been done to obtain a more defined growth medium for keratinocytes. The first
step was to develop culture conditions with the ability to grow keratinocytes in the absen-
ce of feeder cells or conditioned medium [225,226]. And the ultimate aim was to develop defi-
ned culture media for keratinocytes without the addition of serum or other crude protein
extracts (like e.g. bovine brain extract) [227,228]. Since a few years these serum free media are
commercially available.
In our own department we have developed a number of keratinocyte culture models in
which keratinocyte differentiation can be manipulated. Depending on the composition of
the culture medium the keratinocytes differentiate either normally or follow the regene-
rative maturation pathway [229,77]. These models are very useful in the analysis of epidermal
differentiation switches. In addition to cultures of primary keratinocytes one can also use
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immortalised keratinocytes. The great advantage of these immortalised cells is that they
can be passaged indefinitely in contrast to primary keratinocytes. The most commonly
used immortalised keratinocyte cell line is HaCaT [230], a spontaneously immortalised cell
line, but keratinocytes can also be immortalised by viruses [231]. These monolayered 
cell culture systems of human skin cells have several advantages. However submerged
monolayered cultures also have some inherent limitations. For instance, only compounds
soluble in culture medium can be tested and due to the absence of a stratum corneum
many properties of the skin are altered. To overcome these limitations many research
groups are developing artificial skin cultures for both research and therapeutic purposes.
In these culture models keratinocytes are cultured on matrices containing fibroblasts or
on dermis obtained from human cadaver skin [232-234]. One of the main advantages of these
three-dimensional skin cultures is that it their biological and physical properties highly
resemble the actual in vivo situation. Moreover cell-cell, cell-matrix and dermal-epidermal
interactions can be studied in these models. In addition to these skin equivalent cultures
also skin explants can be used. These skin explants are normally fresh skin biopsies that
are maintained in culture for a few days [235,236].
5. SKALP expression as a paradigm for abnormal epidermal maturation
As mentioned earlier Skin Derived AntiLeukoProteinase is a proteinase inhibitor that was
in initially found in, and purified from the scales of psoriasis patients [237,238] and is also
known as elafin [239] or ESI [240] (elastase specific inhibitor). The gene encoding SKALP is
approximately 1.7 kb long and contains 3 exons and 2 introns. The first exon encodes the
hydrophobic signal peptide of the protein with a length of 22 aminoacids and the first 4
aminoacids of the mature protein. The second exon encodes the rest of the mature pro-
tein and the third exon is non-coding. The 5’ non-coding region of the gene contains both
a putative TATA and CCAAT box, located respectively 94 and 120 bases upstream of the
translation start site. Cleavage of the signal peptide results in a mature protein with a
molecular mass of 9.9 kDa comprising two separate protein domains with respect to
structure and function. The N-terminal end of the mature protein consists of a region
containing multiple functional transglutaminase (TGase) crosslinking consensus sequen-
ces [241] (consensus: GQDPVK), suggesting that the protein can be crosslinked into the cor-
nified envelope in the maturing corneocyte. The C-terminal domain of the protein, har-
bouring the proteinase-inhibiting domain of SKALP, contains 8 cysteine residues that can
form 4 disulphide bonds that stabilise this domain. This structure is called a 4 disulphide
core structure also called a whey acidic protein motif (WAP motif/domain). SKALP shares
homology with a number of proteins based upon the first domain (TGase substrate
domain), with a number of proteins based upon the second domain (proteinase inhibiting
domain) and with protein based upon both the domains. Proteins homologous to SKALP
with respect to the TGase are members of the REST family (Rapidly Evolving Seminal
vesicle Transcribed) [242,243] that also share homology with SKALP in non-coding regions of
the gene. A protein that shares homology with SKALP based upon the second protein
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domain (WAP motif and proteinase inhibiting domain) is SPLI also known as ALP. There
are many other proteins that contain a WAP motif like e.g. whey proteins, adhesion mole-
cules and scorpion toxins. And finally a group of proteins that was recently identified as a
new protein family share homology with SKALP based upon both domains in the protein.
These proteins were recently extensively reviewed and assigned the family name
TRAPPINs (stands for TRansglutaminase substrate and wAP domain containing ProteINs
(SKALP now also referred to as trappin-2)), referring to its property of getting ‘trapped’
in a tissue and thereby functioning as an anchored protein [244,241]. These proteins are
thought to have evolved from REST genes and WAP domain containing proteins by means
of exon shuffling.
SKALP is not expressed in normal human epidermis but is induced and highly expres-
sed under inflammatory skin conditions (e.g. psoriasis), in skin tumours and after woun-
ding [245,246]. In general it can be said that SKALP gene expression is induced in differentia-
ting keratinocytes that follow the regenerative maturation/differentiation pathway.
6. Aim and Outline of this thesis.
General aim
The switch in epidermal differentiation pathways/phenotypes from the normal epidermal
differentiation pathway to an activated state of differentiation (known as regenerative
maturation/differentiation), is found in response to a number of environmental stimuli.
These stimuli include inflammatory skin conditions (e.g. psoriasis), wound healing,
osmotic stress (tape stripping) and UV-B irradiation. Very little is known about the regu-
latory mechanisms that are at the basis of these induced changes in human epidermal dif-
ferentiation. The general aim of this thesis was to gain more insight into the regulation of
these switches in epidermal differentiation using SKALP as a read-out. Because SKALP
expression is very tightly associated with the phenotype of regenerative differentiation it
is our working hypothesis that knowledge about the pathways, factors and mechanisms
that regulate SKALP expression will be informative on the regulation of the complete
phenotype. We have used SKALP induction and expression as a paradigm for the induc-
tion and expression of the epidermal phenotype of regenerative maturation/differentia-
tion in order to identify extracellular factors, intracellular signal transduction pathways
and transcription factors involved in the onset of this epidermal phenotype. We speculate
that knowledge of these pathways will contribute to our understanding of physiological
responses of skin to injury (e.g. wound healing) or pathological conditions such as 
psoriasis.
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Specific aims
1. Because SKALP was used as a model protein throughout our studies we first wished to
characterise this molecule extensively at the protein and genetic level. Chapter 2.1 addres-
ses the question of SKALP expression in vivo (tissue localisation, subcellular localisation,
constitutive versus inducible expression), and we investigated its potential function in
tissue homeostatis. In chapter 2.2 we have investigated the possibility that genetic abnor-
malities in SKALP expression could be responsible for the pathology associated with
pustular forms of psoriasis.
2. Using cell culture models recently developed in our lab we have wanted to identify
extracellular factors (cytokines, growth factors) that could induce SKALP gene expression
in cultured human keratinocytes. Chapter 3.1 shows that out of a large array of stimuli
tested, only TNF-α and serum were potent inducers of SKALP expression at the protein
and mRNA level.
3. Once the extracellular factors that could induce SKALP expression were identified, we
wanted to elucidate the signalling pathways that were involved in relaying the external
signals (serum, TNF) to the nucleus a potential inducer. We have investigated the involve-
ment of MAP kinase signal transduction routes in the induction of SKALP gene expres-
sion and found that p38 activity is crucial for the induction of SKALP gene expression by
FCS and TNF-α in cultured human keratinocytes, as described in chapter 3.1. When the
work on SKALP expression by keratinocytes was in progress, we had identified the ext-
racellular matrix molecule tenascin-C as another gene that was expressed by keratinocytes
under conditions of external stress. We therefore wanted to investigate if expression of
tenascin-C and SKALP were subject to similar regulatory mechanisms. We therefore
applied the same culture models to study the regulation of tenascin-C for comparison
with SKALP. Chapter 3.2 shows that p38 activity is not crucial for the expression of
tenascin-C, which can be induced both by IL-4 and TNF-α.
4. Once the main inducers for SKALP (serum, TNF) and a potential signalling pathway
were identified (p38 MAPkinase) in vitro we wanted to know if these factors were relevant
for regulation of expression in vivo. Therefore we developed and characterised an in vivo
model for the induction of SKALP expression in normal human skin. Chapter 3.3 shows
that UV-B irradiation of normal skin leads to the expression of SKALP, and is preceded by
activation of p38 and JNK. In vitro, JNK and p38 are also activated upon UV-B irradiation
but this is not sufficient to induce expression of SKALP. A remarkable finding in these
experiments was that UV-B induced p38 activity appears to be important for cell survival
following UV-B irradiation.
5. Because the in vitro cell culture models used in our studies were not ideally suited to
study induction of SKALP (e.g. lack of SKALP induction by UVB in vitro as opposed to in
vivo) we wanted to develop in vivo or ex vivo models to study regenerative differentiation
and SKALP induction in intact human skin. We therefore used, and further characterised
the nude (immunodeficient) mouse transplantation model. In this model we can indu-
ce/maintain and study both normal and regenerative epidermal differentiation with the
same characteristics as normal human skin. Secondly we have used and characterised a
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whole skin explant model system for the induction of abnormal differentiation. We
demonstrate the usefulness of the latter model for studies using antisense oligonucleotides
directed against SKALP.
6. Finally we wanted to study the transciptional regulation of SKALP by analysis of the pro-
moter region of the SKALP gene. Chapter 4 describes the characterisation of the SKALP
promoter region: determination of the transcription start site, cell-specific expression,
deletion analysis of the promoter region using transient transfection of reporter
constructs. No definite conclusions with regard to regulation by specific transcription
factors could be made.
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Abstract 
Skin-derived antileukoproteinase (SKALP), also known as elafin, is a serine proteinase
inhibitor first discovered in keratinocytes from hyperproliferative human epidermis.
In addition to the proteinase inhibiting domain which is directed against polymorpho-
nuclear leukocyte (PMN) derived enzymes such as elastase and proteinase 3, SKALP con-
tains multiple transglutaminase (TGase) substrate domains which enable crosslinking to
extracellular and cell envelope proteins. Here we show that SKALP is constitutively expres-
sed in several epithelia that are continuously subjected to inflammatory stimuli, such as
the oral cavity and the vagina where it co-localises with type 1 TGase. All epithelia from
sterile body cavities are negative for SKALP. In general, stratified squamous epithelia are
positive, whereas pseudostratified epithelia, simple/glandular epithelia and normal epi-
dermis are negative. SKALP was found in foetal tissues of the oral cavity from 17 weeks
gestation onwards where it continued to be expressed up to adult life. Remarkably, in foe-
tal epidermis SKALP was found from week 28 onwards, but was downregulated to unde-
tectable levels in neonatal skin within 3 months, suggesting a role during pregnancy in
foeto-maternal interactions or in the early maturation phase of the epidermis.
Immunoelectron microscopy revealed the presence of SKALP in secretory vesicles inclu-
ding the lamellar granules. In culture models for epidermal keratinocytes we found that
expression of the endogenous SKALP gene provided protection against cell detachment
caused by purified elastase or activated PMNs. Addition of exogenous recombinant
SKALP fully protected the keratinocytes against PMN-dependent detachment whereas
superoxide dismutase and catalase were only marginally effective. These findings strongly
suggest that the constitutive expression of SKALP in squamous epithelia, and the induci-
ble expression in epidermis participate in the control of epithelial integrity, by inhibiting
PMN derived proteinases.
Introduction
Systemic regulation of proteinase activity is performed by numerous plasma-derived inhi-
bitors that are involved in regulation of complement activation, clotting and fibrinolysis.
In addition to these systemic antiproteinases a number of locally acting inhibitors is
known. These include inhibitors of cysteine proteinases such as the cystatins [247], and tissue
inhibitors of metalloproteinases [248]. Although the vast majority of the serine proteinase
inhibitors are found in the circulation, a limited number of this class is locally active at the
tissue level. Secretory leukocyte proteinase inhibitor (SLPI), an inhibitor of the polymorp-
honuclear leukocyte derived proteinases elastase and cathepsin G, is produced by cells of
mucosal surfaces and is found in the corresponding epithelial lining fluid [249]. In previous
studies we and others have described an epidermal proteinase inhibitor which was found to
be partially homologous to SLPI. This inhibitor, termed Skin-derived antileukoproteinase
(SKALP), otherwise known as elafin or ESI, is absent in normal epidermis but is highly
expressed in psoriatic epidermis and in some epithelial cell lines [239,250-253]. SKALP inhibits
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PMN-derived elastase and proteinase 3 and is therefore putatively involved in regulation of
cutaneous inflammation [254,255]. We have previously characterized SKALP in biochemical and
cell biological studies [246,251]. The cDNA and gene of SKALP have been cloned and sequenced,
and the chromosomal localisation was assigned to chromosome region 20q12-q13 [251,256,257].
Apart from the C-terminal domain that harbours the proteinase inhibiting properties, the
SKALP molecule also contains a domain with putative transglutaminase substrate motifs
that enable crosslinking to the cornified envelope proteins [251,258]. Previous studies in epider-
mis, cultured keratinocytes, and human epidermal tumours showed that SKALP expression
patterns appear to be similar to that of cytokeratin 16, which is known to be expressed in the
context of hyperproliferation (see [259,260] for reviews on epidermal differentiation). We have
recently obtained evidence that decreased levels of SKALP could be implicated in the patho-
genesis of pustular forms of psoriasis [261]. Apart from its presence in inflamed epidermis,
SKALP/elafin has been reported in tracheal tissue [262] and in bronchial secretions, although
the exact cellular source of sputum-derived SKALP/elafin in vivo is unclear [252].
It is not known to what extent SKALP is expressed in normal adult human epithelia, and no
functional studies have been performed so far. Here we report that SKALP is constitutively
expressed in many adult epithelia that are exposed to environmental stimuli. In these tissu-
es the presence of inflammatory cells is physiological, suggesting that SKALP provides pro-
tection against excessive proteolysis. Although normal human epidermis is negative, SKALP
was transiently expressed during foetal and neonatal development of the epidermis. In func-
tional assays using cultured cells we observed a protective effect of epithelial SKALP expres-
sion against the action of leukocytic proteinases, suggesting that SKALP is involved in the
maintenance of epithelial integrity.
Materials and methods
Materials
Goat-anti-rabbit IgG biotin conjugate, avidin-alkaline phosphatase, and the chromogenic
substrates 5-bromo-4-chloro-3-indolyl phosphate, nitroblue tetrazolium, Ca-ionophore
23187 and aminoethyl carbazole (AEC) were obtained from Sigma Chemicals, St. Louis,
MO, USA. Swine-anti-rabbit Ig conjugated with horseradish peroxidase (SwarPO) was
obtained from Dakopatts, Glostrup, Denmark. The Vectastain ABC kits for monoclonal
and polyclonal antibodies purchased from Vector Laboratories Inc., Burlingame, CA, USA.
A synthetic peptide comprising amino acid 23 to 36 of SKALP was synthesised by
Eurosequence, Groningen, The Netherlands; at the C-terminus a cysteine residue was
added for coupling to a carrier protein. The sulfo-SMCC kit and Sulfolink gel were obtai-
ned from Pierce, Rockford, IL, USA. RNA zolTM B was obtained from Cinna/Biotex
Laboratories, Inc., Houston, TX, USA, and [α-32P]-dCTP from Amersham, UK. Ficoll-
paque was from Pharmacia, Uppsala, Sweden.
Recombinant SKALP was a kind gift from Dr. Norman Russell, ICI Pharmaceuticals,
UK. As a probe for ribosomal 28S RNA a 2.1 kb EcoRI/BglII fragment was used (a kind
gift of Dr Jan Bauman, TNO Rijswijk, The Netherlands).
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Tissues
Archival and fresh biopsy/autopsy material was used for this study. The following adult
tissues were studied with respect to SKALP expression: brain; cornea; tongue; palate/lin-
gual tonsil; gingiva; pharynx; larynx; epiglottis; vocal fold; lung; bronchus; esophagus;
duodenum; colon; liver; kidney; urethra; uterine cervix; vagina; skin from various regions
including head, ear, breast, axillar region, mamilla, inguinal region, pubic area, scrotum,
finger, and foot sole; and hair follicle. Punch biopsies from adult skin were taken from
normal human volunteers and psoriatic patients. Foetal and neonatal tissues were availa-
ble from: a 9 week old embryo which could be examined in toto, two second trimester foe-
tuses, five third trimester foetuses and two neonates. Specimens used for immunohisto-
chemistry were fixed in buffered 4% formalin for at least 24 h, and embedded in paraffin.
Tissues for in situ hybridisation and northern blot analysis were snap frozen in liquid nitr-
ogen and stored at -20° C.
Antisera
A polyclonal antiserum against recombinant SKALP was obtained as described previous-
ly [255]. An antiserum against a synthetic peptide comprising amino acids 23 to 36 of SKALP
was prepared by coupling the peptide via a C-terminal cystein residue to chicken ovalbu-
min, using the sulfo-SMCC procedure according to the manufacturer’s instructions. This
conjugate was used for immunisation of a rabbit according to previously described proto-
col [238]. Control serum (preimmune serum) was drawn before the immunisation procedu-
re. The antiserum against the synthetic peptide was affinity purified using the synthetic
peptide coupled to Sulfolink coupling gel according to the manufacturer’s instructions. The
two antisera against recombinant SKALP and against the synthetic peptide gave identical
staining patterns in histological sections. A monoclonal antiserum against type 1 transglu-
taminase was obtained from Sanbio, Uden, The Netherlands. A monoclonal antibody
against human PMN elastase was obtained from DAKO, Denmark. Mon150, a monoclon-
al antibody against involucrin was obtained as previously described [263]. Ks8.12, a mono-
clonal antibody recognising CK 13 and 16 was from Sigma, St Louis MO, USA; a mono-
clonal antibody against CK 10 (DE-K10) was obtained from ICN, Costa Mesa.CA, USA.
Immunohistochemistry
Biopsies were fixed in buffered 4% formalin for at least 24 hours and processed for embed-
ding in paraffin. Sections (6µm) were mounted on 3-aminopropyltriethoxy-silane (Sigma,
St Louis MO, USA) coated slides. Sections were deparaffinised and rehydrated and used
for an indirect peroxidase technique. For antigen retrieval from paraffin sections, the
slides were pre-treated for 15 min in 0.1% trypsin/0.1% CaCl2 pH 7.8 by 37°C for anti-
cytokeratin 10, 30 min in 10mM citrate buffer for Ks8.12 and for Mon150 a pre-treatment
of 10 min in 10mM citrate buffer using a microwave oven (Miele, M720) at 450 Watt was
performed. After preincubation with 20% normal swine or rabbit serum the slides were
incubated for 60 min with the antibodies and after washing with phosphate-buffered
saline (PBS) they were incubated with peroxidase-conjugated swine-anti rabbit Ig or rab-
bit-anti-mouse Ig for 30 min. A solution of AEC in sodium-acetate buffer pH 4.9 contai-
ning 0.01% H2O2 was added for 15 min after preincubation with sodium-acetate buffer
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pH 4.9. When desirable, the slides were counterstained with Mayer’s haematoxylin (Sigma,
St Louis, MO, U.S.A.) and mounted in glycerol gelatine. Appropriate controls with pre-
immune sera or omission of the primary antibodies were performed.
Immunocytochemical staining of human keratinocytes cultured on coverslips
Human keratinocytes were cultured on tissue culture coverslips (Thermanox, LABTEK
Division, Miles Laboratories Inc., Naperville, IL, USA) using different culture conditions
(see below). Cells were fixed using either paraformaldehyde (1%) or aceton/methanol
(50/50). Fixed cells were stored at -20°C. Before usage the coverslips were transferred to
4°C for 30 min and then dried in air at room temperature. Paraformaldehyde fixed cells
were incubated for 15 min in 50 mM NH4Cl (in PBS, pH 7.5), and aceton/methanol fixed
cells were incubated for 15 min in PBS. Cells were incubated for 10 min at 37°C with eit-
her 20% normal goat serum for the polyclonal antibodies (anti-SKALP) or 20% normal
horse serum for the monoclonal anti-TGase antibody. After this incubation the coverslips
were washed for 15 min in PBS and incubated with the primary antibody for 1 hour at
37°C. Coverslips were washed for 15 min in PBS and incubated for 30 min at 37°C with
either goat-anti-rabbit-biotinylated antibody or horse-anti-mouse-biotinylated antibody
in a dilution of 1:200. Following this incubation coverslips were washed and incubated
with a complex of avidine and biotinylated horse radish peroxidase (1:50) for 30 min at
roomtemperature. Finally, coverslips were washed for 15 min in PBS and incubated with
diaminobenzidine tetrahydrochloride (DAB) substrate (metal enhanced DAB substrate
Kit; Pierce, Rockford, Illinois, USA), and the reaction was terminated by incubating the
coverslips in demineralised water. The coverslips were lightly stained with hematoxyline
solution (Harris-type; Sigma Diagnostics, St. Louis, Missouri, USA) and embedded in his-
tological mounting medium (Permount; Fisher Scientific, New Jersey, USA) before
making photographs.
Construction of plasmids and synthesis of RNA probes
We have previously cloned the SKALP cDNA and gene [251,257]. From the cDNA a 251 bp
PCR product was obtained (bp +69 to +320, relative to the translation start site), which
was subcloned into a pGEM-4 T-vector (Promega, Madison, Wi, USA) in both orien-
tations. The plasmid was linearised with Pst1 to synthesise the antisense cRNA, or in the
reverse orientation the control sense cRNA by T7 polymerase, using a digoxigenin RNA
labelling kit (Boehringer Mannheim, Germany). The cRNA’s were fragmented by limited
alkaline hydrolysis and used for in situ hybridisation.
In situ hybridisation 
Frozen sections (10µm) were placed on superfrost slides (Menzel-Glazer) and heated for
2 min at 50°C. The sections were fixed in phosphate-buffered saline (PBS) containing 4%
(v/v) paraformaldehyde for 10 min at room temperature, air-dried and rehydrated in 2x
SSC (standard sodium citrate) 2x 5min. Sections were then prehybridized in hybridisation
buffer for at least 1 hour, consisting of 4x SSC, 10% dextrane, 50% formamide, 0.5mg her-
ring sperm DNA (Boehringer, Mannheim, Germany), 2mM ethylenediaminetetratic acid
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(EDTA) and 1x Denhardt’s solution. Prehybridisation and hybridisation was performed at
37°C. Prehybridisation fluid was drained off and the slides were washed in 2x SSC.
Hybridisation was carried out in humidity chambers using the probe in a concentration
of 100 ng/ml hybridisation buffer. After overnight incubation sections were washed in 2x
SSC at 37°C followed by washes in 0.1x SSC/50% formamide 3 times for 7min.
Hybridisation signals were detected using a Nucleic Acid Detection Kit (Boehringer
Mannheim, Germany). Hybridised sections were processed as follows: sections were was-
hed for 5min in buffer 1 (100mM Tris, 150mM NaCL, pH 7.5) at room temperature fol-
lowed by incubation in buffer 1 containing 1% blocking mix for 30min. Anti-digoxigenin-
antibody conjugate dilute 1:200 with buffer 1 containing 1% blocking mix was applied to
each section at room temperature for 2h in a humidified chamber. Slides were then was-
hed in buffer 2 (100mM Tris, 50mM MgCl, 100mM NaCl, pH 9.5) . A solution of 5-
bromo-4-chloro-indolyl phosphate and nitrobluetetrazolium (obtained from Sigma, St
Louis, MO, USA) in buffer 2 was made immediately prior to use, filtered and placed in a
light-proof glass tray. Sections were developed overnight at room temperature. The sec-
tions were washed in TE-buffer (10mM Tris, 1mM EDTA, pH 8.0), counterstained with
methylene green and mounted using gelatine/glycerol.
RNA isolation and Northern blot analysis
Total RNA from cultured cells or different tissues obtained from autopsy or biopsy were
extracted with RNAzol B as suggested by the supplier. The following epithelial tissues were
studied: tongue, pharynx, larynx, epiglottis, vocal fold, lung, duodenum, colon, liver, kid-
ney, urethra, and inguinal skin. For Northern blot analysis 10 µg total RNA was fractiona-
ted on a denaturing 1% agarose gel containing formaldehyde following standard proce-
dures [246] and blotted by capillary transfer on nylon membrane. After transfer, RNA was
fixed to the membrane by ultraviolet irradiation (312 nm, 0.2 J/cm2). Hybridisation was
performed in phosphate buffer as previously described using a 0.42 kbp PvuII/EcoRI frag-
ment of the SKALP cDNA clone pGESKA as a probe [251]. Control hybridisations for equal
loading were performed using a human 28S ribosomal RNA probe. All probes were label-
led with 32P by random priming following standard procedures. Autoradiography was
done on X-Omat S film (Kodak, France) at -80°C with an intensifying screen.
Immunoelectron microscopy
Punch biopsies from normal and lesional psoriatic skin were fixed in 2% paraformalde-
hyde and divided into small pieces. Cryosubstitution and embedding in Lowicryl HM20
(Agar Scientific Ltd, Essex, England) were performed as follows: fixed tissues were stepwi-
se infiltrated into 30% glycerol and frozen in liquid propane. Dehydration in methanol at
-90°C for 48 h, and embedding in Lowicryl HM20 at -50°C were both performed in a cry-
osubstitytion apparatus (CS-auto, Riechert). Polymerization by indirect UV-light was per-
formed for 48 h at -50°C, followed by 24 h at room temperature. Ultrathin skin sections
on carbon coated copper grids were preincubated with 0.5% bovine serum albumin
(BSA), 0.1% gelatine and 0.15% glycine in phosphate buffered saline (PBS). The grids
were subsequently incubated with a polyclonal rabbit antiserum against recombinant
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SKALP (1:500 in PBS/BSA) or the corresponding preimmune serum at the same dilution,
at 4°C for 16 h. After washing the grids were incubated in protein A conjugated to 10 nm
colloidal gold particles (1:100 in 1% BSA in PBS), for 60 min at room temperature. After
washing the grids were counterstained with uranyl acetate (10 min) and lead citrate (1
min) according to standard protocols. The sections were examined in a JEOL jem1010
electron microscope at 80 kV.
Keratinocyte primary culture 
Human epidermal keratinocytes were initially cultured according to the Rheinwald-Green
system [224]. Primary cultures of keratinocytes were seeded on lethally irradiated (3000 rad,
3 min) Swiss mouse 3T3 fibroblasts in DMEM/F12 (3:1) (v/v) (Flow Laboratories, Irvine,
Scotland) supplemented with 0.4 (g/ml hydrocortisone (Collaborative Research Inc.
Lexington, MA, USA), isoproterenol (10-6 M) (Sigma, St. Louis, MO, USA), 100 U/ml
penicillin plus 100 (g/ml streptomycin (Gibco, Breda, The Netherlands), 6% foetal calf
serum (FCS) (Seralab, Nistelrode, The Netherlands), and 10 ng/ml epidermal growth fac-
tor (EGF) (Sigma, St. Louis, MO, USA). Cells were grown at 37°C, 95% relative humidity
and 8% CO2 in air. Liquid nitrogen stored keratinocytes from the primary culture were
used in further experiments.
First passage and induction of keratinocyte differentiation 
Keratinocytes were seeded at 105 cells in keratinocyte growth medium (KGM) as descri-
bed before [229]. KGM was composed of keratinocyte basal medium (KBM, Clonetics, San
Diego, CA, USA; 0.15 mM Calcium) supplemented with ethanolamine (0.1 mM) (Sigma,
St. Louis, MO, USA), phosphoethanolamine (0.1 mM) (Sigma, St. Louis, MO, USA), bovi-
ne pituitary extract (BPE; 0.4% v/v) (Clonetics, San Diego, CA, USA), epidermal growth
factor (EGF; 10 ng/ml) (Sigma, St. Louis, MO, USA), insulin (5 (g/ml) (Sigma, St. Louis,
MO, USA), hydrocortisone (0.5 (g/ml) (Collaborative Research Inc. Lexington, MA, USA)
, penicillin (100 U/ml) (Gibco, Breda, The Netherlands) and streptomycin (100 (g/ml)
(Gibco, Breda, The Netherlands). For induction of differentiation, at confluence the cul-
ture medium was switched either to KGM supplemented with 5% FCS or to KGM deple-
ted of growth factors (EGF, BPE, insulin) and hydrocortisone [246,256]. Non-differentiated
keratinocytes, present as a confluent monolayer, were obtained by keeping the cells in
KGM alone. After forty eight hours, the cultures were harvested either from 60 mm dishes
(for RNA extraction) or from 24 well plates in which the cells were cultured on coverslips
for immunocytochemistry.
Purification of PMN elastase; determination of anti-elastase activity
Human PMN elastase was purified from cells of a patient with chronic myeloid leukemia
and calibrated as previously described [250]. Elastase activity and anti-elastase activity was
measured using the fluorigenic substrate methoxy-succinyl-ala-ala-ala-pro-val-aminom-
ethylcoumarin (Bachem, Bubendorf, Switzerland), as described previously [266]. The
amount of inhibitor which reduces the activity of 1 nmol elastase with 50% under the
given assay conditions, is defined as 1 unit of anti-elastase activity.
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Cell detachment assays
Keratinocyte cultures on coverslips that were allowed to differentiate for 48 h, were exten-
sively washed with PBS to remove all traces of the induction media. In order to investiga-
te whether SKALP was secreted under these conditions, the culture medium was collected
over a 6 h time period, and the amount of SKALP was determined by a sandwich-type
enzyme-linked immunosorbent assay (ELISA) using a rabbit and a goat antiserum against
recombinant SKALP. In addition the amount of anti-elastase activity in the medium was
determined by a functional assay. PMN were isolated from peripheral blood according 
to standard procedures involving dextrane sedimentation, separation on a Ficoll-paque
gradient and hypotonic lysis. This yielded a suspension of >95% pure PMN. Subsequently,
the keratinocytes were exposed to PMN (2.106 per ml) activated with Ca-ionophore 
(1 µM), or to purified PMN elastase (10-25 µg/ml) in KGM supplemented with 1.8 mM
Ca++. PMN from two different donors were used. When keratinocytes were exposed to
activated PMN, the effect of excess recombinant SKALP (50 µg/ml) or the addition of
superoxide dismutase (500 U/ml) plus catalase 1000 U/ml) was tested. At regular intervals
the coverslips were washed with PBS and fixed in ethanol for histological examination.
The degree of cell detachment from the coverslip was quantitated by image analysis using
the Vidas 2.1 system (Kontron, Germany), and expressed as a percentage of the total
surface of the coverslip.
Results
SKALP is constitutively expressed in several squamous epithelia
We studied SKALP expression in 21 adult human tissues by immunohistochemistry (see
figure 1). In these tissues the stroma was always negative, whereas the epithelium in a
number of tissues studied showed positive staining. The following epithelial tissues were
positive for SKALP expression: tongue, palate, lingual tonsil, gingiva, pharynx, epiglottis,
vocal fold, esophagus, uterine cervix, vagina and hair follicle. The expression varied
considerably from one weakly stained cell layer (as in vocal folds and hair follicles) to
many intensely stained suprabasal layers (as in esophagus and vagina). Staining was never
seen in the basal cells. When multiple layers were stained, the density of the cytoplasmatic
staining increased with increasing differentiation, often in a distinct polarised (apical)
localisation in the cytoplasm, while in other cases staining appeared to be localised close
to the cell membrane.
Normal epidermis and skin adnexae are negative, except for the keratinocytes lining the
epidermal part of the sweat gland ducts (fig 1a) and the infundibular part of the hair
follicle (fig 1b). The suprabasal cells of psoriatic epidermis are strongly positive (fig 1c)
as described previously [255]. The tongue dorsum was strongly positive: up to ten cell lay-
ers were intensively stained (fig 1d). In contrast the ventral part of the tongue was nega-
tive (not shown). The furrows surrounding the vallate papillae of the tongue stained
intensily, but the taste buds were negative. In palate/lingual tonsil a distinct SKALP
expression was observed in destroyed epithelial lining (fig 1e), while staining was absent
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in the intact cover of the tonsil. Keratinising gingiva was moderately positive for three or
four most differentiated cell layers (fig 1f). The lining of the epiglottis was positively stai-
ned in multiple layers (fig 1g). In between, areas of pseudostratified columnar cells, with
ciliated cells common to respiratory epithelia, were negative with respect to expression of
SKALP. True vocal fold was slightly positive (not shown). Oesophageal lining, showed
many positive cell layers, especially the superficial layers which were intensively stained
in a polarised pattern (fig 1h). The uterine cervix and vagina were positive for multiple
cell layers, with varying intensity. The staining appeared to be more cell membrane
associated than cytoplasmatic (fig 1i). In most of these epithelia, infiltrating mononuc-
lear cells and few PMNs are found in the connective tissue or in the epithelium itself, and
their presence appears to be physiological. In pharynx we found a considerable number
of PMN present. Fig 1j shows a double staining for SKALP and PMN elastase. In addition
to the tissues shown in figure 1a-j we examined a number of epithelial and non-epithelial
tissues that were negative for SKALP expression, such as brain, cornea, larynx, lung,
bronchus, duodenum, colon, liver, kidney, urethra, and skin from various body regions
(not shown).
Because SKALP contains a number of repeats in the N-terminal domain that can be used
as TGase substrate a limited number of tissues was examined for type 1 TGase. The known
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Figure 1. Immunohistochemical staining for SKALP in human epithelia. Staining was performed on formalin
fixed paraffin sections, using a polyclonal rabbit antiserum. (a) normal epidermis is negative except for the kera-
tinizing cells lining the sweat gland duct (arrow); (b) hair follicle, positive cells are found in the infundibulum;
in the following tissues SKALP is strongly present in the suprabasal cells: (c) psoriatic epidermis; (d) tongue; (e)
tonsil; (f) gingiva; (g) epiglottis; (h) oesophagus; (i) vagina; (j) pharynx, doublestained for SKALP, which is pre-
sent in the suprabasal epithelial layers, and for PMN elastase which is present as the intensely stained dots in the
epidermis and the underlying dermis. Magnification 90x (a,g) and 180x (b,c,d,e,f,h,i,j).
tissue distribution [267] and our own observations indicate that in psoriatic epidermis,
oesophagus and oral epithelia SKALP and TGase co-localise in the upper half of the
suprabasal compartment (not shown).
SKALP is developmentally regulated in foetal epidermis
Foetal tissues (9, 17, 22 and 28/29 wk gestation) and neonatal tissues (1 and  3 months post
partum) were stained for SKALP. We studied the expression in oral epithelia, that were
shown to be positive in the adult, and in epidermis, which was negative in the adult (see
above). For comparison we stained the tissues for other known differentiation-related
markers such as CK 10, CK 13/16 and involucrin (data not shown). In a 9 wk old embryo,
which could be examined in toto, no SKALP could be detected in any tissue. The periderm
which is at this timepoint starting to show the first signs of stratification was also negati-
ve for CK 10, CK 13/16 and involucrin. At 22 weeks gestation, CK 10, CK 13/16 and invol-
ucrin positive cells are found in the upper suprabasal layer of the epidermis, whereas
SKALP is absent at this timepoint (fig 2a). At 28 weeks, SKALP expression is found in the
granular layer and upper spinous layer of the interfollicular epidermis (fig 2b). At this
timepoint the morphology of the epidermis is similar to adult human epidermis, inclu-
ding full stratification, keratinisation, suprabasal expression of CK 10 and involucrin, and
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Figure 2. SKALP expression in foetal epithelia. Staining
was performed on formalin fixed sections. Foetal epider-
mis was negative up to week 20 (fig 2a). From week 27-28
onwards strong epidermal staining was seen in the supra-
basal cells (figure 2b). SKALP expression was rapidly
downregulated after birth. In neonatal epidermis after 
1 month a faint staining was visible in the upper layer of
the stratum granulosum (figure 2c) and SKALP was
undetectable at 3 months (as in adult skin). In oral
epithelia SKALP was expressed as early as week 17 (fig 2d)
and continued to be expressed during adult life (not
shown). Magnification 90x
the absence of CK 13/16 in the suprabasal cells, as previously described by others [268,269].
In neonatal epidermis one month post partum the expression of SKALP is still faintly
detectable in the upper layer of the stratum granulosum and in the stratum corneum (fig
2c). In neonatal epidermis 3 months post partum SKALP expression is completely down-
regulated as in normal adult skin. The expression pattern of CK 10 remains unchanged
during the postnatal period. Involucrin expression, which was found in the foetal stratum
granulosum and stratum spinosum, is only found in the stratum granulosum of adult epi-
dermis. In adult interfollicular epidermis SKALP is completely absent, but is re-expressed
during the hyperproliferative differentiation program as seen in psoriasis (see fig 1c) and
injury, where it is always co-expressed with CK 16. Remarkably, in the foetal and neonatal
epidermis that was positive for SKALP no positive staining was seen with the Ks8.12 (anti-
CK 13/16) antibody, indicating that SKALP and CK 16 -at least in foetal development- are
subjected to distinct regulatory mechanisms.
In addition to epidermis we investigated the expression of SKALP, CK 10, 13 /16 and
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36 ↑ Figure 3. Northern blot of SKALP mRNA in various
adult tissues. Lower panel. A 0.8 kb message was found
in tongue (lane 1), epiglottis (lane 2), pharynx (lane 3),
vocal fold (lane 9) and in lesional psoriatic skin which
was used as the positive control (lane 13). Larynx, lung,
kidney, urethra, skin of the inguinal region, and liver
(lanes 4, 5, 6, 7, 8 and 10 respectively) were negative.
In the upper panel a probe for 28S ribosomal RNA was
used for control hybridizations to check for equal RNA
loading.
← Figure 4. In situ hybridization of SKALP mRNA in
human epidermis. Cryosections of normal human skin
and lesional psoriatic skin were used for in situ hybridi-
zation with a digoxigenin-labelled SKALP cRNA probe.
Normal skin was negative both with the antisense and
sense probe (figures 4a and 4b). Lesional psoriatic skin
was strongly positive in the suprabasal cells, using the
antisense probe (figure 4c). No signal above background
was detected with the sense probe (figure 4d). The occa-
sional alkaline phosphatase precipitate adjacent to the
basal membrane is non-specific, and was seen both with
the sense and antisense probe. Magnification 90x
involucrin in foetal and neonatal tongue and tonsils. SKALP was found in the suprabasal
keratinocytes of tongue epithelium as early as 17 weeks gestation (fig 2d). In the lingual
tonsils SKALP expression was found from 28 weeks onwards (no material was available
from earlier time points). In contrast to epidermis, SKALP expression in these epithelia
was not downregulated  in neonatal skin, but continued to be present in adult life, as
shown in fig 1.
Expression of SKALP at the mRNA level
Fresh autopsy material was obtained, stored at -80 °C, and used for northern blot analy-
sis. In tongue, pharynx and psoriatic skin a strong expression of SKALP could be demon-
strated whereas in epiglottis and vocal fold moderate levels were present (fig 3). In larynx,
lung, kidney, urethra and normal skin no SKALP mRNA was found. These findings corre-
lated with the expression of SKALP at the protein level, as found with immunohistoche-
mistry.
Because our studies suggested a discrepancy with data from Nonamura et al who repor-
ted the focal expression of SKALP in normal adult epidermis as shown with in situ hybri-
disation, we have examined epidermis from many different locations. We were unable to
demonstrate SKALP expression at the protein level in adult epidermis from ear, breast,
axilla, scrotum, mamilla, palms and soles (not shown). Using mRNA in situ hybridisation
on frozen sections of normal and psoriatic skin from the trunk, our results paralleled the
findings with immunohistochemistry (fig 4). With the antisense cRNA probe a strong
expression was found in the suprabasal compartment of psoriatic epidermis, whereas
normal epidermis was negative. All tissues were negative with the sense cRNA probe. Our
findings at the mRNA level are in agreement with the findings at the protein level as
shown in fig 1.
SKALP is present in secretory vesicles of epidermal keratinocytes
Electron microscopic examination of normal and lesional psoriatic epidermis revealed a
positive staining of suprabasal keratinocytes and the stratum corneum of psoriatic epi-
dermis. No significant signal was present in keratinocytes from normal epidermis or in
melanocytes, which is in accordance with the findings at the light microscopical level.
Staining with the preimmune serum was negative (figure 5a). As shown in figure 5d stai-
ning was mainly observed in the intercellular spaces of the stratum corneum and over the
lamellar granules of the keratinocytes in the upper spinous and granular layer (fig 5b). In
addition, intracellular labelling could also be observed over small vesicular structures and
in the Golgi apparatus of these cells (not shown). Since these structures are implicated in
secretion, these findings indicate synthesis and secretion of SKALP from suprabasal kera-
tinocytes.
Expression of SKALP protects against PMN-elastase mediated cell detachment
The specificity of SKALP for the PMN-derived proteinases elastase and proteinase 3, and
its constitutive expression in epithelia that are subjected to inflammatory stimuli suggests
a role in the control of inflammation. We therefore investigated whether SKALP expres-
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Figure 5. Immunoelectron microscopy of SKALP
in human epidermis. (a) psoriatic epidermis stai-
ned with pre-immune serum. An area of a kerati-
nocyte of the spinous layer is shown, near a des-
mosome. No immunogold labelling was seen in
any of the structures including the lamellar gra-
nules (arrow). (b) psoriatic epidermis stained
with anti-SKALP serum. A group of labelled
lamellar granules is shown (arrow) near a desmo-
some, at the cell membrane. (c) high power mag-
nification of the same preparation as in (b), with
a labelled lamellar granule (arrow) and an empty
lamellar granule (arrowhead). (d) stratum cor-
neum of psoriatic epidermis stained with anti-
SKALP serum. Clear labelling of the outer layers
of the corneocytes is visible. Bar=100nm
Figure 7. Secretion of SKALP in the
medium of cultured keratinocytes. After
induction of diferentiation in KGM/FCS
or in KGM/-GF, the cells were extensive-
ly washed, and incubated in KGM sup-
plemented with 1.8 mM Ca++, which is
the medium used for detachment assays
(see below). During a 6 h time course,
secretion of SKALP in the medium was
measured at the protein level by ELISA
(left-hand Y-axis, open circles and
triangles) or measured functionally and
expresssed as units anti-elastase activity
per ml (right-hand Y-axis, closed circles
and triangles). Under these conditions
the keratinocytes cultured in KGM/FCS
(triangles) continued to secrete SKALP
whereas the keratinocytes cultured in
KGM/-GF (circles)  remained negative.
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Figure 6. Northern blot analysis of SKALP expression in cultured keratinocytes.
Human epidermal keratinocytes were induced to differentiate either in KGM depleted
of growth factors (KGM/-GF) or in KGM with fetal calf serum (KGM/FCS). In
KGM/-GF (lane 2) SKALP is not expressed, whereas a strong signal is seen in
KGM/FCS (lane 1). In the upper panel control hybridization with 28S ribosomal RNA
is shown to check for equal loading.
sion could protect against elastase-dependent cell damage in an in vitro system. Human
epidermal keratinocytes were cultured in KGM to form a confluent monolayer. At this
stage, no differentiation is induced and SKALP is not expressed. Differentiation was indu-
ced either by growth factor depletion [265] or by the addition of foetal calf serum [246]. KGM
depleted of growth factors (KGM/-GF) induces a differentiated phenotype, as assessed by
type 1 TGase expression, and resembles normal skin as witnessed by the expression of CK
1/10 and the absence of SKALP [77]. KGM with foetal calf serum (KGM/FCS) induces dif-
ferentiation, as assessed by the expression of type 1 TGase, with a psoriasiform phenotype
such as sustained hyperproliferation and expression of SKALP [77]. Figure 6 shows the
expression of SKALP in these culture systems at the mRNA level. After induction of
differentiation, these cultures were washed extensively to remove the induction media and
were placed in the culture medium that was used in subsequent experiments for co-
culture with PMN (KGM with 1.8 mM Ca++, without serum). The secretion of SKALP in
the medium was measured by ELISA and in a functional assay as anti-elastase activity.
Figure 7 shows that during a 6 h time-course SKALP is secreted in the medium by cells
that were allowed to differentiate in KGM/FCS, whereas the cells differentiated in KGM/-
GF were negative. Having established that the culture models differed in SKALP expres-
sion, the keratinocytes were exposed to purified human PMN elastase. During a 4 h time
course, cell detachment from the coverslips was visualised by H&E staining and quan-
titated by image analysis (figure 8 and 9). Keratinocytes cultured in KGM/FCS (positive
for SKALP synthesis and secretion) were found to be protected against elastase-dependent
detachment, whereas cells cultured in KGM/-GF (negative for SKALP synthesis and
secretion) were fully detached from the tissue culture dish. Elastase-dependent loss of
adhesion was concentration dependent (not shown). Next we investigated whether ac-
tivated PMN could also induce the effects seen with the purified enzyme. Differentiated
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Figure 8. Time course of cell detachment by
purified PMN elastase. Human epidermal
keratinocytes cultured on coverslips in
KGM/-GF (open circles) or in KGM/FCS
(closed circles), were extensively washed,
and subsequently exposed to PMN elastase
(10 µg/ml) in KGM with 1.8 mM Ca++.
After 2 and 4 h cells were washed, fixed and
stained with H&E. Cell detachment was
quantitated by image analysis.
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cultures of keratinocytes were extensively washed and exposed to calcium-ionophore
activated PMN. Experiments were performed in duplicate with PMN from two different
donors. Within 12 hours, activated PMN caused cell detachment in keratinocyte cultures
grown in KGM/-GF, although to a lesser extent than observed in the concentration range
of purified elastase (approximately 10-15 % detachment after 12 hours). The SKALP-
expressing keratinocytes (grown in KGM/FCS) were fully protected against cell detach-
ment (figures 10 and 11). Addition of recombinant SKALP (50 µg/ml) to keratinocytes
cultured in KGM/-GF gave complete protection against PMN-mediated damage (figure
11e), whereas addition of SOD (500 U/ml) plus catalase (1000 U/ml) was only marginal-
ly effective (figure 11d).
Discussion
The proteinase inhibitor SKALP/elafin was first discovered at the biochemical level in
psoriatic skin, which is reflected in the acronym SKALP [250], as a specific inhibitor of leuk-
ocyte elastase which is reflected in the name elafin [239]. Retrospectively, both these names
are unfortunate, since we now know, firstly, that SKALP is not normally present in epi-
dermis but is constitutively expressed in other epithelia, and secondly that the inhibitory
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Figure 9. H&E staining of keratinocyte cultures exposed to PMN elastase. Human epidermal keratinocytes cul-
tured on coverslips in KGM/-GF or in KGM/FCS, were extensively washed, and subsequently exposed to PMN
elastase (10 µg/ml) in KGM with 1.8 mM Ca++. Cells were washed, fixed and stained with H&E. After 4 hours,
cell detachment and retraction was seen in keratinocytes cultured in KGM/-GF (fig 9a) whereas no signs of cell
detachment were visible in cells cultured in KGM/FCS (fig 9b). Magnification 45x
profile of SKALP also includes leukocyte proteinase-3 [254]. In view of its specificity for
leukocytic proteinases, it was hypothesised that SKALP is involved in the regulation of
cutaneous inflammation either by interfering with PMN migration or by providing
protection against excessive proteolysis of extracellular matrix components. In previous
studies we have documented the expression of SKALP in psoriatic epidermis, in injured
skin and in cell culture [246]. A striking parallel was found with the expression pattern of
CK16, which is not normally expressed in the interfollicular epidermis but is induced in
psoriasis, after injury and in cell culture [6,270]. We hypothesised that both SKALP and CK16
were part of the hyperproliferative differentiation program of normal epidermis, and
subjected to similar control mechanisms. In the present study we show that SKALP 
and CK16 are not co-expressed during foetal and neonatal development. CK16 is not
expressed in any stage of development of foetal epidermis as previously described by
others [269], whereas SKALP is expressed in the third trimester and downregulated in
neonatal skin. In contrast to previous reports that dealt with SKALP in epidermal kerati-
nocytes, either in pathology or in cell culture, here we demonstrate SKALP to be expres-
sed in ‘normal’ squamous epithelia. The adjective ‘normal’ in this respect should be used
with caution. Several normal tissues are subjected to continuous mechanical stress or inf-
lammatory stimuli, which may influence the structure and organisation of the lining epit-
helium. In normal epiglottis, squamous metaplasia can be observed, that is partly func-
tional or due to mechanical stress. Pathogens may be present in the pharynx of healthy
individuals, and in normal pharynx and esophagus PMN infiltration is not considered to
be pathological. Also in the infundibular part of the hair follicle the presence of bacteria
that may induce an inflammatory response is common. SKALP expression was demon-
strated in the tonsillar crypts where destruction of the epithelial lining by lymphocytes
was observed. Lymphocytes transmigrate the tonsillar epithelium into the crypts that also
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Figure 10. Time course of cell detachment by
activated PMN. Human epidermal keratinocy-
tes cultured on coverslips in KGM/-GF or in
KGM/FCS, were extensively washed, and subse-
quently exposed to PMN (2.106/ml) activated
by Ca-ionophore (1 µM). ). Experiments were
performed in duplicate with PMN from two
different donors. The coverslips were washed,
fixed and stained with H&E. Cell detachment
was quantitated by image analysis. Between 6
and 12 h incubation, cells detached from the
cultures that did not express SKALP (keratino-
cytes cultured in KGM/-GF, open circles), whe-
ras the SKALP expressing culture (keratinocytes
cultured in KGM/FCS, closed circles) was fully
protected.
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contain the desquamated cells of the stratified squamous epithelium. This passing through
is accompanied by desolution of the epithelium, which may be the trigger for SKALP
induction as part of the ongoing inflammatory response.
SKALP is specific for elastase and proteinase 3 that are proteinases  present in PMN. In
addition, elastase is found in monocytes, albeit at lower levels than in PMN. Continuous
trafficking of PMNs and mononuclear cells to epithelia could expose these tissues to
breakdown of extracellular matrix proteins as is known from various pathological con-
ditions [266,271]. Studies by several authors have shown that PMN can in vitro degrade
extracellular matrices and cause cell detachment by distinct mechanisms involving
proteolytic enzymes or oxidative molecules [272-275]. Recently it was shown that activated
PMN can express cell-surface bound elastase and cathepsin G which provides a potent
mechanism to egress from the vasculature, penetrate tissues and migrate to sites of
inflammation [273]. Using cultured keratinocytes exposed to purified PMN elastase or to
activated PMN we show that expression of SKALP provides protection against elastase-
mediated detachment in vitro. In this model system we used Ca-ionophore activation of
PMN which is a powerful stimulator of lysosomal enzyme secretion (up to 30% of the
total elastase content) and gives a moderate superoxide production. After 9 h of exposure
to activated PMN a cytopathic effect was seen on keratinocytes that lacked SKALP expres-
sion. The cell damage during this period was clearly elastase/proteinase 3 dependent since
the addition of recombinant SKALP provided protection. In contrast, a high concen-
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Figure 11. H&E staining of keratinocyte cultures exposed to activated PMN. Human epidermal keratinocytes
cultured on coverslips in KGM/-GF or in KGM/FCS, were extensively washed, and subsequently exposed to
PMN (2.106/ml) activated by Ca-ionophore (1 µM). After 12 h incubation, the cells  were washed, fixed and
stained with H&E. Figure 11a shows a confluent culture (KGM/FCS) after 12 h without PMN, which was taken
as the control value. No detachment was seen in these cultures; this was also found for the KGM/-GF cultures
(not shown). SKALP-expressing cultures (KGM/FCS) exposed to activated PMNs did not show significant
detachment of cells (figure 11b), whereas in the cultures that lacked SKALP-expression (KGM/-GF) considerable
cell detachment was noted (figure 11c). Recombinant SKALP (50 (g/ml) could completely prevent cell detach-
ment in the KGM/-GF cultures (figure 11e) whereas addition of SOD (500 U/ml) plus catalase (1000 U/ml) had
only a marginal protective effect (figure 11d).
tration of SOD and catalase did not protect against cell detachment and retraction. SKALP
could protect against elastase mediated damage in two ways. The presence of a signal pep-
tide and its presence in secretory vesicles and lamellar bodies suggests that SKALP is secre-
ted in the extracellular space, where it can neutralise its target proteinases. On the other
hand, the TGase substrate motifs of SKALP enable crosslinking to the pericellular matrix
and the cornified envelope. SKALP/elafin was recently found to be crosslinked to loricrin,
a component of the cornified envelope [258], suggesting that SKALP is crosslinked to int-
racellular proteins, and can also act as an anchored proteinase inhibitor. We have recently
obtained indirect evidence that SKALP is involved in protection of epidermal integrity in
pustular forms of psoriasis [261]. It was shown that in forms of pustular psoriasis, which are
characterized by a massive influx of PMN, the amount of epidermal SKALP is much lower
than in plaque type psoriasis. It remains to be established whether this phenomenon is
caused by an intrinsic (genetic) defect in these patients, or by inactivation/clearance of
SKALP.
Assuming that induction of SKALP  controls excessive proteolysis in adult skin, the
function of foetal SKALP expression is not clear at the moment, since no obvious signs of
inflammation are present in the foetal skin itself. It was, however, recently reported that at
the end of gestation increased levels of inflammatory cytokines are found in the amion
fluid, and evidence for an inflammatory response has been found in the forebag compart-
ment of the uterus presumably as a result of leakage of microbial stimuli from the vagina
and cervix into the uterus [276]. Speculatively, SKALP expression could be induced via this
route to ensure protection of the foetal skin against proteolytic activity in the amnion
fluid at the end of gestation. However, no evidence for the presence of inflammatory cells
or proteinases derived thereof in the amnion fluid, has been published to our knowledge.
Alternatively, SKALP induction could be a mechanism to provide temporary protection 
to the epidermis of the new-born, when switching from the foetal submerged, sterile
environment to a dry environment which allows colonisation of the skin with micro-
organisms. Although a fully keratinised epidermis is present at term, the barrier function
of neonatal skin is incomplete [268]. The observed downregulation of SKALP in neonatal
epidermis could therefore be related to the functional maturation of barrier function. It
has to be noted that under conditions that compromise barrier function such as tape strip-
ping and psoriasis, SKALP is again induced. Recently Nonamura et al have described the
focal presence of SKALP mRNA in normal epidermis, using in situ hybridisation [277]. Here,
we have studied a large number of samples from various locations of normal skin, but we
failed to demonstrate significant expression of SKALP at the protein level. Also with in situ
hybridisation we were unable to demonstrate the presence of SKALP in normal skin.
We do occasionally observe SKALP expression in the epidermis near hair follicles and
acrosyringia, which may explain the focal expression found by Nonomura et al [277].
Remarkably, SKALP in tongue and tonsil epithelium is induced much earlier than in epi-
dermis and continues to be expressed in the neonatal phase and throughout adult life.
In many of the moist oral epithelia (and of course in the tonsils) the presence of inflam-
matory cells is physiological, as a result of continuous exposure to environmental and
microbial stimuli. In adult epidermis which is a dry, keratinising epithelium, inflamma-
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tory cells are not normally present, which may explain the difference in SKALP expression.
On the basis of the pattern of SKALP expression, one would surmise that SKALP expres-
sion is induced by inflammatory cells such as PMN. Interestingly, Sallenave et al. demon-
strated induction of SKALP expression in tumour cell lines by the cytokines interleukin 1
(IL-1) and tumour necrosis factor alpha (TNF-α), but also by the PMN-derived proteina-
ses human leukocyte elastase and cathepsin G [278]. This finding is in line with that of
Perlmutter et al. who reported that neutrophil elastase regulates the synthesis of its inhi-
bitor (1-proteinase inhibitor in human monocytes and bronchoalveolar macrophages [279].
The cytokines IL-1 and TNF-α are considered to be initiating cytokines in inflammatory
processes in cutaneous tissue [271]. In normal tissues where continuous monitoring of the
tissue by inflammatory cells is desired for reasons of host defence, this control mechanism
might explain SKALP presence in epithelia such as esophagus, pharynx, tongue and
vagina. The difference in SKALP expression in the various epithelia could be related to dif-
ferences in inflammatory stimuli to which the tissues are subjected. However, ultimate
proof for its supposed relevance in control of epithelial inflammation has to come from
studies using transgenic mice lacking a functional SKALP gene, which will be the direction
for future research.
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Abstract
Psoriasis is a multifactorial skin disease characterised by epidermal abnormalities and
infiltration by lymphocytes and polymorphonuclear leukocytes (PMN). SKALP, also
known as elafin, is a potent inhibitor of human leukocyte elastase and proteinase 3, two
PMN-derived proteinases implicated in tissue destruction and leukocyte migration. We
have shown that, at least at the protein level, SKALP is significantly decreased in lesional
skin of patients with pustular psoriasis compared to plaque type psoriasis. This finding
raised the possibility that SKALP could be one of the candidate genes for pustular forms
of psoriasis. We therefore performed SSCP analysis on the SKALP gene to screen for muta-
tions/polymorphisms in the exons of 30 patients with plaque type psoriasis, 15 patients
with pustular psoriasis and 48 healthy controls. In exon 1 a polymorphism was detected at
position +43 relative to the translation start site, resulting in a substitution of threonine
for alanine in the signal peptide. In the promoter region a dinucleotide repeat polymorp-
hism was identified. Both polymorphisms were not associated with pustular psoriasis, or
psoriasis in general. Our data indicate that the decrease in SKALP activity in pustular
psoriasis is not caused by mutations in the coding region of the gene, and that there is no
allelic association between pustular psoriasis and SKALP gene polymorphisms.
Introduction
Psoriasis is a polygenic, chronic inflammatory skin disease of unknown aetiology. An
underlying autoimmune process or a defect in keratinocyte growth control mechanisms
has been implicated in the pathogenesis of this disease [280,281]. A genetic base for psoriasis
is likely as indicated by family and twin studies [282]. In a study of 61 monozygotic twins a
concordance of 73% has been reported, indicating a major genetic component in psoria-
sis [283]. Recently, several groups have started genome-wide searches for genes conferring
susceptibility to psoriasis [284-287]. Loci on chromosomes 2 [286], 4 [287], 8 [286], 17 [284], 20 [286] and
within the MHC cluster on chromosome 6p21 were found to be linked with psoriasis of
the chronic plaque type. Psoriasis pustulosa palmoplantaris is associated with and in-
creased frequency of HLA B8 [288] and HLA DR9 [289]. So far no mutations or polymorp-
hisms in individual genes have been found that are linked to plaque psoriasis or pustular
psoriasis.
Histologically, psoriasis is characterised by a disturbed epidermal proliferation and dif-
ferentiation. In the psoriatic lesion a dense dermal infiltrate is present, composed of lymp-
hocytes and polymorphonuclear leukocytes (PMN). PMN can also invade in the epider-
mis, to form microabcesses of Munro or spongiform micropustules of Kogoj. A subform
of psoriasis is pustular psoriasis, which can present itself as a localised form (psoriasis
pustulosis palmoplantaris, acrodermatitis continua of Hallopeau) or a generalised form
(generalised pustular psoriasis of von Zumbusch). The main characteristic of these con-
ditions is the presence of macroscopic pustules, which are the result of an extreme
epidermal infiltration of PMN. The pathogenetic events leading to the formation of
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macropustules in these diseases are unknown. Both an increase of epidermal chemotactic
factors [290,291] and an increased chemotactic response of the PMN [291] have been implicated
as a factor contributing to the massive PMN influx.
PMN-derived neutral proteinases such as elastase, proteinase 3 and cathepsin G are
important inflammatory mediators that have been implicated in tissue damage and PMN
migration. The action of elastase and proteinase 3 is controlled by systemic proteinase
inhibitors like alpha-1-proteinase inhibitor and by locally produced proteinase inhibitors
like SKALP [238], also known as elafin [293]. SKALP is a member of the Trappin gene family
that we have recently described [241]. In normal epidermis SKALP is absent but it is induced
under inflammatory conditions [237,238]. We have recently shown in vitro that SKALP is a
major inhibitor involved in the protection of the epidermis against PMN-dependent
proteolysis [294]. Because of the pronounced presence of PMN in the epidermis of patients
with pustular forms of psoriasis, we hypothesised that deregulation of epidermal anti-
protease activity could contribute to PMN chemotaxis and tissue destruction. We have
recently shown that, at least at the protein level, SKALP is significantly decreased in lesion-
al skin of pustular psoriasis compared to plaque type psoriasis [261]. These findings raised
the possibility that SKALP could be one of the candidate genes for pustular forms of
psoriasis. We therefore performed single strand conformation polymorphism (SSCP)
analysis to screen for mutations/polymorphisms in the exons 1 and 2 of the SKALP gene
of 30 patients with plaque type psoriasis, 15 patients with pustular psoriasis and 48
healthy controls. Here we report a polymorphism in exon 1, which results in an amino
acid substitution. However, this polymorphism was equally distributed in the patient and
in the control population. Similarly, we found a polymorphic CA-repeat in the promoter
region which was not associated with pustular psoriasis, or psoriasis in general.
Materials and methods
Patients
Five ml blood samples in ethylene diamine tetra-acetic acid (EDTA) coated containers
were collected from 30 patients with chronic plaque psoriasis and 15 patients with a
pustular form of psoriasis, either localised or generalised (pustulosis palmoplantaris
n=12, acrodermatitis continua of Hallopeau n=1, generalised pustular psoriasis von
Zumbusch type n=1, non-generalised pustular psoriasis n=1). All patients had active dis-
ease. Furthermore, blood samples were obtained from a three-generation family and from
48 healthy controls, the latter via the transfusion department. Prior to analysis, blood
samples were stored at -80˚C.
Polymerase chain reaction amplification
Genomic DNA was isolated from peripheral blood lymphocytes by standard methods [295]
and used as a template for amplification of exons 1 and 2 of the SKALP gene, coding for
the primary translation product. When the 5’non-coding region of the SKALP gene was
sequenced a dinucleotide repeat in the promoter region of the gene was noted, which was
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polymorphic. For amplification of the regions of interest, oligonucleotide primers (Table
1) were synthesised on the basis of intronic sequences and the nuclotide sequence of the
flanking regions of the dinucleotide repeat (Isogen Bioscience, Maarssen, the
Netherlands). Amplifications were performed in a total volume of 25 (l containing 200 ng
genomic DNA, 5-10 mM MgCl2, 50 mM KCl 10 mM Tris, pH 8.3, 0.2 mM of each dNTP,
10 pM of each primer and 0.5 U Taq DNA polymerase. The PCR cycling profile for all PCR
reactions was as follows: preheating to 95˚C for 5 min, followed by 35 cycles of 94˚C for
30 sec, annealing temperature for 1 min (Table 1), 72˚C for 2 min. The PCR was ended
with a final extension at 72°C for 10 min. All PCR reactions were carried out in a Peltier-
Thermal cycler (MJ Research, Massachusetts, USA).
Non-radioactive single strand conformation polymorphism (SSCP) analysis
Conformation polymorphisms were visualised by SSCP analysis [296,297]. For denaturation of
the DNA, 3.5 (l of the PCR product was mixed with 7 µl of 50 mM NaOH and 1 mM
EDTA, heated at 94˚C for 5 min and subsequently placed on ice. Five µl of this mixture
was loaded in 8 µl wide slots on a CleanGel polyacrylamide gel (Cleangel 10%, Pharmacia
Biotech, Uppsala, Sweden), which was rehydrated in 112 mM Tris-acetate, pH 6.4 with
0.006% bromophenol blue. Electrophoresis was carried out for each PCR product at two
different temperatures (4˚C and 20˚C) at 10 W for 20 min, and 20 W for 60 min in 0.2 M
Tris 0.2 M Tricine 0.55% (w/V) SDS, pH 8.3. Silver staining was performed according to
the manufacturer’s guidelines: After fixation of the gel for 30 min in 10% acetic acid solu-
Chapter 2SKALP: Functional aspects and its putative role in desease prosesses
49
Primers a Sequence b Annealing Size (bp)
temperature (˚C)
EXON 1
For1 (pos. -46 to -25) AAGATTGGTATGGCCTTAGCTC 60 150
Rev1 (pos. +103 to +84) CCAGCAGGTCACCTGTTCAC
EXON 2
For2 (pos. +897 to +917) GCTTACTGGGTATAAATGTGG 53 285
Rev2 (pos. +1181 to +1163) AGCCTTCACAGCACTTCTT
For3 (pos. +1049 to +1068) CCAGTCAAAGGTCCAGTCTC 57 188
Rev3 (pos. +1236 to +1217) TCGTTCTCAAGCTAGTGCTC
REPEAT PROMOTER
For4 (pos. -989 to -968) ACCTTTTCCAGAAGAAGGAACC 58 156
Rev4 (pos. -834 to -851) CCTGACCCCTGACCACAG
a Numbers in brackets are the 5' base position from the translation start site.
b Primer sequences are written 5' to 3'.
Table 1
tion, the gel was washed 3 times in demineralised water. Subsequently, staining with 0.1%
AgNO3 with 0.037% formaldehyde was performed during 30 min followed by washing
with demineralised water and development of the gel using 2,5% Na2CO3 with 0.037%
formaldehyde and 0.002% Na-thiosulphate. Development was stopped with 2% glycine
0.5% EDTA-disodium solution and gels were impregnated with 5% glycerol.
Cloning and DNA sequence analysis
In exon 1 and in the promoter region variations in the mobility patterns in SSCP analysis
were seen, which were further analysed by DNA cloning and sequencing. PCR reactions
were performed in 8-fold, pooled and treated with proteinase K. Subsequently, products
were ligated into the pGEM T-vector  (Promega, Madison, USA) according to the manu-
facturer’s protocol and the clones were sequenced by the dideoxy chain termination
method [298].
Radioactive PCR fragment length analysis
The sizes of the PCR fragments comprising the dinucleotide repeat in the promoter region
were further analysed on an 8% denaturing polyacrylamide gel by comparison with a
sequencing ladder, which was generated using the dideoxy chain termination method [298].
For visualising the PCR products, radioactive α32P-dCTP was added to the PCR reaction.
For denaturation of the DNA, the samples were heated for 3 min at 94˚C . Subsequently,
3.5 µl of the samples was loaded on an 8% denaturing polyacrylamide gel and electrop-
horesed at 60 W during 2 h and developed overnight by autoradiography at -80˚C.
Statistical analysis
Allele frequencies in patient and control groups were compared using a χ2-test.
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Figure 1. Non-radioactive SSCP analysis of exon 1 (a)
and the dinucleotide repeat in the 5' upstream region
(b) of the SKALP gene. (a) Exon 1. Different migra-
tion patterns were seen. Further analysis revealed an
A → G polymorphism at position +43 from the
transcription start site. Lane 1, homozygous A, lane 2
homozygous G, lane 3 the heterozygous pattern. (b)
Dinucleotide repeat in 5' upstream region. Different
migration patterns were seen. Further analysis reve-
aled two additional CA repeats. Lane 1 homozygous
for the allele with 6 CA-repeats, lane 2 the heterozy-
gous pattern showing 2 extra bands, lane 3 the single
patient showing an aberrant pattern. Arrows mark
the different allelic bands.
Results
SSCP and DNA sequence analysis of exons 1 and 2 of the SKALP gene
The human SKALP gene contains 3 exons and 2 introns [299]. The first exon includes the 5’-
non-coding region and the signal sequence as well as the first 4 amino acids of the trans-
glutaminase substrate domain of the mature protein. The second exon encodes the rest of
the transglutaminase substrate motifs, the proteinase inhibiting domain and contains the
first nucleotide of the 3’-noncoding region. The rest of this region, including the polyade-
nylation signal constitutes the third exon.
SSCP analysis using primer pair 1 revealed sequence variation in exon 1 (Fig. 1a), which
suggested that 2 alleles were present with an estimated frequency of the minor allele of
0.095 in the control population. The allele frequencies in the plaque type and pustular
psoriasis group were both 0.12 and were not significantly different from the control group.
One plaque psoriasis patient was homozygous for the minor allele. From this patient and
from a patient who was homozygous for the other allele, the PCR product was cloned and
sequenced. The obtained sequence was compared with published nucleotide sequences of
the human SKALP gene and cDNA [251,252,256]. At position +43 from the translation start 
site an adenosine to guanosine transition was found. This mutation results in an amino
acid substitution of threonine for alanine in the region coding for the signal peptide. In
the SSCP analysis of PCR products from exon 2, using primer pairs 2 and 3, no altered
migration patterns were detected.
A dinucleotide repeat polymorphism in the 5’-upstream region
When we sequenced the flanking region of the human SKALP gene, we noted a dinucleo-
tide repeat in the 5’-upstream region of the gene at position -909 from the translation start
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Figure 2. Identification of the different alleles of the
imperfect dinucleotide repeat by sequencing.
Autoradiographs of sequencing patterns of 2 patients
with abnormal shift patterns in the SSCP analysis of
the dinucleotide repeat in the 5' upstream region of
the SKALP gene (see Fig 1b). (a) Patient homozygous
for the extra dinucleotide repeats. Two extra CA repe-
ats were seen. (b). Patient with an aberrant SSCP pat-
tern. In the third CA repeat an adenosine to guanosi-
ne transition can be seen (compare with Fig 2a).
site. The form of the repeat is TCT(CA)4A(CA)7CT(CA)12CCC. PCR reactions on geno-
mic DNA of 48 unrelated individuals using primer pair 4 (Table 1), showed this repeat to
be polymorphic. The sizes of the alleles were determined with radioactive PCR fragment
analysis revealing a 156 bp PCR product and a 160 bp product. The estimated allele fre-
quencies are 0.135 for the 160 bp allele and 0.865 for the 156 bp in the control group.
Mendelian inheritance was observed in one healthy three-generation family. In the plaque
psoriasis patient group the allele frequency of the minor allele was 0.12 and in the pustu-
lar psoriasis patient group 0.07, which both were not significantly different from the con-
trol group. There was one homozygous patient for the 160 bp allele, who had a plaque type
psoriasis. From this patient and a control person who was homozygous for the 156 bp
allele the PCR products were cloned and sequenced. The 160 bp allele contained two addi-
tional CA repeats, resulting in a sequence as follows: TCT(CA)4A(CA)9CT(CA)12CCC
(Fig. 2a).
Subsequently, SSCP analysis of PCR products from primer pair 4 was performed, which
revealed different migration patterns. Two patterns could be contributed to the poly-
morphism in the repeat and were in concordance with the results of radioactive PCR frag-
ment analysis (Fig. 1b). However, one aberrant pattern was only found in a single patient
with plaque type psoriasis (Fig. 1b). From this patient the PCR product was cloned and
sequenced. The sequence revealed an adenosine to guanosine transition in the third CA-
repeat at position -871 from the translation start site (Fig. 2b).
Discussion
Previous studies revealed decreased protein levels of SKALP in skin extracts of pustular
psoriasis patients compared to plaque psoriasis patients [261]. The same observation was
made in a patient with impetigo herpetiformis; a pregnancy induced form of generalised
pustular psoriasis [300]. These findings made SKALP a candidate gene for pustular forms of
psoriasis, and we therefore investigated whether disease-associated sequence variation was
present in functionally significant areas of the SKALP gene. In this study an SSCP survey
of the SKALP gene in patients with plaque type and pustular psoriasis is presented.
In exon 1 a polymorphism was found which results in an amino acid substitution of
threonine for alanine in the signal peptide encoding region. Because it implies the change
of a relatively hydrophobic amino acid into a hydrophilic amino acid, this could result in
a functional change. However, since there was no association between psoriatic patients
and the minor allele, we conclude that the decrease in SKALP activity in pustular psoria-
sis is not caused by or related to this particular polymorphism. The analysis described
herein was carried out under conditions designed for optimal detection of mutation.
Nonetheless, we cannot exclude the possibility that mutations have been missed, as the
detection efficiency of SSCP analysis is approximately 90-95%.
When the flanking sequences of the SKALP gene were analysed we noted a dinucleotide
repeat in the promoter region of the gene, which was polymorphic. No association was
found between pustular psoriasis and these alleles. We have recently determined multiple
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mRNA transcription startsites of the SKALP gene, and we have mapped relevant promo-
ter elements for transcription factor binding (manuscript in preparation). Previously,
Zhang et al. sequenced the promotor region and identified several putative transcription
factor binding sites [301]. The dinucleotide repeat is situated at pos. -909, and so far does not
coincide with the detected regulatory elements. It is therefore unlikely that the mutation
found in this repeat in one psoriatic patient (adenosine to guanosine), or the variation in
the number of CA repeats will be of functional significance.
In summary, the data presented here strongly suggest that the genetic predisposition to
pustular psoriasis is not primarily determined by variation in the SKALP gene. Further, it
is unlikely that the observed decrease of SKALP protein levels in the epidermis is based on
mutations in the coding regions of the gene. However, because we did not perform SSCP
analysis on exon 3, which encodes the 3’-noncoding region, it is still possible that poly-
morphisms exist in this region that could control translation efficiency. Our present
results are in line with our previous finding that in vivo the transcript levels of SKALP are
equal in pustular and plaque psoriasis patients [261]. Apparently, both are indicating that the
decrease of SKALP in pustular psoriasis is due to post-transcriptional events.
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Abstract
Keratinocytes of inflamed epidermis (psoriasis, wound healing) are hyperproliferative and
display an abnormal differentiation program. This regenerative differentiation pathway is
characterised by the induction of genes that are not expressed by keratinocytes in normal
skin, such as the cytokeratins CK6, CK16, CK17, and the proteinase inhibitor SKALP/elaf-
in. Here we have studied the induction and regulation of SKALP expression as a marker
for regenerative differentiation in epidermal keratinocytes. Various cytokines and growth
factors that are known to be present in psoriatic epidermis were examined for their abili-
ty to induce SKALP gene expression in cultured human keratinocytes. Tumour necrosis
factor-alpha (TNF-α) and serum were found to be potent inducers of SKALP expression
both at the mRNA and protein level. To examine a possible role of the MAP kinase casca-
de in SKALP expression we have investigated the activation of the different members of
the MAP kinase family, using phosphorylation-specific antisera on western blots.
Detectable levels of activated (phosphorylated) components of all three MAP kinase path-
ways were found in undifferentiated and differentiated keratinocytes. When keratinocytes
were induced to undergo differentiation, the phosphorylation levels of ERK1/2 and c-jun,
a major target of JNK/SAPK, remained nearly constant, whereas the phosphorylation
levels of p38 showed a minor increase concomitantly with induction of normal and rege-
nerative differentiation. However, SB202190 or SB203580, two specific p38 MAP kinase
inhibitors could almost completely block the induction of SKALP expression by TNF-α
and serum. These results suggest that in keratinocytes, p38 activation is a necessary, albeit
not sufficient step in the induction of SKALP gene expression. These findings could be
relevant for understanding the mechanisms that are involved in normal and disturbed epi-
dermal differentiation.
Introduction
In normal skin the epidermal keratinocytes follow a highly co-ordinated pathway of pro-
liferation and terminal differentiation leading to the formation of the horny layer which
consists of mature corneocytes [260]. However, keratinocytes are also capable of following an
alternative differentiation route generally known as regenerative differentiation or regene-
rative maturation [6,7]. Regenerative differentiation is a physiological adaptation program
of keratinocytes to a disturbance of epidermal homeostasis, like skin barrier disruption
and ultraviolet light (UV) irradiation [202,302,303]. Also in several pathological skin conditions,
e.g. psoriasis and squamous cell carcinoma, keratinocytes follow this abnormal differen-
tiation pathway [10,245]. Regenerative differentiation is in many ways distinct from the dif-
ferentiation program found in normal, healthy human skin. A number of proteins nor-
mally found in epidermis are overexpressed. These include proteins that are involved in
the formation of the corneocyte such as involucrin and transglutaminase-1. Normally the
expression of these proteins is restricted to the stratum granulosum but during regenerati-
ve differentiation these proteins are also expressed in the stratum spinosum [304]. An even
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more interesting feature, from a mechanistic point of view, is the expression of proteins
that are normally absent in human epidermis but are now highly expressed. Well known
examples are the cytokeratins (CK) 6, 16 and 17 [12] and the epithelial proteinase inhibitor
skin-derived antileukoproteinase (SKALP), also known as elafin, which is a member of the
Trappin gene family that we have recently described [305]. The expression pattern of
CK6/16/17 and SKALP is tightly associated with the keratinocyte phenotype of regenera-
tive differentiation in vivo. We hypothesise that knowledge of the regulatory factors and
pathways that are involved in the expression of these genes in keratinocytes will contribute
to elucidate the processes that are involved in the transition between epidermal differen-
tiation programs, as seen in psoriasis, wound healing and some forms of cutaneous
neoplasia.
Epidermal keratinocytes are in vivo regularly exposed to stimuli such as solar UV irra-
diation, loss of barrier function and inflammation. Studies in many cell types (mostly in
vitro) have demonstrated that stimuli such as UV radiation, osmotic stress and inflamma-
tory cytokines exert their effects on the cell by the activation of the so-called cellular stress
response pathway. The cellular stress response pathway is a conserved eukaryotic signal
transduction route that enables the cell to adapt to damaging environmental stimuli.
Through a tightly regulated cascade, a family of protein kinases known as the Mitogen
Activated Protein kinases (MAP kinases) can become active upon phosphorylation. In an
activated state, these MAP kinases can phosphorylate, and thereby activate, a variety of
transcriptional regulatory factors. In this way, by changing the cells transcription factor
repertoire, activation of the MAP kinase pathway decides on gene expression and thereby
cell fate (apoptosis versus survival) [306,307]. Recently, the relevance of the MAP kinase mem-
bers in UVB induced gene expression in human skin in vivo has been described [130,133,308]. In
addition to its role in stress-induced gene expression, it was recently shown that regula-
tion of the involucrin promoter, a protein associated with normal differentiation, is
dependent on activity of MAP kinase family members [181]. The role of the MAP kinase cas-
cade in the regulation of regenerative epidermal differentiation has not been studied sofar.
Because SKALP is known to be expressed in vivo when keratinocytes are exposed to 
inflammatory cytokines (psoriasis [277,309], wound healing [310]) and osmotic stress (skin bar-
rier disruption by tape stripping [202] or detergent [205]) we have investigated regulation of
SKALP gene expression by keratinocytes as a paradigm for the abnormal regenerative
differentiation program. To study the effects of selected cytokines we used a recently
described submerged keratinocyte model which allows controlled induction of both nor-
mal differentiation (expression of involucrin, transglutaminase, CK1/10) and regenerative
differentiation (expression of SKALP, psoriasin) [77,294]. Furthermore we have investigated
the phosphorylation, and thereby the activation, of the three main MAP kinases, extra-
cellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 MAP
kinase during induction of normal and regenerative differentiation. Using pharmacologi-
cal inhibitors we found that p38 activity is necessary for the induction of SKALP gene
expression following stimulation by TNF-α or serum.
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Materials and methods
Cell cultures
Keratinocytes were seeded in 6 well culture dishes and cultured until confluence in kera-
tinocyte growth medium (KGM) as described before [77]. KGM was composed of keratino-
cyte basal medium (KBM (Biowhittaker, Walkersville, Maryland, USA); 0.15 mM
Calcium), supplemented with ethanolamine (0.1 mM) (Sigma, St.Louis, USA), phosp-
hoethanolamine (0.1 mM) (Sigma, St.Louis, USA), bovine pituitary extract (BPE; 0.4
%v/v) (Biowhittaker, Walkersville, Maryland, USA), insulin (5 µg/ml), (Sigma, St. Louis,
USA), hydrocortisone (0.5 µg/ml) (Collaborative Research Inc.), recombinant mouse
Epidermal Growth Factor (EGF; 10 ng/ml) (Sigma, St. Louis, USA), penicillin (100 U/ml)
(Gibco, Breda, the Netherlands) and streptomycin (100 µg/ml) (Gibco, Breda, the
Netherlands). At confluence the cells were switched to one of the test media, subsequent-
ly the growth factor or cytokine that was to be tested was added to the culture medium in
different concentrations. Induction of keratinocyte differentiation was established by
switching the cells at confluence either to KGM supplemented with 5 %v/v FCS
(KGM/FCS) (FCS from Seralab, Nistelrode, the Netherlands) or to KGM depleted of
growth factors (BPE, Insulin and EGF) and hydrocortisone (KGM/-gf) [265]. Two different
p38 inhibitors were used, SB203580 (a kind gift of Dr. Griswold from SmithKline
Beecham, PA, USA) and SB202190 (Calbiochem, CA, USA). The inhibitors were dissolved
in DMSO and added in different concentrations to the cultured cells one hour prior to the
addition of the differentiation stimulus. Different concentrations of DMSO were tested
for the effect on the cultured cells. The cytokines and growth factors that were tested were
IL-1α, IL-2, and IL-10 (a kind gift from Dr. L. Joosten, Dept. of Rheumatology, University
Hospital Nijmegen), IL-4 (Schering & Plough, Amstelveen, The Netherlands, for research
purposes only), IL-6 (a kind gift from Dr. L. Aarden, Central Laboratory for
Bloodtransfusion, Amsterdam), IL-8, TGF-α, TGF-β, and IFN-γ (R&D systems, Abingdon,
United Kingdom), PDGF, KGF, and TNF-α (Boehringer Mannheim, Mannheim,
Germany). At different time points after the addition of stimulus, the cell culture medium
was collected and the cells were lysed either in RNAse-all for RNA isolation or in SDS-
PAGE sample buffer (recipe see section western blotting) for western blot analysis.
Enzyme-linked immunosorbent assay (ELISA) for measurement of SKALP/elafin levels
SKALP/elafin concentrations were measured in culture supernatants using a sandwich-
type ELISA. In brief, samples were diluted (1:40, 1:60, 1:80) in 0.1 M Tris, 0.1% Tween-20,
1% BSA (ICN Biomedicals, Aurora, Ohio, USA). Microtiter plates (96 flat bottom wells)
were coated overnight with goat anti-SKALP/elafin antiserum. After washing of the plate
with PBS/0.05% Tween-20, microtiter plates were blocked and probed with the test samp-
les for 2 hrs at 37°C. Subsequently, rabbit anti-SKALP/elafin antiserum with 2.5% normal
goat serum (Vector Laboratories, Burlingame, USA) was added and the plates were incu-
bated during 60 minutes at 37°C. Subsequently the microtiterplates were incubated with
peroxidase-conjugated swine-anti-rabbit IgG (DAKO, Glostrup, Danmark) with 2.5%
normal goat serum during 60 minutes at 37°C. Finally o-phenylenediamine dihydrochlo-
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ride (OPD) (Pierce, Rockford, Illinois, USA) was added as chromogenic substrate for 15
minutes at RT. This enzyme reaction was stopped by the addition of 4 M H2SO4.
Absorbencies were measured at 492 nm and at 655 nm. Human recombinant SKALP/elaf-
in in PBS with 0.1% BSA was used as a standard: a calibration curve was made, using
recombinant SKALP in the range of 0.5 - 120 ng/ml. The SKALP/elafin concentrations in
the test samples were read from this curve. The SKALP/elafin concentrations given in ng
secreted SKALP/elafin/ml culture medium.
RNA-isolation and Northern blot analysis
Cells from which total RNA was to be isolated were lysed in 1 ml RNase-All (2.1 M
Guanidine-thiocyanate (Research Organics Inc., Cleveland USA), 8.5 mM N-lauroylsar-
cosine (Sigma, St. Louis, USA), 12.5 mM NaAc pH5.2, 0.35 %v/v β-mercapto-ethanol
(Merck, Darmstadt, Germany) and 50 %v/v Tris-saturated biophenol pH8.0 (Biosolve,
Amsterdam, the Netherlands)), after lysis 100 µl chloroform was added. The samples were
centrifuged for 15 minutes (13000 rpm, 4˚C). The aqueous phase was precipitated and the
pellet was washed and dried. This RNA pellet was resuspended in 150 µl NSE (50 mM
NaAc, 0.2 % SDS and 2 mM EDTA) and 562.5 µl 100% ethanol was added. Samples were
spectrophotometrically quantitated and equal amounts were separated overnight on an
agarose gel. The samples were blotted on positively charged nylon and subsequently used
in hybridisation experiments. Probes were used against SKALP/elafin, CK1 and for nor-
malisation of the amount of RNA loaded on the gel a probe against the ribosomal protein
human Acidic Ribosomal Phosphoprotein (hARP) was used [311]. Autoradiography was
performed using Kodak X-Omat X-ray films and Kodak BiomaxMS X-ray films.
Autoradiograms were quantitatively analysed using the “Imagemaster 1D elite” image
analysis software package (distributed by Hoefer Pharmacia Biotech, Upsala, Sweden).
Western blotting
Using the phosphospecific antibodies kits supplied by New England Biolabs (Beverly, MA,
USA) we performed Western blotting and protein detection according to the protocol of
the manufacturer. In short, cultured keratinocytes were lysed in sample buffer ((approxi-
mately 5000 cells per µl) 62.5 mM Tris pH6.8, 10 % glycerol, 0.1 % bromphenol blue, 2 %
SDS, 50 mM DTE). Cell lysates were sonified two times 10 sec. and subsequently incuba-
ted for 3 min. at 100˚C. Together with caleidoscopic and biotinylated markers, samples
were run on a 10 % SDS PAGE gel (biorad) in Tris-Glycine-SDS buffer (Biorad) at 175
volts. Gels were electro-blotted on PVDF blotting paper (Biorad) in Tris-Glycine-SDS
buffer supplemented with 20 % methanol at 400 mA for 35 min. After blocking using
Blotto (Pierce, Rockford, Illinois, USA), the blots were incubated in the primary antibody
solution (100 mM Tris pH7.5, 0.9 % NaCl, 5 % BSA, 0.1 % Tween-20, 0,1 % NaN3) in
which the phosphospecific antibody (either directed against c-jun phosphorylated at
serine-73 site (New England Biolabs), against p38, dually phosphorylated both at the thre-
onine-180 and the tyrosine-182 site (New England Biolabs) or against tyrosine phos-
phorylated ERK1/2 (New England Biolabs)) was diluted 1:1000. Blots were incubated in
this solution for 2 hrs. at room temperature. After washing the blots in TBS (100 mM Tris,
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0.9 % NaCl) the blots were incubated for 60 min. at room temperature in Blotto in which
the secondary antibodies (against biotinylated marker and against primary antibody) were
diluted 2000 times. Subsequently the blots were washed in TBS and incubated in chemi-
luminescent LumiGlo (New England Biolabs) reagent for 1 min. Finally the blots were
packed in food wrap and several exposures were made on Kodak X-Omat X-ray films. For
quantification the Lumi-Imager system (Boehringer) was used.
In vitro p38 MAP kinase assay
The in vitro p38 MAP kinase assay was performed according to the procedure provided by
the manufacturer (New England Biolabs, Beverly, MA, USA). In short, approximately
2x106 cells were lysed and total p38 was immunoprecipitated. The resulting imunopreci-
pitate was incubated with GST-ATF-2 fusion protein in the presence of ATP.
Phosphorylation of ATF-2 at Thr71 was measured by western blotting using a phospospe-
cific (Thr71) antibody. The same antibody was used to detect phosphorylated endogenous
ATF-2 in keratinocyte extracts.
Results
SKALP expression in human keratinocytes is strongly induced by Tumour Necrosis Factor-α
We tested a number of cytokines and growth factors that are known to be present in inf-
lamed skin and hyperproliferative skin for their ability to induce SKALP expression in
normal human keratinocytes in vitro. These stimuli (see materials and methods) were tes-
ted in a submerged culture model that allows normal differentiation of the keratinocytes,
as we have described previously [77,294]. This model uses growth factor depletion of a cultu-
re that was first grown to confluence in KGM. At 48 hrs after culturing in growth factor
depleted medium (KGM/-gf) involucrin, transglutaminase-1 and cytokeratins 1/10 are
highly expressed, while SKALP is not expressed. As a positive control for induction of
regenerative differentiation we used KGM supplemented with FCS (KGM/FCS) which 
was shown previously to induce expression of SKALP and psoriasin, both markers for
regenerative differentiation. Of all stimuli we tested, only TNF-α induced a strong, dose-
dependent increase of SKALP mRNA of similar magnitude as FCS, as assessed by northern
blot analysis (figure 1). IFN-γ and TGF-α induced a small increase in SKALP mRNA,
whereas all other cytokines and growth factors were negative (data not shown). Induction
of SKALP was found both at intermediate (0.15 mM) and high (1.85 mM) Ca2+. SKALP
expression induced by TNF-α was also found at the protein level as assessed by ELISA
(figure 2). SKALP expression reached a plateau between 5 and 20 ng/ml TNF-α; therefo-
re, a concentration of 20 ng/ml was used in further studies.
In a time course experiment TNF-α rapidly induced SKALP expression both at the mRNA
and protein level. Already 4 hrs after stimulation the mRNA signal was higher than back-
ground, and the peak of mRNA accumulation in keratinocytes could be observed at 48 hrs
after TNF-α stimulation (figure 3), whereas SKALP protein accumulation in the cultured
medium continued up to 96 hrs after TNF-α stimulation (figure 4). For comparison, kera-
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tinocyte cultures that were induced with 5% FCS showed a peak in SKALP mRNA and
protein accumulation after 48 h (figure 4).
Phosphorylation levels of MAP kinase family members remain nearly constant regardless of
keratinocyte differentiation status.
The phosphorylation status of ERK 1/2, p38 and c-jun (a major substrate of the JNK MAP
kinase) during induction of regenerative differentiation was examined, using phosphory-
lation-specific antisera on western blots. The levels of phosphorylated (activated) protein
were compared to the levels of total (phosphorylated plus unphosphorylated) protein as a
reference (see figure 5).
Using an antiserum directed against the phosphorylated serine-73 epitope, it is shown
that there is no significant change in c-jun phosphorylation levels during induction of dif-
ferentiation by FCS (figure 5, panel A, lanes 19-24). Phosphorylated c-jun is already pre-
sent, albeit at low levels, in undifferentiated keratinocytes cultured in KGM (figure 5 panel
A, lanes 13-18). When TNF-α was added to keratinocytes that were already differentiated
by growth factor depletion (KGM/-gf), a small, immediate increase in c-jun phosphoryla-
tion was seen (up to 4 hrs (figure 5, panel A, lanes 7-10)) which returned to control levels
at later time points compared to the KGM/-gf cultures.
The MAP kinase family members ERK1/2 (also known as p42/p44) are activated by
phosphorylation of a tyrosine and a threonine residue. Our experiments were performed
using a polyclonal antibody against tyrosine phosphorylated ERK1/2 (recognising both
phosphorylated ERK1 (p44) and ERK2 (p42)). ERK1/2 were found to be phosphorylated
both in undifferentiated keratinocytes (cultured in KGM) and in keratinocytes induced to
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Figure 1. Northern blot analysis of SKALP expression by cultured human keratinocytes incubated with different
concentrations of TNF-α. The concentrations of TNF-α (ng/ml) are indicated above the lanes. Confluent layers
of keratinocytes were induced to differentiate in KGM depleted of growth factors for 48 hours. Subsequently the
medium was refreshed, different concentrations of TNF-α were added and the cells were cultured for another 48
hours. Addition of TNF-α results in a concentration dependent expression of the SKALP gene that reaches its
maximum level around 121/2 ng/ml TNF-α. Foetal calf serum (FCS) a known inducer of SKALP gene expres-
sion was used as a positive control (first lane). The human Acidic Ribosomal Phosphoprotein PO (hARP) was
used for control hybridisation to check for equal RNA loading (bottom row).
differentiate with FCS (figure 5, panel B). An increase of phosphorylated ERK 1/2 is seen,
during differentiation. However, the relative phosphorylation levels remain more or less
constant as the levels of total ERK 1/2 rise concomitantly. No gross changes in relative
phosphorylation levels were noted in normally differentiated cultures that were stimula-
ted with TNF-α relative to the control culture (KGM/-gf).
The MAP kinase family member p38 can become active upon dual phosphorylation of a
tyrosine residue at position 182 and a threonine residue at position 180. We have used an
antiserum that recognises dually phosphorylated p38 (figure 5, panel C). Undifferentiated
keratinocytes contain detectable levels of dually phosphorylated p38 at time zero (KGM).
These levels remain low or decrease even further, up to 48 hrs after confluence in KGM.
The level of phosphorylated p38 remains nearly constant during the first hours after the
induction of differentiation by FCS. Twenty-four and 48 hrs after induction there is a
small increase in the p38 phosphorylation levels in the keratinocytes. Quantitative image
analysis of the blots indicated a 2.5 fold increase of p38 phosphorylation levels at 24-48
hours compared to undifferentiated cultures in KGM. When keratinocytes were induced
to differentiate by growth factor depletion (KGM/-gf), which leads to expression of the
normal differentiation phenotype, p38 phosphorylation levels were also found to be incre-
ased at 48 hrs after induction (not shown here). Addition of TNF-α to a normally diffe-
rentiated culture only induced a marginal additional increase in p38 phosphorylation at
24-48 hrs compared to the control culture (KGM/-gf). These findings indicate that alt-
hough there is a mild increase in p38 phosphorylation during differentiation, the increa-
se in p38 phosphorylation levels is not specific for the normal or regenerative differentia-
tion phenotype.
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Figure 2. Analysis of the induction of SKALP secretion by keratinocytes incubated with different concentrations
of TNF-α. The concentrations of TNF-α (ng/ml) are indicated under the columns. Confluent layers of keratino-
cytes were induced to differentiate in KGM depleted of growth factors for 48 hours. Subsequently the medium
was refreshed, different concentrations of TNF-α were added and cells were cultured for another 48 hours. The
concentration SKALP secreted in the culture medium by the keratinocytes was determined using a sandwich-
type ELISA. The concentration of SKALP secreted in the medium is given as a fold-increase relative to unstimu-
lated cells (which was 44 ng/ml). Foetal calf serum (FCS) a known inducer of SKALP gene expression was used
as a positive control (first column).
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This finding was further illustrated by measuring p38 MAPkinase activity in keratinocyte
extracts using an vitro kinase assay (figure 6) with recombinant ATF-2 as a substrate.
Similar levels of kinase activity were found both in normally differentiated keratinocytes
that do not express SKALP (KGM/-gf (figure 6, panel A, lane 2)) and in keratinocytes that
have undergone regenerative differentiation and express SKALP (figure 6, panel A, lanes 1
(KGM/FCS) and 3 (KGM/TNF)). This finding correlates with the level of phosphorylated
p38 under these culture conditions (panel B). As a reference the level of total p38 is depic-
ted in panel C. These levels of endogenous p38 expression, phosphorylation and activity,
however, do not correlate with the presence of phosphorylated, endogenous ATF-2, a
putative major downstream target for p38 (panel D).
Inhibition of p38 activity in keratinocytes abolishes SKALP expression induced by FCS and
TNF-α
To investigate whether p38 activity, present in differentiated keratinocytes, is required for
SKALP gene expression following stimulation by FCS or TNF-α, we tested the effects of
the p38 specific inhibitors SB203580 and SB202190. These pyridinyl-imidazole comp-
ounds were previously shown to be very potent, highly specific inhibitors for several p38
MAPkinase isoforms that showed no appreciable activity towards other kinases. SB202190
almost completely blocked the induction of SKALP gene expression, both at the protein
and mRNA level (figure 7 and 8). Similar results were obtained for SB203580 (data not
shown). The expression level of the household gene hARP was unaffected by the p38 inhi-
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Figure 3. Northern blot analysis of the time course of SKALP expression induced by TNF-α or FCS. The time
(in hrs) after the inducer (TNF-α or FCS) was added is indicated above the lanes. Keratinocytes were grown to
confluence in KGM. Differentiation was induced by the addition of 25 ng/ml TNF-α in the presence of 1.85
mM Ca++ or by the addition of 5 % FCS. At regular time intervals the culture medium was collected and the
cells were harvested. Approximately eight hours after TNF-α is added to the cells, SKALP mRNA levels begin to
rise. This rise continues until at least 48 hours after the induction of SKALP expression by TNF-α. At the mRNA
level the induction of SKALP expression by FCS reaches a peak 48 hrs after FCS was added to the cells. The
human Acidic Ribosomal Phosphoprotein PO (hARP) was used for control hybridisation to check for equal
RNA loading. At the bottom row the relative expression levels of SKALP are given as a fold increase in the
SKALP/hARP ratio relative to the situation at t=0 (assigned the value 1).
bitors. No apparent cytotoxicity was found either by morphological examination or LDH
release, in the concentration range that induced inhibition of SKALP expression (not
shown).
Discussion
A distinct feature of abnormal epidermal differentiation (as seen in psoriasis, after UV
irradiation, during wound healing and in epithelial neoplasia) is the de novo synthesis of
a set of proteins which are absent in normal epidermis. These include the cytoskeletal pro-
teins CK6, CK16 and CK17 and the proteinase inhibitor SKALP/elafin [12,13,77,312]. Although
these proteins are not necessarily relevant for the pathogenesis of these skin conditions per
se, their expression is tightly associated with the alteration of keratinocyte differentiation
in the context of hyperproliferation. We hypothesise that elucidation of signalling path-
ways and factors that are relevant for regulation of these de novo expressed genes, could
contribute to understanding the general mechanism of altered epidermal differentiation
as seen in e.g. psoriasis. In this study we have used the induction and regulation of SKALP
gene expression as a paradigm for the induction and regulation of regenerative differen-
tiation. We have previously shown that SKALP is highly expressed in psoriatic lesional
skin, and that it is induced upon external stress such as osmotic stress (tape stripping) [246],
chemical stress (low doses of detergent) [205] and UV-irradiation (Pfundt et al, in prepara-
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Figure 4. Time course of SKALP secretion by cultured human keratinocytes after induction by TNF-α or FCS.
Keratinocytes were grown to confluence in KGM. Differentiation was induced by the addition of 25 ng/ml TNF-
α in the presence of 1.85 mM Ca++ or by the addition of 5 % FCS. At regular time intervals (X-axis) the culture
medium was collected and the cells were harvested. The SKALP concentration in the collected culture media
was measured. The SKALP levels are given as a fold-increase relative to unstimulated cells. Approximately eight
hours after the addition of TNF-α, massive induction of SKALP expression can be measured (open triangles).
SKALP secretion continues even after 96 hours. After induction by FCS the keratinocytes express SKALP with a
peak expression after 48 hours (closed circles). Note that 48 hours after the induction was induced the cells were
given fresh culture medium explaining the drop in SKALP levels in the medium at time point 96 hours after
FCS addition.
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tion). Recently we have shown that SKALP expression can be induced in submerged cul-
ture models for keratinocyte differentiation, which are used here to test the effect of cyto-
kines and growth factors that are relevant for skin conditions such as psoriasis and wound
healing [77]. The finding that TNF-α is a potent inducer of SKALP gene expression is in
agreement with the notion that in lesional psoriatic skin the infiltrating T-lymphocytes
are of the Th1 phenotype (high levels of IL-2, IFN-γ and TNF-α) [313,314]. Interestingly, IFN-
γ and TNF-α both have a growth inhibitory effect on keratinocytes in vitro, rather than
promoting hyperproliferation which is characteristic for the regenerative differentiation
phenotype [315,316]. These results imply that the mere exposure of keratinocytes to TNF-α or
IFN-γ can not be the sole trigger to induce the complete phenotype of keratinocytes found
in hyperproliferative epidermis.
Because in vivo we have found that stress factors, as mentioned above, can induce
SKALP expression we asked whether cellular stress response pathways would be involved
in regulation of SKALP expression. The activity of these proteins in many cell types inclu-
ding keratinocytes has been described in detail. The major role of these proteins is to relay
external stress signals to the nucleus. Through multiple phosphorylation levels this path-
way changes the cellular transcription factor repertoire and thereby regulates gene expres-
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Figure 5. Analysis of the phosphorylation status of proteins of the stress response pathway (c-jun, ERK1/2 and
p38) by western blot analysis. Confluent cells were cultured for another 48 hours in either KGM before FCS sti-
mulation (KGM/FCS) or in KGM depleted of growth factors (KGM/-gf) before TNF-α stimulation
(KGM/TNF). Subsequently the culture medium was replaced by fresh medium with (FCS or TNF-α) or without
(for control analysis) stimulus. At regular time intervals (as indicated above the blots and under the lane num-
bers) the cells were harvested in sample buffer and stored for western analysis. The western blots were stained
for total and phosphorylated c-jun (panel A), ERK1/2 (panel B) and p38 (panel C). Note that only for p38,
changes in relative phosphorylation levels were found upon FCS or TNF-α stimulation. Quantitative analysis
indicated a 2.5 fold increase 48 hours after FCS stimulation (panel C, lane 24) compared to unstimulated cells
(panel C, lane 18). For TNF-α quantification revealed a slight increase in relative p38 phosphorylation (1.5 fold)
48 hours after TNF-α stimulation (panel C, lane 12) compared to unstimulated cells (panel C, lane 6). The spe-
cificity of the antibodies was checked by using control cellysates (control) containing either phosphorylated
forms of c-jun, ERK1/2 and p38 (indicated by +) or unphosphorylated forms of these proteins (indicated by -).
sion patterns of the cell or determines the fate of the affected cells (survival versus apop-
tosis) [317-319]. The ERK family members seem to act as regulators of cell proliferation and
have repressive effects on cell differentiation [320-323]. Here we have found that phosphory-
lated ERK 1/2 is present in cultured keratinocytes. Induction of differentiation did not
appreciably alter the relative phosphorylation levels of ERK 1/2. We could not examine the
effect of ERK 1/2 inhibition in this system because the addition of a pharmacological inhi-
bitor of MEK1 (PD98059), which would prevent ERK 1/2 phosphorylation resulted in cell
death even at very low concentrations (R. Pfundt unpublished results). Taken this into
account it appears that ERK1/2 is essential for keratinocyte proliferation and survival and
could play a role in the hyperproliferative component of the regenerative differentiation
phenotype.
Phosphorylated c-jun, which is major substrate of the JNK MAP kinase family mem-
ber [306,324] can homodimerise or form heterodimers with several other proteins leading to
the formation of AP-1 transcription factor complexes. It has been well documented that
AP-1 transcription factor complexes play a major role in the regulation of normal kerati-
nocyte differentiation [325-328]. In vivo, c-jun was found to be predominantly localised in the
differentiated compartment [326,329]. In our cultures phosphorylated c-jun is found both in
undifferentiated and differentiated keratinocytes. No strong increase in c-jun phosphory-
lation was noted during induction of differentiation with FCS. Addition of TNF-α to a
normally differentiated culture induced a rapid minor increase in c-jun phosphorylation.
It remains to be investigated if phosphorylated c-jun is directly involved in SKALP gene
transcription, as was suggested by promoter studies in breast tumour cells [330].
In many cell types p38 MAP kinase is known to be activated shortly (30-60 minutes)
after stimulation e.g. with UV or TNF-α [142,331,332]. This is in contrast with our experiments
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Figure 6. Analysis of p38 activity by and in vitro kinase assay. Confluent cultures of keratinocytes were allowed
to differentiate for 48 hours in different media, either with the expression of SKALP i.e. KGM/FCS (lanes 1) 
and KGM/tnf (lanes 3) or without the expression of SKALP i.e. KGM/-gf (lanes 2). The cells were harvested
either in lysis buffer for kinase assays or in sample buffer for western blot analysis. An in vitro kinase assay was
performed on the samples to measure p38 MAP kinase activity (panel A). In addition the western blot samples
were stained for phosphorylated p38 (panel B), total p38 (panel C) and phosphorylated endogenous ATF-2
(panel D).
where we did not find significant increases in p38 phosphorylation shortly after TNF-α or
serum stimulation, but rather a gradual small increase in p38 phosphorylation levels
during induction of differentiation. A recent paper describes the involvement of p38 MAP
kinase in the regulation of involucrin gene expression, an important marker for the nor-
mal terminal differentiation route in keratinocytes [181]. These findings couple normal kera-
tinocyte differentiation with p38 activity. However the family of p38 MAP kinases consists
of at least 5 isoforms (i.e. p38, p38-β, p38-β2, p38-γ and p38-δ) [137]. With respect to sub-
strate specificity and sensitivity to inhibition by the pyridinyl-imidazoles, SB203580 and
SB202190, there is some controversy in the literature. Some authors demonstrate inhibi-
tory activity against the α-, β-, and γ-isoforms [136] whereas others show that the activity of
the β1- and γ-isoforms is not affected [137]. It is however clear that the pyridinyl-imidazole
compounds are p38 specific and show little or no inhibitory effects on the ERK or JNK
MAP kinase family members [333,334]. Here we used the selective p38 inhibitors SB202190
and SB203580 to show that both FCS and TNF-α induced SKALP expression are p38
dependent. Hence, the activity of piridinyl imidazole sensitive p38 isoforms seems essen-
tial. However since we can not demonstrate a difference in p38 phosphorylation or activi-
ty levels between cells that do or do not express SKALP, we speculate that the differential
expression is regulated at a level downstream of p38, or by a p38 isoform that is inhibited
by SB202190 but is not recognised by the antibodies used in the western blot analysis and
kinase assay. With respect to p38 activity it remains unclear what downstream effects and
substrates play a role in the induction of SKALP gene expression in our in vitro models for
epidermal differentiation. It is, however, remarkable that, in the samples used for the in
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Figure 7. Northern blot analysis of the effect of different concentrations p38 MAP kinase inhibitor SB202190 on
the induction of SKALP gene expression. The cells were incubated with p38 inhibitor one hour prior to stimula-
tion by either FCS or TNF-α; RNA was isolated 48 hours after stimulation. The culture conditions are indicated
in the boxes above the blots. The concentrations SB202190 given to the cells were 0 µM (lanes 2), 3.8 µM (lanes
3), 7.5 µM (lanes 4) and 15 µM (lanes 5). Lanes 1 contain RNA of cells that were not stimulated (note that in
the case of KGM/gf and KGM these conditions are identical to those of lane 2). The human Acidic Ribosomal
Phosphoprotein PO (hARP) was used for control hybridisation to check for equal RNA loading (Bottom row).
Lanes 2-5 of FCS and TNF-α stimulated cells show a dose dependent decrease of SKALP mRNA expression by
SB202190. At the bottom row the relative expression levels of SKALP are given as a fold increase in the
SKALP/hARP ratio relative to the situation at t=0 of each culture condition (lanes 1, assigned the value 1).
vitro kinase assay, the levels of phosphorylated, endogenous ATF-2, a presumed major
downstream target for p38, do not correlate with the p38 activity found. Therefore, fin-
dings using a substrate in an in vitro kinase assay, should be interpreted with some cau-
tion, and do not necessarily reflect the kinase action within the cell. These findings, and
the fact that p38 could be involved in transcription of the involucrin gene, suggest that p38
is involved both in normal and regenerative differentiation, but could confer its activity
through different substrates. Further experiments are required to establish if p38 activity
is necessary for other aspects of epidermal differentiation as well. Preliminary experiments
indicate that not all markers for keratinocyte differentiation are equally affected by p38
inhibition (Pfundt et al, unpublished results). Because a number of antipsoriatic agents
(e.g. retinoids, vitamin D derivatives) are known to alter epidermal differentiation
pathways and can suppress SKALP expression [335,336], this raises the possibility that p38
inhibitors could be effective for therapeutic applications. It would be interesting to inves-
tigate whether the p38 pathway is effective in suppressing other features of the regenera-
tive keratinocyte phenotype as seen in psoriasis, such as hyperproliferation and increased
cytokine production. Based on the fact that p38 was initially discovered as an inducer of
cytokine production [140] and its effect on keratinocyte differentiation, we would hypothe-
sise that p38 MAP kinase inhibitors could be potentially useful as a new generation of
antipsoriatic agents.
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Figure 8. The effect of different concentrations p38 inhibitor SB202190 on the secretion of SKALP by keratino-
cytes. The cells were incubated with p38 inhibitor one hour prior to stimulation by either FCS or TNF-α,
SKALP protein concentrations in the culture media were measured 48 hours after stimulation. SKALP produc-
tion is given as folds increase relative to unstimulated keratinocytes. Error bars represent the standard error of
the mean (SEM) based on three independent experiments. Black columns represent the relative increase in
SKALP secretion by the keratinocytes that were stimulated by either FCS (panel A) or TNF-α (panel B). Grey
columns represent the relative increase in SKALP secretion in the control conditions, i.e. KGM (panel A) or
KGM/gf (panel B). Note that both FCS and TNF-α induced SKALP expression show a dose dependent decrease
by the addition of the p38 inhibitor SB202190 (p<0.05, ANOVA).
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Abstract
Recently, it was shown that ultraviolet B irradiation of human skin leads to activation of
cellular stress response pathways that induce expression of metalloproteinases. These fin-
dings, which offer an explanation at the molecular level for UVB-induced photodamage
to dermal collagen and elastin, prompted us to investigate if UVB could also induce pro-
tective mechanisms in human skin in vivo. Here we describe the response of human epi-
dermis and cultured human keratinocytes to UVB irradiation, with respect to the induc-
tion of genes that are associated with host protection against tissue damage and infection,
in the acute phase of cutaneous inflammation. Two of these genes, SKALP/elafin and SLPI
both serine proteinase inhibitors and antimicrobial proteins were found to be highly
expressed following UVB irradiation of human skin in vivo. Expression of these genes by
differentiated keratinocytes was preceded by activation of cellular stress response path-
ways such as phosphorylation of c-jun and p38 MAP kinase as determined in situ by
immunohistochemistry using phosphorylation-specific antisera. In vitro studies with cul-
tured keratinocytes indicated that SKALP and SLPI expression could be induced by TNF-
α or serum, and that this process was dependent on p38 MAP kinase. Although UVB irra-
diation of cultured keratinocytes was followed by a huge increase in p38 activation, this
was not sufficient to increase SKALP or SLPI expression levels suggesting that induction
of these genes by UVB in vivo require additional signals. More strikingly, inhibition of p38
MAP kinase activity following UVB irradiation resulted in massive cell death, suggesting
that p38 MAP kinase could have a dual role in the cutaneous response to UVB. These data
show that UVB, in addition to its deleterious effects on dermal matrix proteins, can also
rapidly induce protective mechanisms in human epidermis directed at inhibition of seri-
ne proteinases and control of infection.
Introduction
Exposure to ultraviolet B light (UVB) has a strong impact on human skin, and causes
acute and long term changes. Acute effects include altered gene expression, induction of
inflammation and immunosuppression. Long term effects of chronic UVB exposure are
carcinogenesis, and damage to dermal extracellular matrix proteins such as elastin and
collagen. UVB exposure initiates a cascade of inflammatory events that modify gene
expression profiles and alters the innate and adaptive immune system of the skin. The
exact sequences of events and cellular interactions that are critical for induction of this
response in vivo have not yet been fully elucidated. However, at the cellular level both the
keratinocytes and the Langerhans cells, and at the molecular level DNA photoproducts
and cytokines have been implicated as key players in this response. At the level of cellular
signalling it was shown in vitro, using cultured keratinocytes, that cellular stress response
pathways such as the MAP kinase cascade and the NFκB pathway are activated following
UV irradiation [130,133,337-339]. Many studies have reported that a high dose of UVC radiation,
to which human are not normally exposed, activates the JNK pathway [340]. More recent
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studies have shown that also physiologically relevant UVB doses are able to activate p38,
JNK and to a lesser extent ERK in cultured keratinocytes. The initial signal is probably
generated at the cell surface and includes clustering of cell surface receptors for growth
factors or cytokines [341] although the exact mechanism remains to be elucidated. Similarly,
low doses of UVB were found to cause activation of NFκB, independently of chromo-
somal DNA damage [338,342]. Signalling by (pro)inflammatory cytokines has been suggested
as a mechanism by which UVB effects are mediated [341,343-345]. Recently it was suggested 
that UVB induced signalling events such as activation of NFκB and AP-1 cause enhanced
transcription of metalloproteinase genes, which leads to degradation of collagen and elas-
tin [133,346,347]. Other examples of UVB induced alterations in gene expression pattern 
of human keratinocytes in vivo are the upregulation of ICAM-1 [348], upregulation of cyto-
keratins (CK)1/10 and 5/14 [349], and induction of CK16 [350]. The outcome of UVB irra-
diation of human skin is strongly dose-dependent. High doses of UVB will lead to the for-
mation of apoptotic cells (sunburn cells) that is initiated via a p53 dependent pathway,
and causes removal of severely damaged cells, thus minimising the risk of skin cancer [351,352].
Lower doses of UVB allow cell survival and repair of genetic damage, but the price of the
cell survival response is a state of local and systemic immunosuppression, which in itself
may be deleterious and contribute to cutaneous carcinogenesis [353,354].
In previous studies we have described the expression of genes in human epidermis that
are involved in host protection during skin inflammation, barrier disruption and infec-
tion. We found that under such conditions (psoriasis, wound healing) the proteinase inhi-
bitor SKALP/elafin, which protects against epidermolysis and was recently shown to have
antibacterial properties [335], and SLPI a proteinase inhibitor with anti-microbial properties
are strongly induced [294,310,356]. Recently we have found that induction of SKALP and SLPI
gene expression in cultured keratinocytes is dependent on p38 MAP kinase activation
(Pfundt et al, Arch.Dermatol.Res., accepted). Other studies have indicated that SKALP 
is transcriptionally regulated by AP-1 [301,330], whose activity is regulated by the c-jun N-
terminal kinase (JNK) stress response pathway. Since SKALP/elafin and SLPI were found
to be induced in human skin by osmotic and chemical stress, we were interested to know
if these genes were also induced by UVB irradiation, and to determine the possible role of
cellular stress response pathways herein. We found that UVB irradiation of human skin in
vivo causes induction of SKALP and SLPI expression by the suprabasal keratinocytes,
which is preceded by activation of cellular stress response pathways.
Material and methods
UV irradiation of human skin
A group of 9 healthy volunteers (18-36 years old) with no past or present history of skin
diseases participated in this study. All subjects were irradiated using a Waldman UV 7001
k light cabin. For each individual the M.E.D. (minimal erythema dose (24 hrs. After irra-
diation)) was determined. The subjects were irradiated with three different doses of UV
light, 0.5 M.E.D., 1 M.E.D. and 2 M.E.D.. Four-millimetre full thickness punch biopsies
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were taken of the non-irradiated skin and 2 hrs, 4 hrs, 16 hrs, 24 hrs and 48 hrs after the
skin had been irradiated. The biopsies were fixed in 3.8 % buffered formalin and embed-
ded in paraffin. Six-µm sections of these biopsies were used for immunohistochemical
characterisation.
Immunohistochemistry
Biopsies were fixed in buffered 3.8% formalin for at least 4 hours and processed for
embedding in paraffin. Sections (6µm) were mounted on 3-aminopropyltriethoxy-silane
(Sigma, St Louis MO, USA) coated slides. Sections were deparaffinized and rehydrated.
For antigen retrieval from paraffin sections, the slides were pre-treated two times 5 min in
10mM citrate buffer for Ks8.12 (CK16), for MIB-1 (Ki-67) and for anti c-jun-p using a
microwave oven (Miele, M720) at 450 Watt. For immunohistochemical detection of
NFκB, SLPI/ALP and SKALP/elafin no pre-treatment was necessary. After preïncubation
with 20% normal swine or rabbit serum the slides were incubated for 60 min with the pri-
mary antibodies and washed with phosphate-buffered saline (PBS). Samples for the detec-
tion of NFκB, phosphorylated c-jun, CK16 and Ki67 were subsequently incubated with
the appropriate biotinylated secondary antibody for 30 minutes. To enhance the staining
the sections were incubated with an Avidin-Biotin-Complex (ABC) after which they were
developed with metal enhanced DAB as a chromogenic substrate. Samples for the detec-
tion of SLPI and SKALP were incubated with peroxidase conjugated secondary antibodies,
and these sections were developed with aminoethylcarbazole (AEC) as chromogenic sub-
strate. When desirable, the slides were counterstained with Mayer’s haematoxylin (Sigma,
St Louis, MO, U.S.A.) and mounted in glycerol gelatine. Apoptotic cells were identified
using TUNEL staining as described before [357]. Immunohistochemical detection of phos-
phorylated p38 was performed using an enhancement kit for rabbit polyclonal antibodies
(CSA kit, DAKO, CA, USA) as described by the manufacturer using polyclonal rabbit-anti-
dually-phosphorylated-p38 (New England Biolabs, USA). Appropriate controls with pre-
immune sera, blocking peptides or omission of the primary antibodies were performed.
Cell cultures
Primary keratinocytes were seeded in 6 well culture dishes and cultured until confluence
in keratinocyte growth medium (KGM) as described before [77]. KGM was composed of
keratinocyte basal medium (KBM (Biowhittaker, Walkersville, Maryland, USA); 0.15 mM
Calcium), supplemented with ethanolamine (0.1 mM) (Sigma, St.Louis, USA), phosp-
hoethanolamine (0.1 mM) (Sigma, St.Louis, USA), bovine pituitary extract (BPE; 0.4
%v/v) (Biowhittaker, Walkersville, Maryland, USA), insulin (5 µg/ml), (Sigma, St. Louis,
USA), hydrocortisone (0.5 µg/ml) (Collaborative Research Inc.), Recombinant Mouse
Epidermal Growth Factor (EGF; 10 ng/ml) (Sigma, St. Louis, USA), penicillin (100 U/ml)
(Gibco, Breda, the Netherlands) and streptomycin (100 µg/ml) (Gibco, Breda, the
Netherlands). Induction of keratinocyte differentiation was established by switching the
cells at confluence either to KGM supplemented with 5 %v/v FCS  (KGM/FCS) (FCS from
Seralab, Nistelrode, the Netherlands) resulting in regenerative differentiation or to KGM
depleted of growth factors (BPE, Insulin, EGF and hydrocortisone (KGM-GF)) [265] resul-
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ting in normal keratinocyte differentiation. Normally differentiated keratinocytes were
stimulated either with Tumour Necrosis Factor-alpha (TNF-α (Boehringer Mannheim)),
FCS (Seralab) or with UV-B irradiation. Ultra violet light was generated using a Fluo-Link
(Vilber Lourmat) with a peak wavelength of 311 nm.
Enzyme-linked immunosorbent assay (ELISA) for measurement of SKALP/elafin levels
SKALP/elafin and ALP/SLPI concentrations in supernatants of cultured human keratino-
cytes were measured using sandwich-type ELISA. In short, microtiter plates (96 flat bot-
tom wells) were coated overnight with either goat anti-SKALP/elafin antiserum or with
monoclonal anti-SLPI (clone 31). After washing of the plate with PBS/0.05% Tween-20,
microtiter plates were blocked and probed with the dilutions of test samples and standards
for 2 hrs at 37˚C. As second antibodies we used either rabbit anti-SKALP/elafin antiserum
or rabbit anti-SLPI antiserum with 2.5% normal goat serum (Vector Laboratories,
Burlingame, USA). Subsequently the microtiterplates were incubated with peroxidase-
conjugated swine-anti-rabbit IgG (DAKO, Glostrup, Danmark) with 2.5% normal goat
serum during 60 minutes at 37˚C. Finally o-phenylenediamine dihydrochloride (OPD)
(Pierce, Rockford, Illinois, USA) was added as chromogenic substrate for 15 minutes at
RT. This enzyme reaction was stopped by the addition of 4 M H2SO4. Absorbencies were
measured at 492 nm and at 655 nm. The SKALP/elafin and ALP/SLPI concentrations in
the test samples were read from a calibration curve of recombinant SKALP/elafin or
ALP/SLPI.
Western blotting
Using the phosphospecific antibodies kits supplied by New England Biolabs (Beverly, MA,
USA) we performed Western blotting and protein detection according to the protocol of
the manufacturer. In short, cultured keratinocytes were lysed in sample buffer ((approxi-
mately 5000 cells per µl) 62.5 mM Tris pH6.8, 10 % glycerol, 0.1 % bromphenol blue, 2 %
SDS, 50 mM DTE). Cell lysates were sonified two times 10 sec. and subsequently incuba-
ted for 3 min. at 100˚C. Together with caleidoscopic and biotinylated markers, samples
were run on a 10 % SDS PAGE gel (biorad) in Tris-Glycine-SDS buffer (Biorad) at 175
volts. Gels were electro-blotted on PVDF blotting paper (Biorad) in Tris-Glycine-SDS
buffer supplemented with 20 % methanol at 400 mA for 35 min. After blocking using
Blotto (Pierce, Rockford, Illinois, USA), the blots were incubated in the primary antibody
solution (100 mM Tris pH7.5, 0.9 % NaCl, 5 % BSA, 0.1 % Tween-20, 0,1 % NaN3) in
which the phosphospecific antibody (either directed against c-jun phosphorylated at seri-
ne-73 site (New England Biolabs), against p38, dually phosphorylated both at the threo-
nine-180 and the tyrosine-182 site (New England Biolabs) or against tyrosine phosphory-
lated ERK1/2 (New England Biolabs)) was diluted 1:1000. Blots were incubated in this
solution for 2 hrs. at room temperature. After washing the blots in TBS (100 mM Tris, 0.9
% NaCl) the blots were incubated for 60 min. at room temperature in Blotto in which the
secondary antibodies (against biotinylated marker and against primary antibody) were
diluted 2000 times. Subsequently the blots were washed in TBS and incubated in chemi-
luminescent LumiGlo (New England Biolabs) reagent for 1 min. Finally the blots were
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packed in food wrap and several exposures were made on Kodak X-Omat X-ray films. For
quantification the Lumi-Imager system (Boehringer) was used.
Results
UVB irradiation of human skin causes induction of the regenerative epidermal differentiation
program as witnessed by expression of SKALP, SLPI and CK16 whereas apoptosis is limited.
Normal human skin was irradiated with different doses of UV-B light (peak wavelength of
311 nm) ranging from 0.5 – 2 MED (1 MED is reached after irradiating an average skin
type with 0.05-0.15 J/cm2 of UV-B light). The effects of UV-B on the expression of host
defence proteins SKALP/Elafin and ALP/SLPI, the differentiation specific proteins CK16
and involucrin and the proliferation rate of the epidermal keratinocytes were studied by
immunohistochemistry. Twenty-four to 48 hours after irradiation we observed a high de
novo expression of a number of proteins. SKALP, a protein that is otherwise absent from
normal human epidermis (figure 1A) but is found in hyperproliferative skin (psoriasis,
wound healing) is also expressed in the stratum spinosum after UV-B irradiation (figure
1B). SLPI, a proteinase inhibitor with antimicrobial properties, which is normally restric-
ted to the granular layer (figure 1C), was also found in the stratum spinosum following
UV-B irradiation (figure 1D). Involucrin, a structural protein involved in the formation of
the cornified envelope, which is normally restricted to the granular layer (figure 1E), was
also found in the stratum spinosum following UVB irradiation (figure 1F). In addition, in
figure 1G/1H the induction of cytokeratin 16 a classical marker for epidermal activation
is shown, indicative for a switch of differentiation program by these suprabasal keratino-
cytes. As can be seen in figure 1, the localisation of SKALP, SLPI and CK16 positive cells is
distinct from that found in psoriatic epidermis where the entire stratum spinosum is posi-
tive. Following UV-B the upper layers remain negative and a band of positive cells is obser-
ved in the centre of the epidermis. As assessed by the expression of the proliferating nucle-
ar antigen Ki67, within 24-48 hours the percentage proliferating keratinocytes in the basal
layers of the epidermis increased from approximately 5% in normal skin (figure 1I) up to
80-90 % in skin irradiated with 2 MED of UV-B (figure 1J). This means that nearly all
cells of the germinal layers are actively cycling, very similar to what is found in psoriatic
skin or following skin injury.
Previous studies have shown that p53 mediated apoptosis is an important event in the
surveillance against UV-B induced carcinogenesis [351,358]. At the doses used here (0.5 to 2
MED), a distinct increase in the number of p53 positive cells and in the intensity of p53
staining was found (not shown). The number of apoptotic cells as determined by coun-
ting of sunburn cells on H&E stained sections, or as determined by TUNEL staining was
limited (figure 1K/1L). Only scattered apoptotic cells could be seen in the upper levels of
the epidermis following 2 MED irradiation (figure 1L).
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Figure 1. UV-B irradiation induces epidermal proliferation
and expression of genes involved in host protection. Normal
human epidermis does not express the proteinase inhibitor
and antibacterial protein SKALP (1A). However 48 hours
after 2 MED of UV-B irradiation high expression levels of
SKALP can be detected in the suprabasal layers of the irradia-
ted epidermis (1B). A similar effect can be seen for the pro-
teinase inhibitor and antimicrobial protein SLPI (1C and 1D)
although SLPI is also expressed in the granular layer of nor-
mal epidermis (1C). Involucrin, a protein involved in corni-
fied envelope formation, is expressed in the stratum granulo-
sum of normal epidermis (1E) whereas after UV-B irradiation
it can be found throughout the suprabasal compartment
(1F). The expression of cytokeratin 16, a marker for hyper-
proliverative epidermis in not expressed in normal skin (1G)
but is also upregulated after UV-B irradiation (1H). Note that
the expression of SKALP, SLPI, CK16 and to a lesser extent
involucrin, is restricted to the middle layers of the stratum
spinosum of the irradiated epidermis (1B/1D/1F/1H). In nor-
mal epidermis only 5 % of the basal keratinocytes is prolif-
erative as assessed by the expression the nuclear antigen Ki67
(1I) 48 hours after irradiating the epidermis with 2 M.E.D. of
UV-B light the complete basal layer stains positive for Ki67
indicating a massive recruitment of cells into the cell cycle
(1J). Identification of apoptotic cells by TUNEL staining
revealed no apoptotic cells in normal skin (1K) and few
apoptotic cells in the upper layers of the stratum spinosum
after mild (2 MED) UV-B irradiation (see arrows (1L)).
Stress response pathways are highly activated directly after UV-B irradiation
We used conventional and phospho-specific antibodies against several cell stress related
proteins (p38, c-jun, and NFκB) in order to investigate the activity/localisation of these
proteins in human epidermis in the course of the cellular response to UV-B irradiation. In
normal skin phosphorylated c-jun can only be found in the granular layer of the epider-
mis where approximately 5 % of the cells stain positive (figure 2D). However when nor-
mal skin is irradiated with UV-B light (2 MED), within 2-4 hours massive levels of phosp-
horylated c-jun can be found throughout the whole epidermis (figure 2E). Even 24-48
hours after UV-B irradiation, levels of phosphorylated c-jun are still markedly elevated
(figure 2F) indicating that c-jun phosphorylation is an immediate response to UV-B that
persists for a longer period of time. Phosphorylated p38 MAP kinase can not be detected
in the keratinocytes of normal skin (figure 2A). When the skin is irradiated with UV-B
light (2 MED) within 2 hours high levels of dually phosphorylated p38 can be detected
(figure 2B). Unlike c-jun these phosphorylation levels return back to almost normal
within 16-24 hours (figure 2C) suggesting that p38 activity is a rather early response to
UV-B irradiation in vivo. In normal skin the transcription factor NFκB is mainly localised
in the cytosol where it is held inactive by binding to IκB (figure 2G). When skin is
irradiated with UV-B light (2 MED) there is a translocation of NFκB to the nuclei of
the keratinocytes as observed by profound nuclear staining of the keratinocytes 2 hours
after the irradiation (figure 2H). This nuclear staining decreases already after 4 hours (not
shown) and returns to normal levels within 16-24 hours after skin irradiation (figure 2I).
Taken together, these results indicate that a number of proteins that are part of the mam-
malian stress response pathway are activated prior to the transition from normal to
regenerative epidermal differentiation.
UV-B irradiation of cultured keratinocytes is not sufficient to induce SKALP or 
SLPI expression in vitro
In order to further study the role of UVB on the activation of epidermal keratinocytes we
used a culture model that we have described previously which allows normal differentia-
tion in a submerged system [77]. Confluent keratinocyte cultures were allowed to differen-
tiate for 48 hours by depleting the culture medium of its growth factors. These differen-
tiated keratinocyte cultures were then irradiated with a non-cytotoxic doses of UV-B light
(0.015-0.025 J/cm2; peak wavelength 312 nm). As a positive control we used TNF-α (25
ng/ml) or 5% FCS which were previously shown to be potent inducers of SKALP [294] and
SLPI [356] gene expression. In contrast to TNF-α and FCS, UV-B irradiation did not induce
significant increases of SKALP or SLPI protein in the culture media, up to 48 h (figure 3).
When higher doses of UV-B were applied this resulted in cytotoxicity as determined by
LDH release (not shown).
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UV-B irradiation of keratinocytes results in a rapid and extensive phosphorylation 
of p38 MAP kinase and c-jun
The in vitro findings suggested that UV-B induced expression of SKALP and SLPI in vivo,
as described above, was dependent on additional factors that were absent in culture.
Because from previous studies (Pfundt et al, submitted) it was known that SKALP expres-
sion, induced by FCS or TNF-α, was dependent on p38 MAP kinase activity and studies
on the SKALP/elafin promoter have suggested a role for AP-1 [301,330], we investigated
whether activated p38 MAP kinase and c-jun could be found in the UV-B irradiated cul-
tures. Using western blot analysis with the phosphorylation specific antibodies against p38
and c-jun we checked the activation status of these proteins in cultured keratinocytes at
different time points after UV-B irradiation. Like normal skin in vivo, in normal differen-
tiated cultured keratinocytes the basal levels of phosphorylated c-jun are low (figure 4,
panel C, lane 1). However upon UV-B irradiation, within 30 minutes, the phosphorylation
levels of c-jun strongly rise (figure 4, panel C, lane 2). This increase persists for 48 hours
after irradiation (figure 4, panel C, lanes 3-5) and drops close to initial levels 72 hours after
UV-B irradiation (figure 4, panel C, lane 6), more or less similar to the in vivo situation.
In normal differentiated cultured keratinocytes detectable levels of phosphorylated p38
are present (figure 4, panel A, lane 1). Like c-jun, p38 is heavily phosphorylated shortly
after the keratinocytes have been irradiated with UV-B (figure 4, panel A, lane 2). This
increase in phosphorylation status of p38 lasts for at least 6 hours after irradiation 
(figure 4, panel A, lanes 3-4). Normal p38 phosphorylation levels are reached 48 hours
after irradiation, indication that, as in vivo, activation of p38 is an early response to UV-B
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Figure 2. Members of stress response pathways are activated
upon UV-B irradiation of human skin in vivo. In normal
skin stress response proteins like p38 or c-jun are not pre-
sent in their phosphorylated (activated) forms (2A and 2D).
However when skin is irradiated with UV-B light (2MED)
within 2 hours phosphorylation of these proteins is already
detected (2B and 2E). p38 is dephosphorylated within 16
hours after irradiation (2C) whereas high levels of phospho-
rylated c-jun remain in the epidermis until 16-24 hours
after UV-B irradiation (2F). In addition to phosphorylation
of c-jun and p38 also the cellular stress associated transcrip-
tion factor NFκB is being activated and translocated to the
nucleus. In normal skin it is mainly localized in the cyto-
plasm of the keratinocytes (2G). Whereas upon UV-B irra-
diation within 2 hours translocation of NFκB to nuclei was
found (2H). Sixteen hours after the irradiation NFκB is
localized again mainly is the cytoplasm (2I).
irradiation. The kinetics of p38 and c-jun phosphorylation are distinct from those found
following the addition of FCS or TNF-α, which do not cause an immediate burst of
phosphorylation, but only a mild, gradual increase (Pfundt et al, Arch.Dermatol.Res.,
accepted).
Inhibition of p38 directly after UV-B irradiation in vitro results in massive cell death 
From the experiments described in the previous section it was clear that the lack of SKALP
induction by UV-B in vitro was not due to an absence of p38 activation, since huge levels
of phosphorylated p38 were found directly after UV-B irradiation. We therefore conside-
red the possibility that UVB-induced p38 hyperphosphorylation could still be involved in
regulation of basal levels of SKALP expression, or alternatively could be a negatively regu-
lating factor. Surprisingly, treatment of keratinocytes with a pharmacological p38 inhibi-
tor (SB202190) directly after or before UV-B irradiation results in massive cell death. Cell
death was obvious by morphological criteria, and was quantified by measurement of LDH
release in the media (see figure 5). The same concentrations of these inhibitors are non-
cytotoxic for keratinocytes cultured under basal conditions, or when stimulated with FCS
or TNF-α. When keratinocytes are treated with SB202190, 24 hours after exposure to UV-
B, significantly lower levels of cytotoxicity were observed (not shown). These observations
suggest that the early activation of p38 in response to UV-B irradiation could be impor-
tant in processes involved in cell survival after UV-B irradiation.
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Figure 3. UV-B irradiation does not directly induce SKALP or ALP gene expression in cultured human epider-
mal keratinocytes. The induction of SKALP secretion was measured 48 hours after stimulating the cells with
TNF-α, FCS or UV-B irradiation (150 and 225 J/m2). The concentration SKALP secreted in the culture medium
by the keratinocytes was determined using a sandwich-type ELISA. The concentration of SKALP secreted in the
medium is given as a fold-increase relative to unstimulated cells. Treatment of keratinocytes with FCS or TNF-α
results in SKALP secretion whereas SKALP is not induced by UV-B irradiation. Error bars indicate the standard
error of the mean (SEM).
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Discussion
In a number of in vivo and in vitro studies, UVB-induced activation of cellular stress
response pathways such as the MAP kinase cascade and the NFκB route has been demon-
strated in cultured keratinocytes or in vivo in whole skin extracts using biochemical
assays. The activation of these proteins has been implicated in several physiological
responses to UVB irradiation. JNK activation has been implicated in the expression of
several AP-1 dependent genes like e.g. the matrix metalloproteases. It has been demon-
strated that repression of AP-1 formation by retinoic acid prevents the expression of these
proteinases. These findings, that offer an explanation at the molecular level for UVB
induced photodamage to dermal collagen and elastin [133,134], prompted us to investigate
whether the opposite was also true, i.e. the induction of protective mechanisms by UVB.
Our studies show that SKALP and SLPI, which are both implicated in host defence and
protection [294,356], are highly upregulated. In addition, this is, to our knowledge, the first in
situ demonstration of the cellular source of the phosphorylating activities induced upon
UVB irradiation. Using phosphorylation-specific antisera we found that high levels of
phosphorylated p38 MAP kinase and c-jun can be found in the nuclei of basal and supra-
basal keratinocytes. Previous studies by others and us have shown that p38 and c-jun
(being a component of the AP-1 complex) are involved in transcriptional regulation of
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Figure 4. UV-B irradiation of cultured human epidermal keratinocytes results in the activation of stress respon-
se pathways. The phosphorylation status on c-jun and p38 was assessed by western blot analysis using phospho-
rylation specific antibodies. In normally differentiated keratinocytes in vitro, low levels of phosphorylated (acti-
vated) p38 and c-jun can be found (lanes 1 panels A and C). Upon UV-B irradiation (150 J/m2) p38 and c-jun
are rapidly (within 30 min) phosphorylated (lanes 2). The levels of phosphorylated c-jun and p38 remain equal-
ly high 60 min (lanes 3) and 240 min (lanes 4) after UV-B irradiation. After 48 hours (lanes 5) the phosphoryla-
tion levels of p38 returned back to the initial level (panel A) whereas the level of phosphorylated c-jun remains
high (panel C). After 72 hours also the level of phosphorylated c-jun returns back to starting level (lane 6, panel
C). As a reference for total amounts of c-jun and p38 in the keratinocytes (phosphorylated as well as unphosp-
horylated) western blot analysis was also performed using antibodies recognizing both phosphorylated and
non-phosphorylated forms of the proteins (panels B and D).
SKALP [330,301] (Pfundt et al, submitted). Moreover, AP-1 has been implicated in the regula-
tion of a significant number of epidermal genes [326]. Our observations that c-jun phos-
phorylation levels rise quickly after UV-B irradiation and remain high for several days
indicate that c-jun complexes could be involved both in early immediate and late adap-
tation processes. This in contrast to p38 activation, which is only an early event in respon-
se to UV irradiation, already 48 hours after UV-B irradiation, the levels of phosphorylated
p38 drop to initial amounts. In our in vitro studies we could not find a direct effect of
UVB irradiation on cultured keratinocytes, with respect to SKALP expression. This sug-
gests that in vivo other secondary factors generated by UVB are required. Two major indu-
cers of SKALP expression in vitro (serum and TNF-α) are known to be present in in-
flamed skin. Firstly, Andriessen et al [359] have shown that during inflammation, plasma
proteins from the oedematous dermis enter the epidermal compartment which is nor-
mally impermeable for high molecular weight proteins from the circulation. Secondly,
Strickland et al [360] have shown that UVB irradiation of human skin causes a strong
upregulation of TNF-α. We would hypothesise that TNF-α production and oedema-
formation resulting from UVB irradiation can induce SKALP and SLPI expression. Our in
vitro experiments revealed a second, rather unexpected finding. Inhibition of p38 activity
by SB202190 at non-cytotoxic concentrations inhibits serum or TNF-α induced SKALP
expression, as we have shown before. However when SB202190 was applied shortly before
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Figure 5. Inhibition of p38 activity leads to massive cell death in response to UV-B irradiation. The cytotoxic
effect of the inhibition of p38 directly after stimulating the cells with FCS, TNF-α or UV-B irradiation was
measured. As a read out for cytotoxicity, LDH activity was measured in the culture medium 48 hours after sti-
mulation. When unstimulated cells (black bars) or cell stimulated with FCS (white bars) or TNF-α (gray bars)
were treated with a p38 inhibitor, low levels of cytotoxicity could be measured after 48 hours (<5% at 10 µM
SB202190). However when cells that were irradiated with UV-B (150 J/M2 (dotted bars) or 225 J/m2 (striped
bars)) were treated with SB202190, high levels of cytotoxicity could be found after 48 hours (up to 100% at 10
µM SB202190). Note that irradiation with 225 J/m2 results in 20 % cytotoxicity even when cells are not treated
with SB202190.
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or after UVB irradiation massive cell death was observed as assessed by LDH release.
Because only a minor (two-fold) increase in the number of TUNEL positive cells was
observed, and a mild increase in caspase activity (not shown) most of the cells appear to
die without going into apoptosis. The exact mechanism and kinetics of UVB induced cell
death in combination with p38 inhibition require further investigation. These observa-
tions are in contrast with recent data on a pro-apoptotic effect of p38 [141].
An important conclusion that can be drawn from our observations is that instead of being
merely subject to local and systemic responses to UVB, keratinocytes are very active play-
ers in this process. It becomes more and more clear that keratinocytes can express an
impressive array of proteins with various protective properties. Either constitutively, or
upon cellular stress the epidermal keratinocytes can load the epidermis and dermis with
antiviral, antibacterial and anti-inflammatory activity, thereby regulating immune
responses and fighting potential pathogens [355,356,361-364]. SLPI, originally described as an
inhibitor of leukocytic proteinases also displays antiviral and antibacterial activity and a
recent study has identified SLPI as an anti-inflammatory protein that interferes with
NFκB activation [365]. We have previously shown that SLPI associates with the dermal elas-
tic fibers, and preliminary investigations have shown that upon chronic UVB irradiation,
SLPI accumulates in the dermis, thereby protecting against elastolysis (Pfundt et al, unpu-
blished observations). Similarly we have shown in a previous study that SKALP expression
by keratinocytes can directly result in protection against elastase mediated tissue destruc-
tion [294]. I a recent article of Zaidi et al overexpression of SKALP in a transgenic mouse
results in protection against elastase mediated cardiac dysfunction [366]. All these studies
show that proteinase inhibitors like SKALP and SLPI play crucial roles in regulating acute
inflammatory responses. Although chronic exposure of human skin to UVB will even-
tually lead to photodamage of dermal matrix proteins, UVB can apparently also recruit
cellular defence mechanisms. Our data illustrate that UVB-induced metalloproteinase
induction and serine proteinase inhibitor induction are two sides of the same coin.
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Abstract
Recently we showed that human epidermal keratinocytes express the extracellular matrix
protein tenascin-C during wound healing, but not in normal adult skin. In order to gain
further insight into the regulation of epidermal tenascin-C expression, we tested the effect
of various stimuli on tenascin-C expression by cultured keratinocytes. Our results indica-
te that IL-4 is a very strong inducer of tenascin-C protein and mRNA expression in nor-
mal keratinocytes. Furthermore, TNF-α and IFN-γ moderately increased tenascin-C
expression. All other cytokines and growth factors that we tested, including various factors
that stimulate tenascin-C expression in mesenchymal cells, did not significantly affect
tenascin-C secretion by cultured keratinocytes. The regulation of tenascin-C expression in
keratinocytes is distinct from that of fibronectin, since IL-4 and IFN-γ did not affect fibro-
nectin expression in our experiments and TNF-α only slightly increased fibronectin levels.
To investigate the role of cellular stress response pathways that can be activated by TNF-α
in the regulation of tenascin-C expression, we tested the effect of different inhibitors and
an activator of these intracellular signalling cascades. The results show that the p38 MAP-
kinase pathway is not involved in TNF-α-induced tenascin-C expression in cultured kera-
tinocytes. Activation of the JNK/SAPK-1 pathway by the addition of sphingomyelinase
resulted in a dose-dependent increase of tenascin-C expression. Tenascin-C expression by
squamous carcinoma cell lines was differentially affected by the cytokines that stimulated
tenascin-C expression in normal keratinocytes: TNF-α again increased tenascin-C secre-
tion, but IL-4 and IFN-γ had little effect. We conclude that there are distinct regulation
mechanisms for tenascin-C expression in normal keratinocytes, tumour-derived keratino-
cytes and mesenchymal cells. The observation that tenascin-C is abundant in inflamed
skin is a strong indication that inflammatory cytokines such as IL-4, TNF-α and IFN-γ
could also be involved in the regulation of epidermal tenascin-C expression in vivo.
Introduction
Tenascin-C is a large hexameric extracellular matrix glycoprotein with a modular struc-
ture. For review see [367,368]. Tenascin-C is abundant during embryogenesis, particularly at
epithelial-mesenchymal interaction sites, but expression is limited in adult healthy tissues.
In adult human skin, tenascin-C is present in the dermis where it is sparsely distributed at
the dermal-epidermal junction and surrounds blood vessels and epidermal adnexal struc-
tures [369-371]. Tenascin-C expression in skin is markedly increased, however, in pathologic
conditions that are characterised by inflammation and epidermal hyperproliferation,
like psoriasis [372], epidermal tumours [373,374], UV-irradiation [375,376] and injury [370,377,378,] (and
references herein). In vitro studies suggested various functions for tenascin-C, including
modulation of cell proliferation, differentiation, adhesion and migration, and suppression
of the immune response [367,368]. The role of tenascin-C in vivo, however, remains elusive
especially because knocking out the tenascin-C gene in mice caused no marked phenoty-
pic changes [379,380]. Interestingly, however, in man deficiency for tenascin-X, which is anot-
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her member of the tenascin family, affects skin, is associated with Ehlers-Danlos syn-
drome [381].
Previously we showed that tenascin-C expression in human skin is not confined to
mesenchymal cells in the dermis: epidermal keratinocytes can produce tenascin-C as well,
and they do so in vivo during wound healing and when cultured in vitro, but not in nor-
mal non-wounded skin [377]. Aukhil and colleagues also observed epidermal tenascin-C
expression in healing wounds in rat [382]. In other studies, tenascin-C protein [383-385] and
mRNA [386] was detected in epidermal tumour cells. These data indicate that keratinocytes
can also produce tenascin-C in vivo in case of malignancy.
Many factors have been described that modulate tenascin-C expression, and the regula-
tion of tenascin-C expression seems to be cell-type specific (reviewed in [367,387]). Among the
factors that stimulate tenascin-C expression by mesenchymal cells and tumour cell lines
are TGFβ1, EGF, KGF, PDGF, bFGF, TNF-α, IL-1α, and IL-4. Knowledge of the regulation
of tenascin-C expression by skin cells, however, is limited. Immunohistochemical studies
showed that tenascin-C in skin is more abundant in conditions that are characterised by
inflammation and epidermal hyperproliferation, suggesting that inflammatory cytokines
and growth factors could be involved in the induction of tenascin-C expression. Recently
Makhluf et al. indeed showed that addition of IL-4, and to a lesser extent PDGF and bFGF,
increased tenascin-C expression by cultured skin fibroblasts [388], but no data are available
yet with respect to keratinocytes. In order to gain further insight into the regulation of
tenascin-C expression by epidermal keratinocytes, we tested the effect of growth factors
and cytokines on tenascin-C expression in an in vitro model using cultured keratinocytes.
The results show that tenascin-C expression by keratinocytes is upregulated by various
inflammatory cytokines. Regulation of expression in normal keratinocytes seems to be
distinct from the regulation in tumour-derived keratinocytes and skin fibroblasts.
Materials and methods
Cells and culture conditions
Human epidermal keratinocytes from skin biopsies of healthy donors were initially cul-
tured according to the method of Rheinwald and Green as previously described [224,377]. In
this study we used second passage normal keratinocytes that were grown in serum-free
keratinocyte growth medium (KGM). KGM was composed of KBM (keratinocyte basal
medium, Clonetics, San Diego, CA; 0.15 mM Calcium) supplemented with 0.1 mM
ethanolamine (Sigma, St.Louis, MO), 0.1 M phosphoethanolamine (Sigma), 10 ng/ml
EGF (recombinant mouse EGF; Sigma), 5 µg/ml insulin (Sigma), 0.5 µg/ml hydrocor-
tisone (Collaborative Research Inc., Lexington, MA), 0.4% v/v bovine pituitary extract
(Clonetics), and 100 units/ml penicillin plus 100 µg/ml streptomycin (Gibco, Breda, the
Netherlands). To investigate the effect of human cytokines and growth factors on tenas-
cin-C secretion, keratinocytes were seeded in 6-well plates in KGM and grown until the
cultures were nearly confluent. Then, the medium was changed for KGM/-GF to which the
factor to be tested was added. KGM/-GF is KGM without growth factors or hydrocortiso-
Chapter 3 Cutaneous stress Response pathways
90
ne (i.e. KBM supplemented with 0.1 mM ethanolamine, 0.1 M phosphoethanolamine, 100
units/ml penicillin and 100 µg/ml streptomycin). Medium was collected after 48 hours
and tenascin-C concentrations were determined by means of an enzyme-linked immuno-
sorbent assay (ELISA). The cells of the cultures were washed with PBS and processed for
RNA-isolation. The human cytokines and growth factors that were tested are summarised
in Table I. IL-1α and IL-10 were kindly provided by L. Joosten (Rheumatology
Department, University Hospital, Nijmegen, the Netherlands). IL-4 was a kind gift from
Schering & Plough (Amstelveen, The Netherlands; accepted for research purposes only),
and IL-6 was a kind gift from Dr. L. Aarden (Central Laboratory for Bloodtransfusion,
Amsterdam, the Netherlands). IL-8, TGF-α, TGF-β, and IFN-γ were obtained from R&D
systems (Abingdon, U.K.) while IL-2, bFGF, PDGF, KGF, and TNF-α were from
Boehringer (Mannheim, Germany). Recombinant human EGF was kindly provided by Dr.
E. van Zoelen (Cell Biology Department, University of Nijmegen, the Netherlands). In
addition, we tested the effect of foetal calf serum (FCS; Seralab, Nistelrode, the
Netherlands) on tenascin-C expression.
To compare the regulation of tenascin-C expression between normal keratinocytes and
transformed keratinocytes derived from epithelial tumours, we investigated tenascin-C
secretion by the squamous cell carcinoma cell lines SCC-4, SCC-12 and SCC-15 that were
a kind gift of Dr. J. Rheinwald (Division of Dermatology, Harvard Medical School, Boston,
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Compound Concentration range tested
FCS 5%
IL-1α 0.04 - 10 ng/ml
IL-2 0.03 - 17 units/ml
IL-4 1.95 - 1000 units/ml
IL-6 0.78 - 400 units/ml
IL-8 0.97 - 500 ng/ml
IL-10 0.36 - 22.8 ng/ml
TNF-α 0.16 - 83 ng/ml
IFN-γ 15.6 - 1000 units/ml
TGF-α 0.02 - 10 ng/ml
TGF-β 0.04 - 20 ng/ml
EGF 0.02 - 10 ng/ml
KGF 0.20 - 100 ng/ml
PDGF 0.10 - 50 ng/ml
bFGF 0.31 - 20 ng/ml
SMase1 1.50 - 200 munits/ml
SB2035802 0.63 - 10 µM
SB2021902 0.63 - 10 µM
PD980593 1.60 - 25 µM
1 SMase stands for sphingomyelinase
2 SB203580 and SB202190 specifically inhibit p38
MAP kinase
3 PD98059 specifically inhibit the MAP kinase kinases
MEK1 and MEK2, which activate the ERK MAP
kinases
Table 1
MA). SCC-4 and SCC-15 are derived from squamous cell carcinomas of the tongue, while
SCC-12 is derived from a cutaneous squamous cell carcinoma [389]. Cell lines were initially
cultured on a feeder layer of irradiated 3T3 cells in DMEM/F12 (3:1, v/v; Flow
Laboratories, Irvine, Scotland, U.K.) supplemented with 0.4 (g/ml hydrocortisone, 5%
FCS, penicillin (100 U/ml) and streptomycin (100 µg/ml). Keratinocytes from these cul-
tures were subsequently seeded in 6-well plates in the same medium but without feeder.
After 3-6 days, the medium was changed for KGM in which the cultures were grown until
near confluence. Then, the cells were incubated with KGM/-GF to which the factor to be
tested was added. After 48 hours, medium was collected to determine tenascin-C concen-
trations by ELISA, and cells were harvested for RNA-isolation.
Kinase agonists and antagonists
To investigate intracellular signalling events involved in the stimulation of tenascin-C
expression by TNF-α, we tested the effects of specific inhibitors of intracellular phos-
phorylation cascades involved in the regulation of gene expression by TNF-α and other sti-
muli [307]. SB203580 and SB202190 specifically inhibit the mitogen-activated protein (MAP)
kinase p38, while PD98059 inhibits the MAP kinase kinases MEK1 and MEK2 (where MEK
stands for mitogen-activated, extracellular-signal-related kinase) that can phosphorylate
the MAP kinases p42 and p44 (also known as ERK1 and ERK2, which stands for extracel-
lular-signal-related kinases 1 and 2). The third of the three MAP kinase pathways known to
date involves the MAP kinase JNK (c-jun amino-terminal kinase), also referred to as SAPK-
1 (stress-activated protein kinase 1). For this MAP kinase pathway, no specific inhibitor was
available. Instead, we tested whether activation of the JNK/SAPK-1 pathway by the addition
of sphingomyelinase affected tenascin-C expression. The inhibitors SB203580, SB202190 or
PD98059 were added to confluent cultures of normal keratinocytes in KGM/-GF, one hour
prior to the subsequent addition of TNF-α or sphingomyelinase. Medium was harvested
after 48 hours and tenascin-C levels were measured by ELISA. To check for possible cyto-
toxic effects of the inhibitors, lactate dehydrogenase levels in the medium were determined
using the Cytotoxicity Detection Kit (LDH) from Boehringer (Mannheim, Germany)
according to the manufacturer’s instructions. SB203580 was a kind gift of Dr. D. Griswold
(SmithKline Beecham Pharmaceuticals, King of Prussia, PA). SB202190 was obtained from
Calbiochem (La Jolla, CA) and PD98059 from Biomol (Plymouth Meeting, PA). The
sphingomyelinase preparation that we used was purified from Staphylococcus aureus and
obtained from Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands). The test concentra-
tions of the compounds are mentioned in Table I.
ELISA
To quantify tenascin-C concentrations in conditioned medium, a modification of the
sandwich type ELISA that we developed previously was applied . Normal goat serum (1%
in PBS) was used instead of BSA to block free protein binding sites and binding of the
secondary antiserum against tenascin-C was assessed with the peroxidase Vectastain Elite
ABC-kit (Vector Laboratories, Burlingame, CA) to make the assay more sensitive. The
detection limit was approximately 5 ng tenascin-C per ml.
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Fibronectin concentrations were measured according to the sandwich-ELISA method that
we described previously [377]. The detection limit was approximately 80 ng fibronectin per ml.
Construction of plasmid and DNA probe synthesis
Total RNA was isolated from cultured human dermal fibroblasts and cDNA was synthesi-
sed by reverse transcription with oligo-dT primers. By means of a polymerase chain reac-
tion part of the cDNA was amplified. The PCR-product, corresponding to nucleotides
6015-6647 of the human tenascin cDNA-sequence as submitted by Gherzi and colleagues
to the EMBL Database Library (accession number X78565) and thus spanning part of the
most C-terminally located fibronectin type III repeat and part of the fibrinogen-like
domain, was cloned in pGEM-3. The insert was used to synthesise 32P-dCTP labelled
tenascin-C probes with Klenow DNA-polymerase and random hexanucleotides.
RNA isolation and Northern blot analysis
Total RNA was isolated from cultured cells according to the guanidium-thiocyanate
method as previously described (Pfundt et al., submitted). As a positive control we used
total RNA from the human glioblastoma cell line U138-MG that is known to express
tenascin-C at high levels [377,390]. 15 µg total RNA was dissolved in 10 mM sodium phosphate
(pH 7.0), 1 M glyoxal, 50% DMSO, and electrophoretically separated in a 1% agarose gel
in 10 mM sodium phosphate buffer (pH 7.0) [391]. The gel was blotted by capillary transfer
onto a positively charged nylon membrane (Boehringer, Mannheim, Germany) using 10x
salt sodium citrate (10x SSC consists of 1.5 M NaCl and 0.15 M trisodium citrate). After
transfer, the blot was rinsed in 2x SSC, and RNA was fixed to the membrane by ultravio-
let irradiation (312 nm, 0.2 J/cm2). To visualise the molecular weight markers (5 µg of gly-
oxalated HindIII-digested λ-DNA [391] and ribosomal RNA bands, the blot was stained with
0.03% (w/v) methylene blue in 0.3 M sodium acetate (pH 5.2). After photography the blot
was destained in water, and glyoxal-guanosine adducts were dissociated by incubation
with 20 mM Tris (pH 8.0) for 5 minutes at 65˚C. Pre-hybridisation and hybridisation were
performed at 65˚C. Control hybridisation for equal RNA loading was performed using a
28S human ribosomal RNA probe. For processing of the autoradiographs the
Imagemaster™ data image system (Pharmacia, Biotech Inc., Uppsala, Sweden) was used.
Results
Inflammatory cytokines increase tenascin-C expression of keratinocytes
Previously we reported that tenascin-C mRNA could not be detected by in situ hybridisa-
tion in the epidermis of normal skin, while epidermal keratinocytes do express tenascin-
C during wound healing and also in vitro [377]. We therefore were interested to investigate
which stimuli would regulate the expression of tenascin-C by keratinocytes in vitro. To
rule out major effects of the stimuli on keratinocyte proliferation and consequently on cell
number, cultures were grown till confluence before addition of the agents. After 48 hours,
the conditioned medium was harvested and the tenascin-C concentration was determined
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Figure 1. IL-4, TNF-α and
IFN-γ increase tenascin-C
secretion by cultured normal
keratinocytes. Confluent cul-
tures were incubated with IL-
4 (A), TNF-α (B) or IFN-γ
(C) in medium devoid of any
other growth factors or cyto-
kines. After 48 hours medium
was harvested and tenascin-C
concentrations were determi-
ned by ELISA. Values were
normalised, and expressed
relative to the tenascin-C
concentration in the medium
of control cultures without
cytokine which was 48 ± 3
ng/ml. Data shown represent
mean values of triplicate
experiments ± SD.
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by ELISA. Addition of 5% FCS to basal medium (KGM or KGM/-GF), induced a minor
increase in tenascin-C levels. TGFα, TGFβ1, EGF, KGF, PDGF and bFGF, which increase
tenascin-C expression in mesenchymal cells and tumour cell lines, did not significantly
affect tenascin-C secretion by the cultured keratinocytes, not even at high concentrations
(see Table I). Also IL-1α, IL-6, IL-8 and IL-10 did not significantly alter tenascin-C levels
in the medium. In contrast, TNF-α and IFN-γ moderately increased tenascin-C concen-
trations in the medium, and addition of IL-4 resulted in a marked increase in tenascin-C
levels (figure 1).
To investigate the effect of selected cytokines on tenascin-C mRNA levels, total RNA was
isolated from keratinocyte cultures that were also used to quantify tenascin-C protein
levels in the culture supernatant. Tenascin-C mRNA was analysed on northern blots that
were hybridised with a tenascin-C specific probe (see figure 2). In control RNA samples
derived from a human glioblastoma cell line that expresses tenascin-C at high levels, a
major RNA band of approximately 7500 nucleotides hybridised with the tenascin-C
probe. A second band of approximately 5800 nucleotides was only visible after prolonged
exposure. Because of the long exposure times needed to visualise tenascin-C mRNA-bands
in keratinocyte samples, the two individual tenascin-C bands in the glioblastoma RNA can
not be discerned properly in figure 2. In RNA samples from control cultures of normal
keratinocytes without cytokines, two tenascin-C mRNA bands of approximately 7500 and
5800 nucleotides were detected. In samples from keratinocyte cultures that were incuba-
ted with TNF-α, IFN-γ or IL-4, both tenascin-C mRNAs were markedly upregulated. The
amount of tenascin-C RNA was quantified and normalised for the amount of RNA
loaded, by measuring the optical density of the hybridisation signals on the autoradio-
graph. TNF-α increased the amount of tenascin-C mRNA approximately 5 times compa-
red to the control culture without cytokine. IFN-γ upregulated tenascin-C mRNA
approximately 3 times, and in the presence of IL-4, about 9 times as much tenascin-C
mRNA was expressed. Note that for IL-4, the increase in tenascin-C mRNA is considera-
bly smaller than the increase in tenascin-C protein that we measured in the medium of
that culture. This could be explained by the fact that the mRNA is examined at a single
time, whereas the protein detected by ELISA reflects tenascin-C that is synthesised and
secreted into the medium during 48 hours. For TNF-α- and IFN-γ-stimulated cultures,
increase in tenascin-C mRNA is nearly similar to the rise in tenascin-C protein levels.
Co-stimulation of normal keratinocytes with submaximal concentrations of TNF-α
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Figure 2. TNF-α, IFN-γ and IL-4 increase tenascin-C mRNA. Total RNA (15
µg) from normal keratinocytes cultures was incubated with a 32P-labeled cDNA
probe specific for human tenascin-C. As a control, 15 µg total RNA from the
human glioblastoma cell line U138-MG, which is known to express tenascin-C
at high levels, was used. In addition, hybridisation with a 32P-dCTP labeled
human 28S rRNA probe is shown as a control for RNA loading. Lane 1; kerati-
nocytes cultured in KGM/-GF without cytokines. Lanes 2-4; keratinocytes cul-
tured in KGM/-GF in the presence of 83.3 ng TNF-α per ml, 1000 units IFN-γ
per ml, and 1000 units IL4 per ml, respectively. Lane 5; U138-MG cells.
plus IL-4, or IFN-γ plus IL-4 showed that the increase in tenascin-C protein that was indu-
ced by these combinations was comparable to the sum of the effect of the individual com-
ponents. Combinations of TNF-α plus IFN-γ, however, had a much stronger effect on
tenascin-C secretion than TNF-α or IFN-γ alone, suggesting that the effect of these cyto-
kines is synergistic rather than additive (Fig. 3).
Tenascin-C and fibronectin expression in cultured keratinocytes is differentially affected by
TNF-α, IFN-γ and IL-4.
In the previous section we showed that TNF-α, IFN-γ and IL-4 increase tenascin-C secre-
tion by cultured normal keratinocytes. To investigate whether the cytokines have a gener-
al effect on secretion of extracellular matrix proteins or more specifically affect expression
of tenascin-C, we quantified the concentration of another extracellular matrix protein in
addition to tenascin-C. By means of a specific ELISA, fibronectin concentrations in con-
ditioned medium of the keratinocyte cultures were determined (Fig. 4). The results indi-
cate that keratinocytes secreted 100 to 250 times more fibronectin than tenascin-C: while
tenascin-C levels were in the range of 48-77 ng/ml, fibronectin levels were as high as 6.3-
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Figure 3. TNF-α and IFN-γ have a synergistic effect on tenascin-C secretion by cultured normal keratinocytes.
The effect of combinations of TNF-α, IFN-γ and IL-4 in submaximal concentrations was compared to the effect
of the individual components. Cytokine concentrations were 5.2 ng TNF-α per ml, 62.5 units IFN-γ per ml and
62.5 units IL-4 per ml (open bars), or 20.8 ng TNF-α per ml, 250 units IFN-γ per ml and 250 units IL-4 per ml
(closed bars), respectively. The cytokines were added to confluent cultures in medium devoid of any other
growth factors or cytokines. After 48 hours medium was harvested and tenascin-C concentrations were determi-
ned by ELISA. Values were normalised, and expressed relative to the tenascin-C concentration in the medium of
control cultures without cytokine which was 77 ± 9 ng/ml. Data shown represent mean values of triplicate expe-
riments ± SD.
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Figure 4. IFN-γ and IL-4
induce tenascin-C expression
but not fibronectin expres-
sion in cultured normal kera-
tinocytes. The effect of IL-4
(A), TNF-α (B) and IFN-γ
(C) on tenascin-C secretion
by normal keratinocytes was
compared to their effect on
fibronectin secretion.
Confluent cultures were incu-
bated with the cytokines for
48 hours. Tenascin-C (open
bars) and fibronectin (closed
bars) concentrations were
determined by ELISA. Values
were normalised, and expres-
sed relative to the tenascin-C
and fibronectin concentra-
tions in the medium of con-
trol cultures without cytokine
which were 48 ± 3 ng/ml for
tenascin-C and 6.3 ± 0.4
µg/ml for fibronectin respec-
tively.
Data shown represent mean
values of triplicate experi-
ments ± SD.
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23 µg/ml. TNF-α not only increased expression of tenascin-C in the keratinocytes, but
also slightly increased fibronectin levels in the medium of the same cultures. At all con-
centrations tested, TNF-α increased fibronectin approximately half as much as tenascin-
C. In contrast to TNF-α, IFN-γ and IL-4 did not affect fibronectin secretion and therefore
appear to be more specific inducers of tenascin-C.
Tenascin-C expression is increased by sphingomyelinase
In an attempt to elucidate if activation of cellular stress response pathways could be
responsible for the TNF-α-induced upregulation of tenascin-C expression by normal
keratinocytes, we tested the effect of specific MAP kinase and MAP kinase kinase inhibi-
tors. SB203580 and SB202190, that inhibit the p38 MAP kinase, did not significantly
decrease TNF-α-induced tenascin-C secretion. No toxic effects of SB203580 and
SB202190 were noted at the indicated concentrations (see table I). In addition, we tested
the effect of PD98059 that inhibits the MAP kinase kinases MEK1/2, which can phospho-
rylate the MAP kinases p42 and p44. Addition of different concentrations of PD98059
decreased tenascin-C secretion by cultured keratinocytes to some extent. However, meas-
urement of lactate dehydrogenase levels in the medium revealed that PD98059 had mar-
ked cytotoxic effects. Therefore, the decrease in tenascin-C levels in the presence of
PD98059 may not represent a specific effect of the compound on TNF-α-induced tenas-
cin-C expression. We have previously shown that TNF-α stimulation of keratinocytes
leads to a strong increase of JNK/SAPK-1 activity (Pfundt et al., Arch. Dermatol. Res.,
accepted). To investigate the involvement of the JNK/SAPK-1 pathway in the regulation of
tenascin-C expression, we stimulated keratinocytes with sphingomyelinase, thereby gene-
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Figure 5. Sphingomyelinase increases tenascin-C secretion by cultured normal keratinocytes. Sphingomyelinase
was added to confluent monolayers of normal keratinocytes. After 48 hours, medium was collected and tenas-
cin-C concentrations were determined by ELISA. Values were normalised, and expressed relative to the tenascin-
C concentration in the medium of control cultures without sphingomyelinase which was 16 ± 7 ng/ml.
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Figure 6. Regulation of tenas-
cin-C expression by tumour-
derived keratinocytes differs
from the regulation in nor-
mal keratinocytes. The effect
of IL-4, TNFα and IFNγ on
tenascin-C secretion by the
squamous cell carcinoma cell
lines SCC-4, SCC-12 and
SCC-15 was investigated and
compared to the effect on
normal keratinocytes. Stimuli
were added to nearly conflu-
ent cultures. After 48 hours
medium was harvested and
tenascin-C concentrations
were determined by ELISA.
Values were normalised, and
expressed relative to the
tenascin-C concentration in
the medium of control cultu-
res without cytokine. Data
shown represent mean values
± SD from two independent
experiments for all cells
except SCC-12 for which data
from a single experiment are
shown. Mean tenascin-C
concentrations in medium
without stimulus were 53 ±
17 ng/ml for normal kerati-
nocytes, 67 ± 20 ng/ml for
SCC-4, 111 ± 1 ng/ml for
SCC-12 and 79 ± 17 ng/ml
for SCC-15 respectively.
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rating intracellular ceramide that is a known activator of the JNK/SAPK-1 pathway [307]. As
illustrated in figure 5, sphingomyelinase increased tenascin-C secretion by cultured nor-
mal keratinocytes in a dose-dependent manner. To elucidate whether sphingomyelinase
indeed affected tenascin-C secretion through activation of the JNKs/SAPK-1 pathway and
not one of the other MAP kinase pathways, the effect of kinase inhibitors on sphingomy-
elinase-induced tenascin-C secretion was investigated. The effect of the p38 MAP kinase
and MEK 1/2 inhibitors on sphingomyelinase-induced tenascin-C secretion was compa-
rable to their effect on TNF-α-induced tenascin-C secretion: SB203580 and SB202190 did
not significantly inhibit the sphingomyelinase-induced upregulation of tenascin-C, while
the minor inhibiting effect of PD98059 again could not be discerned from its cytotoxic
effects.
Tenascin-C expression by SCC cell lines is upregulated by TNF-α,
but IFN-γ or IL-4 have little effect
Tenascin-C is abundant in the stroma of epidermal tumours, and previous reports sugge-
st that part of the tenascin-C is produced by tumour cells [383-386,392]. Here, we investigated
whether the squamous cell carcinoma cell lines SCC-4, SCC-12 and SCC-15 express tenas-
cin-C. The results show that these transformed keratinocytes secrete tenascin-C into the
medium when cultured in KGM or KGM/-GF. Tenascin-C levels in the medium (41-112
ng/ml) were similar to those measured for normal keratinocytes (48-77 ng/ml). To com-
pare the regulation of tenascin-C secretion between normal keratinocytes and transfor-
med keratinocytes, we investigated the effect of selected cytokines in KGM/-GF on tenas-
cin-C secretion by the squamous cell carcinoma cell lines. Addition of TNF-α moderately
increased tenascin-C secretion by the cell lines, but IFN-γ and IL-4 had very little effect.
Results are summarised in figure 6. FCS strongly increased tenascin-C expression by the
tumour cells, while it induced only a minor increase in tenascin-C levels in cultures of
normal keratinocytes. Addition of 5% FCS to SCC-4 cells gave rise to tenascin-C levels
that were 6.5 times the levels in control cultures without FCS. Tenascin-C levels in FCS-
stimulated cultures of SCC-12 and SCC-15 cells, were 2.6 and 5.5 times the tenascin-C
levels in control cultures, respectively. In contrast, normal keratinocytes produced in the
presence of 5% FCS only 1.2 times the amount of tenascin-C that was measured in con-
trol cultures. Tenascin-C expression, therefore, seems to be differently regulated in the
SCC cell lines compared to normal keratinocytes.
Discussion
During the last few years it has become clear that, in addition to mesenchymal cells, epit-
helial cells can produce tenascin-C as well. With respect to human skin, we previously
showed by in situ hybridisation that tenascin-C is not expressed in the epidermis of intact
normal skin, but is expressed by basal keratinocytes in the regenerating epidermis of
healing wounds [377]. The results presented here confirm our previous finding that normal
human keratinocytes start expressing tenascin-C when cultured in vitro [377]. This might
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reflect the more general finding that keratinocytes acquire an ‘activated’ phenotype upon
removal from their in vivo environment and subsequent in vitro culture, which phenoty-
pe resembles wound keratinocytes more than normal keratinocytes [5]. This correlates with
our in situ hybridisation results showing that wound keratinocytes but not normal kera-
tinocytes express tenascin-C mRNA in vivo and our finding that normal keratinocytes do
produce tenascin-C in vitro. The basal tenascin-C production of keratinocytes in vitro is
low when compared to the production by cultured skin fibroblasts and glioblastoma cell
lines [377]. Yet, the results presented here indicate that tenascin-C expression can be up-
regulated by the inflammatory cytokines IL-4, TNF-α and IFN-γ. These cytokines have
been previously reported to increase tenascin-C expression by other cell types [393-394]. Their
effect on tenascin-C expression by dermal fibroblasts from healthy volunteers and sclero-
derma patients was recently investigated by Makhluf et al. [388]. They showed that IL-4 was
a very potent inducer of tenascin-C production by the skin fibroblasts. TNF-α and IFN-γ
had no significant effect, neither alone nor in combination. In contrast to our findings
with epidermal keratinocytes, PDGF and bFGF moderately increased tenascin-C expres-
sion by the dermal fibroblasts. Together with the results presented herein, these data
suggest that tenascin-C expression in skin is differently regulated for normal epidermal
keratinocytes and dermal fibroblasts: while IL-4 is a strong inducer for both cell types,
PDGF and bFGF only induce tenascin-C expression by dermal fibroblasts, and TNF-α and
IFN-γ specifically affect tenascin-C expression by epidermal keratinocytes.
Since in skin tenascin-C is increased in conditions that are characterised by inflamma-
tion, IL-4, TNF-α and IFN-γ might be important for the increase in tenascin-C that is
observed in vivo by inducing epidermal tenascin-C production. This hypothesis is sup-
ported by the fact that these inflammatory cytokines are upregulated in healing skin, a
condition where keratinocytes produce tenascin-C. The dynamics of TNF-α expression in
skin wounds have been investigated in detail in mice [395,396]. Experimental wounding
revealed a strong and rapid induction of TNF-α during the early phase of wound healing.
TNF-α was mainly produced by polymorphonuclear leukocytes but at later stages of the
repair process, expression of TNF-α was also seen in macrophages and in the hyperpro-
liferative epithelium of the wound edge. After completion of the proliferative phase of
wound healing, the TNF-α expression level had returned to the basal level. The dynamics
and location of TNF-α expression described in these studies correlate with the dynamics
and location of tenascin-C expression in healing skin wounds [377,382]. Therefore, TNF-α
might induce tenascin-C production by the wound keratinocytes. Interestingly, glucocor-
ticoid-treatment of mice significantly reduces expression of TNF-α as well as tenascin-C
during wound repair [395,397]. The results presented here suggest that a decrease in TNF-α
levels in response to glucocorticoid treatment might possibly cause the concurrent decre-
ase in tenascin-C, by reducing epidermal tenascin-C expression in the wounds.
TNF-α is known to activate cellular stress response pathways that are involved in the
regulation of gene expression [307,398]. To investigate intracellular signalling events involved
in the stimulation of tenascin-C expression by TNF-α, we tested the effects of specific
inhibitors and an activator of MAP kinase pathways. Inhibitors of the MAP kinase p38 did
not affect TNF-α-induced tenascin-C expression. Activation of the JNK/SAPK-1 pathway
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by the addition of sphingomyelinase markedly increased tenascin-C expression by the
keratinocytes. These results suggest that TNF-α may increase tenascin-C expression
through activation of the JNK/SAPK-1 pathway. Activation of the JNK/SAPK-1 pathway
ultimately leads to activation of at least two different transcription factors: ATF-2 and c-
jun. Recently Mettouchi et al. showed that c-jun binds to the human tenascin-C promoter
and induces transcription of the tenascin-C gene [399]. It seems likely, therefore, that both
TNF-α and sphingomyelinase increase tenascin-C expression by activating the
JNK/SAPK-1 pathway and subsequent transcription of the tenascin-C gene by c-jun. IL-4
and IFN-γ, the other two inducers of keratinocyte tenascin-C expression, do not affect the
MAP-kinase pathways. They can regulate gene expression via another cell-signalling path-
way involving different cytoplasmic protein kinases, the Janus kinases (JAKs) [400-402].
Binding of IL-4 and IFN-γ to their cell surface receptors activates specific JAKs in the cyto-
plasm and these JAKs subsequently activate members of the STAT transcription factor
family (signal transducers and activators of transcription). These STATs activate trans-
cription after dimerisation and binding to specific DNA sequences called gamma-
interferon activation site (GAS) elements. GAS elements are defined by a small palin-
dromic consensus sequence TTCN2-4GAA [403]. Several regions in the human tenascin-C
promoter [404] conform to this consensus sequence and might therefore be regarded as
putative GAS elements. We hypothesise that the induction of tenascin-C expression by 
IL-4 and IFN-γ that we observed in the keratinocyte cultures depends on activation of the
JAK/STAT pathway by IL-4 and IFN-( and subsequent transcription of the tenascin-C
gene. Since IL-4 and IFN-γ did not affect fibronectin expression by the epidermal kerati-
nocytes, the intracellular signalling pathway that is activated by these cytokines seems not
to induce expression of fibronectin.
In agreement with recent data of [392] we found that squamous cell carcinoma cells secrete
tenascin-C in culture. We showed that, in addition to cells from oral squamous cell carci-
nomas, the cutaneous tumour cells SCC-12 express tenascin-C in vitro. Our results further
indicate that inflammatory cytokines differentially affect tenascin-C expression in cul-
tured tumour cells and normal keratinocytes. This suggests that the regulation of tenas-
cin-C expression in skin not only differs between keratinocytes and fibroblasts, but also
between normal keratinocytes and transformed keratinocytes from epithelial tumours.
Tenascin-C has been implicated in the modulation of adhesion, migration and prolifera-
tion of cells. Whether the distinct regulation of tenascin-C expression that we observed in
the SCC cell lines has any relevance for the behaviour of tumour cells in vivo remains to
be investigated.
In conclusion, we found that TNF-α, IFN-γ and IL-4 increase tenascin-C expression by
normal keratinocytes. Since in skin, increased tenascin-C expression correlates with inf-
lammation, we hypothesise that these inflammatory cytokines might be involved in the
induction of epidermal tenascin-C expression in vivo, during wound healing, malignancy,
and possibly other conditions in which keratinocytes express tenascin-C.
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Abstract
Keratinocytes of inflamed epidermis (psoriasis, wound healing, irradiated skin) are hyper-
proliferative and display an abnormal differentiation program. This so-called regenerati-
ve maturation pathway is characterised by the induction of a set of genes that is not
expressed by keratinocytes in normal skin, such as the cytokeratins CK6, CK16 and CK17,
and the proteinase inhibitor SKALP/elafin. In a previous study we showed that in cultured
keratinocytes, SKALP expression can be induced by the addition of FCS or TNF-α to
undifferentiated primary keratinocytes, and that this induction depends on the activity of
the P38 MAP kinase. Here we have studied the regulation of SKALP/elafin gene expression
in epidermal keratinocytes at the molecular level as a paradigm for the regenerative matu-
ration pathway. We have constructed deletion mutants of the SKALP/elafin promoter
region that conferred keratinocyte-specific expression upon transient transfection.
Unfortunately the promoter-constructs were not subjected to identical regulation media-
tion as the endogenous gene since they were highly active, independent of stimulation by
TNF-α or FCS. A two step deletion of a region that contained several potential NF-IL6
binding sites and two NFκB binding sites resulted in a 90% reduction of promoter activi-
ty. However upon the induction of the endogenous SKALP gene expression by either FCS
or TNF-α, a specific and quick translocation of the transcription factor NFκB in the
nuclei of the keratinocytes was observed. Transcription factors AP-1 and NF-IL6 were
found to be constitutively present in the nuclei of both resting and activated keratinocy-
tes. These findings suggest that SKALP gene expression could be regulated by a NFκB
dependent mechanism. We speculate that SKALP expression by keratinocytes is part of an
epidermal stress response pathway which is characteristic for e.g. psoriatic epidermis and
healing skin wounds and in which NFκB and p38 are likely to play crucial roles.
Introduction
Human epidermis is mainly composed of keratinocytes, which follow a highly co-ordina-
ted process of terminal differentiation. This normal epidermal differentiation pathway
ultimately leads to the formation of a protective layer of dead corneocytes [259,260]. There are
however circumstances, e.g. wounding and inflammation, in which the epidermis is for-
ced to follow an alternative pathway. This alternative pathway, that is characterised by
hyperproliferation and alternative differentiation, is a functional physiological response to
conditions that require rapid epidermal regeneration and protective gene expression like
e.g. wound closing. This pathway is generally referred to as regenerative maturation [6,7].
There are however a number of skin conditions where this pathway seems inappropriate
and is part of a pathological skin condition, like e.g. psoriasis [10]. There is not much known
about the molecular changes that are at the basis of this change in epidermal differen-
tiation pathways. Insight into these earliest changes at the molecular level could provide
us with knowledge about the regulation of epidermal differentiation routes, and could
ultimately lead to the identification of novel targets for the therapy of skin diseases.
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In this study we present data derived from a number of experiments in which we have
studied the expression regulation of the serine proteinase inhibitor SKALP (Skin Derived
AntiLeuko- Proteinase) at the molecular level. Similar to the expression of the cytokera-
tins 6,16 and 17 [12,13], the expression of the SKALP gene is tightly correlated with abnor-
mal epithelial differentiation in a context of hyperproliferation. SKALP is highly expres-
sed in psoriatic epidermis [255,277] and is inducible in vivo by tapestripping (standardised
model for epidermal injury and trans-epidermal water loss) [202,204] and UV-B irradiation
(Pfundt et al in submitted). SKALP expression is therefore a model for gene expression
that is characteristic for the epidermal phenotype generally referred to as regenerative
maturation. Assuming a general mechanism, it is our belief that knowledge on the mole-
cular regulation of SKALP expression should be informative on the molecular regulation
of the epidermal phenotype of regenerative maturation. In previous studies we have
shown that SKALP gene expression can be induced in vitro by subjecting cultured undif-
ferentiated primary keratinocytes to either FCS or TNF-α [77,294] (Pfundt et al in press). This
in vitro induction of SKALP was shown to be dependent on the expression of the activity
of the MAP kinase family member p38. In addition we were able to show that SKALP
expression in vivo induced through UV-B irradiation of normal human skin, is also cor-
related with p38 activation (Pfundt et al, submitted). This led to the hypothesis that the
expression of SKALP is part of an epidermal stress response that is aberrantly induced and
maintained in pathological skin conditions like psoriasis. We were therefore interested to
investigate the regulation of SKALP gene expression at the molecular level.
By determining the transcription initiation point of the SKALP gene we show that the
region which was presumed to be the SKALP promoter region, indeed is the promoter
region of the SKALP gene. Transcription initiation can occur at multiple sites in a region
10-24 bases upstream of the ATG startcodon, resulting in a very short 5’-untranslated
region. We demonstrate the specificity of SKALP promoter activity with respect to cell
type. In addition we also demonstrate that induction of SKALP expression is accompanied
with the presence of high levels of activated transcription factor NFκB in the nuclei of the
stimulated keratinocytes, whereas AP1 and NF-IL6 levels remain unchanged.
Promoter/reporter constructs that comprised 4500 bp of upstream and 1600 bp of down-
stream SKALP gene sequence (relative to translation start-site) were analysed in transient
transfection experiments in keratinocytes under various culture conditions. These experi-
ments showed that the promoter/reporter constructs are highly active under all culture
conditions in contrast to the endogenous SKALP gene. This discrepancy between the pro-
moter/reporter constructs and the endogenous SKALP gene suggest regulation of SKALP
gene expression at other levels like chromatin structuring and/or methylation. We specu-
late on the importance of the NFκB activation, the potential consequences of the short 5’-
untranslated region of mRNA derived from SKALP gene expression and on the potential
mechanisms involved in the regulation of the SKALP gene.
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Material and methods
All chemicals were obtained from Merck (Merck, Darmstadt, Germany) unless specified
differently. Restriction enzymes were provided by Boehringer (Boehringer, Mannheim,
Germany). Primers were provided by Isogen (Isogen, Amsterdam, the Netherlands).
Isolation and cloning of the human SKALP gene promoter region in/construction 
of reporter gene constructs
We have previously reported the cloning of a 9kb HindIII genomic fragment in
pBluescript (Stratagene, USA) which was characterised as containing the human SKALP
gene [257]. This clone was designated pSKAG. From this clone an EcoRI/XbaI fragment con-
taining approximately 1-kb promoter region in addition to a small part of the first exon
was cloned in pBluescript KS+ resulting in clone pSPRO29. Construct pSPRO29 was used
as template in a PCR reaction synthesising the 1 kb promoter fragment (pos. -1012/+13;
all nucleotide positions in this paper are given relative to the start site of translation (see
figure 1)). Two primers (forward: 5’-GAATTCCCGGGTTCATATAT-3’ (pos.-1012/-993,
(mutated nucleotide is underlined)), reverse: 5’-TGCTGGCCCCCATGGTGTCA (pos. -
7/+13)) were used to introduce a SmaI site and a NcoI at the 5’ and the 3’ site of the PCR
product respectively. The PCR-product was cloned in the pGEM-4 T-vector (Promega,
Madison, USA) and sequenced for verification. From this clone a 1-kb SmaI/NcoI frag-
ment (pos. -1004/+3) was directionally subcloned in frame with the firefly luciferase gene
in pSla4, a modified pSla3 vector [405], directly fused to the ATG of the luciferase gene
through the NcoI site. The resulting clone was designated pSPL1000. From this clone dele-
tion mutants were derived, designated pSPL440, pSPL290, pSPL170 and pSPL130. All
these constructs were prepared according to standard cloning techniques using available
restriction sites, except clone pSPL130. To generate this clone we used a mutagenic for-
ward primer (5’-GTGGATATCTCCCAATAC-3’ (pos. -132/-115)) in a PCR reaction with
the previously mentioned reverse primer to introduce an EcoRV site at position -126.
From the resulting PCR product an EcoRV/NcoI fragment was cloned in a SmaI/NcoI dige-
sted pSLA4 vector. The largest transfection construct pSPL4500 was constructed via direc-
tional cloning of an approximately 4 kb HindIII/BglII promoter fragment (pos. -4500/
-435) in a SmaI/BglII digested pSPL1000 construct. The two promoter constructs
pSPL1000int+ and pSPL1000int- contain the entire genomic sequence of the SKALP gene
in the correct and reverse orientation respectively. Both constructs containing the geno-
mic SKALP sequence were constructed by directional cloning of a PCR product contai-
ning the entire gene sequence (pos. +3/+1631) in the KpnI site of construct pSPL1000
between the stop codon and the first polyadenylation signal of the luciferase gene. Finally
a construct containing the insert from clone pSPL1000 in the reverse orientation, designa-
ted pSPL1000rev was generated. To obtain this clone, the previously mentioned 1 kb
SmaI/NcoI fragment was used. A blunt end was generated at the NcoI site, and the com-
plete fragment was subcloned in the SmaI site from pSla4, thus maintaining the original
translation start codon from the luciferase gene. Figure 2 gives a schematically representa-
tion of these 9 constructs.
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Cell cultures
Keratinocytes were seeded in 6 well culture dishes and cultured until confluence in kera-
tinocyte growth medium (KGM) as described before [77]. KGM was composed of keratino-
cyte basal medium (KBM (Biowhittaker, Walkersville, Maryland, USA); 0.15 mM
Calcium), supplemented with ethanolamine (0.1 mM) (Sigma, St.Louis, USA), phos-
phoethanolamine (0.1 mM) (Sigma, St.Louis, USA), bovine pituitary extract (BPE; 0.4
%v/v) (Biowhittaker, Walkersville, Maryland, USA), insulin (5 (g/ml), (Sigma, St. Louis,
USA), hydrocortisone (0.5 µg/ml) (Collaborative Research Inc.), Recombinant Mouse
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Figure 1. Nucleotide sequence of the human SKALP gene promoter region. Numbering is relative to the first
base of the ATG translation codon (printed in bold). The borders of the fragments used for the luciferase trans-
fection constructs are indicated with arrows (⇓). The putative ‘CCAAT’ and ‘TATA’ boxes are double underlined.
The region of multiple transcription start sites is underlined with a dotted line, the preferential transcription
start sites are printed in italics and bold. Consensus binding sequences for known transcription factors are indi-
cated by name and underlined.
-1012 GAATTCCCTG GTTCATATAT ATCACCTTTT CCAGAAGAAG GAACCCCCGT TTTCCCCTTT
-952 CATTACTCAT TCAAATAAAA TATGTTAATA GACCAGACCA AGTCTCACAC ACAACACACA
-892 CACACACACT CACACACACA CACACACACA CACACCCCTA CCTGTGGTCA GGGGTCAGGC
-832 TTTCATGATT AGCAGTCCCC ATTAGACTCA CAAGTTGATG GTTCAAAGAG ACAACAATTC
-772 TTCACAAGAA ACAGGGTGCT GTTCAAAGAA GTGGGGAGGC ATGCTGGACA CACACACTGT
-712 AGATGTCCAA TGTATACATG ATACATGTTT TCTACTACTT TCTGATTATT TTCTCCCTAC
-652 CACTGTGATT TCAAGGGCAT CATCCCTCTT CAGACCTAGA ATTCCACCTT CCAATTACTT
-592 TCTTGATGCA TCTGAAAGGC CGTCTCTGAA ACAGCAAAGT GCAATAATTA GTCATTATGT
-532 ATTCAAGGCA AATTTGTCTT ACAGAGTTTT TTGCAGGACC AGGGAAGAAG GAAGGAAATG
-472 CCCAGTTTGA TGCTGGGAGT GGTAAAATGA TAAAGTAGAT CTGGGTGGGG TTTGTAGCAC
-412 CAGAGCATAA TGGAGAAACA CCTTGGTTTT GTAATCAAGA CTGGATCTAC CAGTGACTTG
-352 CTGAATAACC TTCGGTGATT CCTTTCTCTT CTTGGGTCTC ACTGTATTTC AAAACATGAA
-292 GAATTTCATT GTAATGTTAC CTAATAAGTG AGCCAGCACT TCTACTCTGT GAGAAAGTAG
-232 GAAAACTCTT GGGACAATCA GAGATGATGT GATGTAATGT CCATTAGTTC TTCCTGTGAA
-172 TAATCCTGAG GGAAAGCCCC CAGGTCCCTC CCAGAATGGG GTGGATATTT CCCAATACAG
-112 CTAAGGAATT ATCCCTTGTA AATACCACAG ACCCGCCCCT GGAGCCAGGC CAAGCTGGAC
-52 TGCATAAAGA TTGGTATGGC CTTAGCTCTT AGCCAAACAC CTTCCTGACA CCATG
pSPL1000⇓ NFκB
AP-1 
pSPL440⇓
NF-IL6 NF-IL6 
NF-IL6/AP-1 NF-IL6 
SPL290⇓
AP-1 NFκB pSPL130⇓ NF-IL6
SP1 
+1
NF-IL6 pSPL170⇓ AP-1 
Epidermal Growth Factor (EGF; 10 ng/ml) (Sigma, St. Louis, USA), penicillin (100 U/ml)
(Gibco, Breda, the Netherlands) and streptomycin (100 µg/ml) (Gibco, Breda, the
Netherlands). At confluence the cells were either transfected or switched to one of the test
media, subsequently the growth factors or cytokines that were to be tested were added in
different concentrations. Induction of keratinocyte differentiation was established by
switching the cells at confluence either to KGM supplemented with 5 %v/v FCS
(KGM/FCS) (FCS from Seralab, Nistelrode, the Netherlands) or to KGM depleted of
growth factors (BPE, Insulin and EGF) and hydrocortisone (KGM-GF) [265]. Human skin
fibroblasts derived from healthy volunteers, glioblastoma cells and A431 cells were seeded
and cultured in 6 well culture dishes in A1 medium (DMEM/F12 (Flow Laboratories,
Irvine, Scotland) in a ratio of 3:1 supplemented with 100 U/ml penicillin, 100 µg/ml strep-
tomycin and 10 %v/v FCS). At 50-70 % confluence the cells were transfected.
Transfections
Keratinocytes were transfected at confluence. Prior to transfection the cells were washed
twice with 1 ml KBM and 900 µl KBM was added. Transfection mixes were made contai-
ning 0.75 pmol transfection construct 0.5 pmol EF2-βGAL normalisation construct (a
kind gift from Dr. G.Swart, department of Biochemistry, University of Nijmegen) and 25
µl lipidfection reagent (lipidfection reagent consisted of 0.8 mM DDAB (di-methyldioc-
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Figure 2. Schematic representation of the luciferase constructs containing deletion fragments from the promoter
region of the SKALP gene. Nucleotide positions are given relative to the translation start codon and indicate the
orientation of the deletion fragment.
tadecylammonium bromide (Sigma, St. Louis, USA), and 1.7 mM PtdEtn (dioleoyl-L-α-
phosphatidylethanolamine (Sigma, St. Louis, USA), prepared according to [406]) in a final
volume of 100 µl KBM. These mixes were incubated for 20 minutes at room temperature,
and added drop-wise to the cells, resulting in a final transfection volume of 1 ml. After 6
h of incubation 1 ml KGM was added to the cells. Twenty-four hrs. after transfection the
medium was aspirated and the cells were switched either to KGM/FCS or to KGM-GF, and
incubated for another 24 h. after which the cells were harvested.
The human fibroblasts, glioblastoma cells and A431 cells were transfected at 50-70 %
confluence. Prior to transfection the cells were washed twice with 1 ml DMEM/F12 (ratio
3:1) and 900 µl DMEM/F12 was added. Transfection mixes were made containing 1.3
pmol transfection construct, 0.5 pmol EF2-βGAL and 25 µl DOSPER (Boehringer,
Mannheim, Germany) in a final volume of 100 µl DMEM/F12. These mixes were incuba-
ted for 20 minutes at room temperature and added drop-wise to the cells. After 6 h of
incubation 1 ml A1 medium was added to the cells. Twenty-four h after transfection the
medium was aspirated and two ml A1 was added. After a final incubation of 24 h the cells
were harvested.
Cell harvesting and Luciferase and β-Galactosidase assays
Transfected cells were washed twice with PBS (NPBI, Emmer-Compascuum, the
Netherlands) and lysed in 150 µl reporter lysis buffer (Promega, Madison, USA).
Luciferase enzyme assay was performed with the Luciferase Assay System (Promega,
Madison, US) as suggested by the manufacturer using 10 µl cell lysate and 50 µl assay
reagent. Beta-galactosidase enzyme assay was performed with the ‘Galacto-Light Plus’ che-
miluminescent reporter assay for the detection of β-galactosidase (Tropix, Bedford
Massachusetts, USA) as suggested by the manufacturer using 20 µl cell lysate. Promoter
activities were measured as the ratio between the luciferase activity and β-galactosidase
activity per sample.
Determination of SKALP mRNA transcription start-site using S1-nuclease mapping
S1 nuclease mapping using a single stranded DNA probe was used to determine the start-
site of transcription of the SKALP gene. To obtain a suitable DNA probe we cloned a
BglII/XbaI fragment (pos. -435 to +62) in a XbaI/BamHI digested pBluescript KS+ vector.
This subclone was used for transformation of XL1-Blue cells (Stratagene, USA). From a
single XL1-Blue colony containing the appropriate clone 2 ml of TYP/Amp broth (16 g
Bacto-tryptone, 16 g Bacto-yeast extract, 5 g NaCl and 2.5 g K2HPO4 per liter with ampi-
cillin (50 mg/ml)) was inoculated and cultured for 16 h (37˚C, 250 rpm). The next day 100
µl of this culture was used to inoculate 5 ml TYP/Amp broth. After 30 minutes 40 µl of a
M13K07 helper phage stock (5x1010 plaque forming units) was added, and the culture was
grown overnight. The following day single stranded DNA was isolated using standard pro-
cedures. To prepare the radiolabeled probe, T7 primer (Promega, Madison, USA) was
annealed to 250 ng single stranded DNA, and primer extension was performed with 5
units of T7 DNA polymerase (Pharmacia, Upsala, Sweden). The primer extension was per-
formed in a 30 µl reaction containing 0.5 µM [α-32P]-dCTP (3000 Ci/mmol, (Amersham,
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Buckinghamshire, England)), 0.4 mM dATP, 0.4 mM dTTP, 0.4 mM dGTP and 1.3 µM
dCTP (Pharmacia, Upsala, Sweden). After 15 minutes incubation at 37˚C, 2 µl 10 mM
dCTP and 5 units T7 DNA polymerase were added. The reaction was terminated by incu-
bation at 65˚C for 10 minutes. This inactivation was followed by digestion with EcoRI for
2h at 37˚C in order to remove the insert. After digestion the DNA was denatured and sepa-
rated on a 4 % polyacrylamide gel. The radiolabeled probe was isolated from this gel.
Total RNA isolated from keratinocytes grown in the presence of 5 % FCS was used as a
source for SKALP mRNA. Fifty µg of this total RNA was mixed with 8x105 cpm single
stranded probe DNA, precipitated, and washed once with 70 % ethanol. As a negative con-
trol Yeast tRNA (Boehringer, Mannheim, Germany) was used. The pellets were dissolved
in 30 µl hybridisation buffer (40 mM PIPES (piperazine-N,N,-bis[2-ethanesulfonic acid])
pH8.0, 0.5 M NaCl, and 80 % formamide) and incubated for 10 minutes at 85˚C followed
by an incubation for 16 h at 50˚C. After this probe hybridisation, 300 µl nuclease S1 reac-
tion mix (280 mM NaCl, 5 mM NaAc pH4.5, 4.5 mM ZnSO4, 20 (g/ml herring sperm
DNA (Boehringer, Mannheim, Germany) and 1000 U/ml Nuclease S1 (Pharmacia, Upsala,
Sweden)) was added and the reaction was incubated at 37˚C for 60 minutes. As a control
reaction to check for sufficient nuclease S1 activity, free radiolabeled probe was subjected
to nuclease S1 digestion. The nuclease S1 reactions were terminated by addition of 80 µl
stop buffer (4M NaAc, 50 mM EDTA pH8.0 and 50 (g/ml yeast tRNA), followed by ethanol
precipitation. The pellets were washed with 70 % ethanol, dried, resuspended in 3 µl H2O
and incubated at 65˚C for 5 minutes. After this incubation 4 µl formamide loading dye (95
% Formamid, 10 mM EDTA, 0.1 % bromephenol blue and 0.1 % xylene cyanol) was
added, and the samples were boiled for 4 minutes and chilled on ice to denature the DNA.
The samples were separated on an 8 % polyacrylamide gel, and autoradiography was per-
formed using Kodak X-Omat 100 X-ray film.
Determination of SKALP mRNA transcription start site using 5’-RACE
Rapid amplification of cDNA ends (RACE) was used to reconfirm transcription start sites
found with S1-nuclease mapping. Using the 5’/3’-RACE kit (Boehringer, Mannheim,
Germany) we performed 5’ RACE on 10 (g of total RNA isolated from keratinocytes grown
in KGM/FCS, as suggested by the manufacturer. In the RACE reaction the SKALP specific
primers (SP) used were the primers SP1 (+1013/+1037), SP2 (+942/+966) and SP3
(+30/+48). The produced RACE fragment was purified on an agarose gel and cloned into
the pGEM-T vector (Promega, Madison, USA). The RACE clones obtained were sequen-
ced by means of the dideoxy chain termination method.
Preparation of nuclear extracts
At different time points after the stimulation of confluent primary human keratinocytes
the cells were harvested for nuclear protein extraction. Nuclear extracts were prepared as
described by Scott et al [407]. In short, approximately 3-6 106 cells were washed with ice cold
PBS and harvested by gently scraping using a rubber policeman and collected in ice cold
buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT). This cell suspension
was incubated on ice for 15 min allowing the cells to swell in the hypotonic solution.
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Subsequently Nonidet NP-40 solution was added to the swelled cells to a final concentra-
tion of 0.2 %. The keratinocytes were lysed in a dounce homogeniser by 20 strokes with
pestle B. The nuclei were pelleted by centrifugation (30 sec. 13000 rpm) and the nuclear
pellet was resuspended in 150 µl ice cold buffer C (20 mM HEPES, 10 % glycerol, 420 mM
NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM EDTA, 1 mM PMSF). This nuclear suspen-
sion was shaken vigorously on a shaking platform at 4˚C for 10 minutes, after which the
nuclear fragments were pelleted by centrifugation (5 min, 13000 rpm). The supernatant
containing the nuclear proteins was aliquoted and stored at -70˚C. One aliquot was used
for protein quantification by means of a colorimetric assay (Bio-Rad DC Protein Assay
Kit, BioRad).
Electrophoretic mobility shift assay (EMSA)
For the protein-ODN binding reaction, 105 cpm of 32P-labeled ODN, 1 µg of non-speci-
fic competitor DNA poly(dI-dC) (Pharmacia Biotech, Upsala, Sweden), and 10 µg nucle-
ar protein extract were added to a buffer containing 10 mM Tris pH7.6, 50 mM KCl, 1 mM
EDTA, 5 % glycerol, and 1 mM DTT. This mixture was incubated for 30 minutes at room
temperature. Reaction mixture was run on a 4 % non-denaturing polyacrylamide gel at
10-15 Volts/cm during 2 h. Gels were dried on a gel dryer (Savant model SGD2000) and
autoradiographed at -80˚C using X-Omat X-ray films (Kodak) at -80˚C with an intensi-
fying screen. The specificity of the protein-DNA interaction was checked by the addition
of a 10-50 molar excess of unlabeled double stranded oligonucleotide to the binding reac-
tion. In order to investigate the potential involvement of a particular protein in a specific
DNA protein interaction, supershift experiments were performed using a rabbit polyclo-
nal antibody directed against the NFκB p65 subunit (SantaCruz, Santa Cruz, CA, USA) as
follows. The nuclear protein extracts were preïncubated with different concentrations of
the antibody for 10 min at roomtemperature before radiolabeled oligonucleotide was
added. The total mixture was incubated for another 20 min before loading on the gel.
Chapter 4 Transcriptional regulation of the SKALP/elafin gene
112
Table 1 Overview of oligonucleotides that were used for EMSA analyses
Transcriptionfactor Strand Sequence of oligonucleotide
NFκB
Upper 5'-AGTTGAGGGGACTTTCCCAGGC-3'
Lower 3'-TCAACTCCCCTGAAAGGGTCCG-5'
AP1
Upper 5'-CGCTTGATGACTCAGCCGGAA-3'
Lower 3'-GCGAACTACTGAGACGGCCTT-5'
NF-IL6
Upper 5'-TGCAGATTGCGCAATCTGCA-3'
Lower 3'-ACGTCTAACGCGTTAGACGT-5'
Results
The human SKALP gene contains multiple transcription start sites
The cloning and partial structural characterisation of the SKALP gene and cDNA has been
described previously [256,257,408]. Based upon the presence of consensus sequences for a TATA
and CCAAT box (see figure 1), the region directly 5’ of the translation start site was assig-
ned as the putative promoter. In order to verify this region as being the SKALP promoter,
the S1-nuclease mapping technique was used to determine the transcription start site of
the SKALP gene. Using this technique, multiple transcription start sites were found 13 to
24 basepairs 5’ of the translation start site of the SKALP gene (figure 3). Identical results
were found at different hybridisation temperatures (not shown). Since these positions
would result in an unusually short 3’ untranslated region (3’UTR), an independent
method was used to confirm this region as being the region where SKALP transcription
can start. Using the 5’ RACE technique we found identical results (see figure 4). Figure 4
also shows that although multiple transcription start sites have been identified there seems
to be a preference for the positions -16, -17, and -18. Sixty percent of the RACE clones that
were analysed started at one of these nucleotides (see figure 4).
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Figure 3. Determination of the region where transcription of the SKALP gene initiates. A number of major
transcription startpoints are indicated at the right side of the figure with nucleotide numbers (relative to trans-
lation startsite) corresponding with bands found in S1 treated keratinocyte RNA (lane 1). In the control lane,
which was loaded with S1 treated tRNA no bands are visible confirming specificity (lane 2). At the left side of
the figure a sequence pattern is visible that was used as a molecular weight marker.
The region between -290 and -440 basepairs 5’ of the translation startsite of the SKALP gene
is important for promoter activity in human keratinocytes 
In order to scan the SKALP promoter for sequences relevant for transcriptional activity in
human keratinocytes, a set of 9 reporter constructs was designed covering approximately
4500 basepairs of upstream and approximately 1600 basepairs of downstream gene
sequences for testing in transiently transfected human keratinocytes (see figure 2).
Because of previous reports describing side effects of lipidfection on keratinocytes [409] we
verified that the transfection procedure as such did not induce any endogenous SKALP
expression in cultured human keratinocytes. Stepwise deletion of the region between -
4500 and -440 did not influence SKALP promoter activity, as can be seen by the relative
luciferase activity of the transfection clones pSPL4500, pSPL1000, and pSPL440. Based on
the relative luciferase activity of the transfection clones pSPL1000int+ and pSPL1000int-,
containing the intron sequences of the SKALP gene in both orientations, it appears that
the intron sequences do not have any effect on promoter activity in either orientation.
However deletion of the region -440 and -290 (clone pSPL290) resulted in a dramatic
decrease of SKALP promoter activity in human keratinocytes of about 75 % (see figure 5).
Further deletion of promoter sequences down to 170 basepairs 5’ of the translation start
site (pSPL170) resulted in a further decrease of promoter activity down to 10 % (see figu-
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Figure 4. Relative distribution of transcription start sites in the SKALP gene promoter determined by 5'-RACE.
Nucleotide positions (relative to the translation startsite) are indicated on the X-axis. In the promoter region
between -16 and -24, transcription can initiate at several positions. However there seems to be a preference for
the position -16/-17/-18. These results confirm the region found using nuclease S1 mapping (figure 3).
Distribution of transcription startsites in the SKALP promoter
0,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
-16 A-17 A-18 A-19 C-20 C-21 G-22 A-23 T-24 T
Base residue (number)
%
 o
cc
u
re
n
ce
re 5). Transfection clone pSPL130, containing only minimal promoter consensus binding
sequences showed almost no promoter activity in keratinocytes. Clone pSPL1000rev, in
which the upstream sequence of the SKALP gene is cloned in reverse orientation, resulted
in a luciferase activity comparable to the empty luciferase gene vector pSLA4 (results are
shown in figure 5). Figure 5 shows the activity of the various promoter constructs trans-
fected in keratinocytes that were subsequently induced to differentiate in KGM with foetal
calf serum (KGM/FCS). FCS also induces expression of the endogenous SKALP gene [77].
When the transfected cells were induced to differentiate by growth factor depletion
(KGM/-GF), under which condition the endogenous SKALP gene is only expressed at low
levels, also high levels of the luciferase constructs were found, although at somewhat lower
levels than in KGM/FCS (not shown). These findings suggest additional regulatory
mechanisms for expression of the endogenous gene compared to the promoter region
used in this study, as will be discussed below.
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Figure 5. Relative promoter activity of the various SKALP promoter reporter constructs, defined as the relative
luciferase activity. The bars represent the relative luciferase activity found in cell lysates of transfected keratino-
cytes cultured in KGM/FCS. The error bars indicate the standard error of the mean of three independent trans-
fection experiments. Deletion of the sequence region between -4500 and -440 (pSPL4500/pSPL1000/pSPL440)
does not affect promoter activity. Intron sequences have virtually no effect in either orientation
(pSPLint+/pSPLint-). Deletion of the region between -440 and -290 (pSPL290) results in a dramatic loss of pro-
moter activity of 75%. Upon further deletion of promoter sequences (pSPL170/pSPL130), the promoter loses all
activity. The negative construct pSPLrev has no significant promoter activity.
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The SKALP promoter confers keratinocyte specific gene expression
To investigate whether the promoter region that was used in this study could confer cell-
type specific expression, reporter constructs were transfected in human fibroblasts, glio-
blastoma cells, and A431 cells. Figure 6 shows the relative activity of the transfection clone
pSPL1000 in the different cell types, compared to the relative activity of the empty luci-
ferase gene vector pSLA4. As can be seen in figure 6, the SKALP promoter was highly acti-
ve in keratinocytes, cultured in KGM/FCS. Whereas in fibroblasts, glioblastoma cells, and
in A431 cells the SKALP promoter showed hardly any transcriptional activity. This effect
was also observed with other transfection constructs (data not shown).
In contrast to AP1 and NF-IL6, the transcription factor NFκB is activated upon 
the induction of SKALP expression.
Analysis of the promoter region of the SKALP gene reveals potential binding sites for
transcription factors that are known to be involved in early stress responses, such as AP-1,
NF-IL6 and NFκB (see figure 1). This is compatible with the idea that induction of SKALP
expression is part of an epidermal stress response (see chapter 3.1). In order to investigate
the activation and presence of these transcription factors in the nuclei of keratinocytes
that are induced to express SKALP, we have performed a number of electroforetic mobili-
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Figure 6. SKALP promoter activity in different cell types. The bars represent the promoter activity of transfec-
tion clone pSPL1000 compared to the empty reporter construct pSLA4 (assigned a value of 1). In keratinocytes
cultured in KGM/FCS, the SKALP promoter shows high promoter activity. However in the glioblastomas, the
fibroblasts, or in the A431 cells the promoter shows almost no activity.
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ty shift assays (EMSAs or bandshifts). In these EMSAs we have used probes that contain
consensus-binding sequences for either AP1, NF-IL6 or NFκB (see table 1) combined with
nuclear extracts of keratinocytes that were harvested at different timepoints after the
induction of SKALP expression (1, 8, 24 and 48 hours after induction). These transcrip-
tion factors all have multiple potential binding sites in the SKALP promoter (see figure 1)
and could be relevant for the regulation of its expression. Moreover there have been a
number of papers that found the relevance of these factors in the regulation of keratino-
cyte gene expression in general or [326,410], as is the case for AP1, for the regulation of SKALP
expression in particular [301,330]. We found that upon the induction of SKALP expression by
either FCS or TNF-α, within one hour the transcription factor NFκB is activated and
translocated to the nucleus (see figure 7). After serum stimulation NFκB can be found in
the nucleus until at least 8 hours after stimulation. Twenty four hours after the induction
of SKALP using serum we could no longer detect NFκB in the nuclei. This in contrast to
TNF-α where NFκB remained in the nuclei until at least 48 hours after stimulation. In
unstimulated keratinocytes (KGM-gf or KGM) no activated NFκB could be found in the
nuclei of the cells. The specificity of this binding reaction was confirmed with competi-
tion experiments. Moreover, supershift experiments using an antibody directed against
the p65 subunit of the NFκB transcription factor complex confirm the involvement of
NFκB in the mobility shifts that we had seen (see figure 7). This antibody was also used to
reconfirm NFκB translocation upon TNF-α and FCS addition immunocytochemmically.
These experiments gave identical results (data not shown).
We also performed EMSA experiments using nuclear extracts identical to those used in
the NFκB experiments combined with oligonucleotide probes harbouring consensus bin-
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Figure 7. Electrophoresis mobility shift analysis of nuclear
extracts from keratinocytes combined with labeled double
stranded oligonucleotide comprising a NFκB consensus motif
(see table 1). The lanes correspond with EMSA’s using NFκB
probe combined with extract from keratinocytes Lane1: no
extract added, lane 2: nuclear extract after 1.5 hrs with 5 %
FCS, lane 3: as lane 2 with 10 times excess cold specific probe,
lane 4: as lane 2 with 10 times excess non-specific cold probe,
lane 5: as lane 2 preïncubated with 1 µg NFκB antibody, lane
6: as lane 2 preïncubated with 0.1 µg NFκB antibody, lane 7:
as lane 2 preïncubated with 0.04 µg NFκB antibody, lane 8:
nuclear extract after 1.5 hrs without FCS.
ding sequences for the transcription factors AP1 and NF-IL6. For both AP1 and NF-IL6
we observed identical mobility shifts in all the nuclear extract samples. However, no diffe-
rences were found between nuclear extracts derived from cells that were or were not indu-
ced to express SKALP at any timepoint after induction (data not shown).
Discussion
Analysis of wounded epidermis or epidermis affected by various diseases (including neo-
plasia) reveals a gene expression pattern that is different from that found in normal unaf-
fected epidermis. A large number of genes show changes in the level of gene expression or
in their spatial regulation with respect to stratum specificity. Beside these genes there is
also a group of genes that is not expressed in normal skin but is specifically de novo expres-
sed in disturbed epidermis. To this group of genes belong structural proteins like the cyto-
keratins CK6, CK16 and CK17, also referred to as hyperproliferation- or disease-associa-
ted keratins [12,13,200]. It should however be emphasised that these keratins are not specific for
hyperproliferative epidermis. They are also found in various non-epidermal keratinocytes
undergoing hyperproliferation and are considered as markers for hyperproliferative kera-
tinocytes in general [270]. In addition to these structural proteins also the proteinase inhibi-
tor and antimicrobial [355] protein SKALP is de novo expressed under these abnormal
epidermal circumstances. We have shown in an earlier study that this protein is not only
expressed in disturbed epidermis but also in other epithelia that are constantly exposed to
environmental stress and where the presence of inflammatory cells and hyperproliferation
is physiological [294]. In general SKALP expression seems to be induced upon hazardous/
stressful stimuli in epithelia. As mentioned earlier in this paper the expression of SKALP
in the epidermis is correlated with the activation of response proteins like p38. Moreover
in cultured keratinocytes FCS and TNF-α inducible SKALP expression is mediated
through p38 dependent processes. There is however little known about the regulation 
of SKALP gene expression at the molecular level. The co-expression of CK6, CK16, CK17
and SKALP either in physiological or pathological conditions suggests common regula-
tory mechanisms. In this paper we have described the results of experiments intended to
reveal the regulatory mechanisms that are directly involved in the regulation of SKALP
gene activity and could be indicative for regulation of abnormal epidermal gene expres-
sion as well.
By determining the transcription start site of the SKALP gene, the putative SKALP pro-
moter could be positively identified as such. However transcription starts in a different
region than was expected, based upon previously designated consensus sequences, resul-
ting in a messenger RNA with a unusually short 5’-untranslated region (5’-UTR) [411].
Originally a sequence ranging from position -94 until -89 (relative to translation start)
was thought to function as TATA box [253,256] and transcription was expected to start somew-
here around position -60. Our results indicate that transcription can start in a region ran-
ging from 9 to 24 bases upstream of the translation startsite. In view of these results we
claim that the TATA-box like sequence at positions -94/-89 is non-functional. At positions
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-48/-42 we found a sequence TAAAGAT, that is, with respect to spacing, more likely to
serve as the actual TATA box. The fact that this proposed TATA-box deviates from the con-
sensus sequence for TATA boxes (TATA[A/T]A[A/T]) might explain the existence of mul-
tiple transcription start points [412]. In a previous paper [299] we have speculated on the regu-
latory properties of an open reading frame (ORF) in the 5’-UTR (ranging from pos. -37
to -5) of the SKALP messenger RNA. These kind of small ORFs are, once expressed,
known to have regulatory properties with respect to translation of the messenger [413-415].
Based upon the results presented in this paper this in no longer a valid option. Transcripts
starting between -24-and -12 (instead of around -60) no longer carry this complete ORF
in their 5’-UTR.
With respect to transcription factors that might be involved in the initiation of abnor-
mal epidermal gene expression, the CK6 and CK16 genes have been investigated at the
molecular level. Several groups have used gel retardation assays to identify a great number
of functional transcription factor binding sites in their promoters. These factors include
AP1, AP2 and Sp1 [13,45,195,416], suggesting involvement of these transcription factors in regu-
lating the expression of these genes in the context of abnormal differentiation and
inflammation. However all these transcription factors have been implicated in the regula-
tion of normal epidermal differentiation as well [325,326]. Nevertheless with respect to AP-1
binding sites, immunohistochemical data have shown that each member of the jun/fos
family has its own pattern of expression with respect to the distribution over the strata,
probably resulting in the presence of specific AP1 complexes in each stratum [329,417]. There
have been a number of reports that have described the binding of different AP-1 com-
plexes to different AP-1 sites within one promoter that can have both enhancing or repres-
sing effects [418-420]. It might very well be possible that genes expressed during normal diffe-
rentiation and genes expressed during regenerative maturation are both regulated through
different members of the AP1 transcription factor family. In this respect it is also interes-
ting to look at a study in which SKALP promoter activity has been studied in normal
mammary epithelial cell [301,330], and which suggests that that SKALP gene expression is dif-
ferentially regulated between these cells and epidermal keratinocytes. Deletion and muta-
tion experiments showed that an AP1 consensus-binding site at position 440 in the SKALP
promoter was important for SKALP expression in these mammary cells. However, in our
in vitro model system for the induction of regenerative maturation we did not see any
changes in the binding capacities of nuclear proteins to AP-1 consensus sites using EMSA,
but this does not rule out a change in AP-1 protein repertoire.
Transfection experiments with SKALP promoter constructs in keratinocytes showed a
discrepancy between the expression of these clones and the endogenous gene with respect
to inducibility. Whereas the endogenous SKALP gene can be induced in cultured kerati-
nocytes (addition of 5 % FCS), the reporter gene constructs are active under all culture
conditions. Analysis of these constructs in keratinocytes under SKALP expressing culture
conditions showed a major decrease of promoter activity upon the deletion of a sequence
region (-440/-290) containing three NF-IL6 consensus binding sequences. However the
EMSA experiments in which an oligo harbouring a NF-IL6 consensus binding sequence
was used, did not show any changes in NF-IL6 binding capacities in nuclear extracts from
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keratinocytes that (are induced to) express SKALP. As mentioned before identical EMSA
results were obtained with an oligo containing and AP-1 consensus-binding site. These
experiments suggest that AP-1 and NF-IL6 could still be relevant for SKALP transcription
but certainly not sufficient.
Further reduction of the SKALP promoter region down to -130 left only 10 percent of
the initial promoter activity. In this region of the SKALP promoter a consensus sequence
for the transcription factor NFκB is present. In total the SKALP promoter harbours two
NFκB consensus-binding sequences. One located at position -163/-154, fitting the con-
sensus sequence ‘GGGRNNYYCC’ [169] and one located at position -972/-965, fitting the
consensus sequence ‘GGGRNTYYC’ [421]. The EMSA experiments revealed a rapid activa-
tion and translocation of the transcription factor NFκB into the nuclei of keratinocytes
that were induced to express SKALP suggesting a possible causal relation. In addition we
could confirm this translocation by immunocytochemical analysis of cultured keratinocy-
tes and in a previous paper we have also described the correlation between NFκB translo-
cation and SKALP expression through UV-B irradiation of normal human epidermis
(Pfundt, et al, submitted). In a study by Ma et al, NFκB (p65 homodimer) is also implica-
ted in the possible regulation of CK6 and a synergistical effect for AP-1 and NFκB is sug-
gested [46]. Further mutation analysis is required to analyse the functional role for NFκB is
the regulation of SKALP expression. However all together these data suggest a regulatory
role for NFκB in the induction of regenerative maturation related gene expression. With
respect to consensus binding sequences, analysis of the known 5’-promoter regions of
CK6 (381 bp), CK16 (507 bp) and CK17 (450 bp) revealed that only CK17 contains a
NFκB consensus binding sequence. This in contrast with the fact that in the study of Ma
et al, that was mentioned earlier CK17 expression was not affected by the presence of acti-
ve NFκB. However in this study only the p65 (RelA/RelA) homodimer was used whereas
active NFκB complexes can be formed by homo- and hetero- dimerization of a variety of
NFκB family member’s [169].
The discrepancy between transcription of the naked DNA of promoter constructs and
the nuclear DNA wrapped in highly organised chromatin structure has been observed fre-
quently [184,422,423]. Therefore, also other processes like silencing elements not present in the
transfection clones, mRNA stability or higher order chromatin structure might be invol-
ved in transcription regulation of the endogenous SKALP gene. In that respect p38 kinase
activity, which is crucial for SKALP expression in vitro, could play a role. Recently it has
been described in a number of papers that mRNA’s can be stabilised through a MAP ki-
nase mediated processes including p38 [424-429], upon cellular stress. With respect to mRNA
stability the somewhat aberrant length of the 5’-untranslated region of the SKALP mRNA
could be of some significance, although it has been described that the 3’-UTR is more
important for mRNA stability [430-432]. In addition it has also been described in a large num-
ber of cell types that (TNF-α mediated) NFκB activation and translocation is regulated by
activated MAP kinases and particularly by p38 MAP kinases [433-438]. Based upon the inte-
gration of the results presented in this paper into the literature we hypothesise that SKALP
expression is part of an epidermal stress response in which p38 and NFκB play a central
role and might be functionally linked to each other in activated keratinocytes.
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Abstract
The availability of reliable models for epidermal growth and differentiation is crucial for
dermatological research. Due to the effort of many research groups, there now are a num-
ber of well-established cell culture models in which keratinocyte biology can be studied.
These models obviously differ in various respects from the actual situation in skin. It is
therefore very important to also develop and characterise model systems that, although
more complicated to handle and less flexible, better mimic the in vivo situation. Here we
present the further characterisation of two whole-skin models in which epidermal growth
and differentiation can be studied. The first model is an explant model that uses 4 mm
punch biopsies of healthy human skin, which are cultured for 24 hours in serum-contai-
ning medium. This culture period itself induces an altered differentiation route in the epi-
dermis of the explants. Based upon de novo expression of SKALP/elafin and cytokeratin 16
and the upregulation of SLPI and involucrin we conclude that the differentiation pathway
that is induced in these skin explants resembles the differentiation pathway that is found
in activated keratinocytes, the so-called regenerative maturation phenotype. The second
model that we have characterised is a transplantation model in which normal healthy
human skin was transplanted on the back of athymic mice. We observed that after a
healing/normalisation period of approximately 40 days the differentiation and prolifera-
tion status in the skin grafts resembles normal skin. Based upon the expression profiles of
a large number of epidermal markers we concluded that, as in the in vivo situation, the
regenerative maturation pathway could be induced in these grafts by either tape stripping
or UV-B irradiation. In addition the recruitment of a number of stress response proteins
that are thought to be involved in the regulation of epidermal responses preceded the
transition from normal to abnormal epidermal differentiation.
Introduction
The epidermis is a dynamic, continually renewing tissue that forms the interface between
the organism and its environment. The major epidermal cell type, the keratinocyte,
undergoes a complex and highly controlled program of terminal differentiation leading to
the formation of the horny layer of skin [259,260]. There are, however, conditions in which the
keratinocyte deviates from the normal differentiation program and follows an alternative
maturation route, called regenerative maturation [6,7]. This regenerative maturation path-
way is characterised by abnormal keratinocyte differentiation in the context of epidermal
hyperproliferation. This epidermal phenotype is a physiological epidermal adaptation to
conditions that disturb the barrier function of the skin and disrupt epidermal homeosta-
sis, like e.g. wounding and UV-B irradiation. There are however situations in which the
epidermal phenotype of regenerative maturation does not seem to be of any physiological
relevance and, moreover, is the cause of pathological skin conditions in for instance the
skin disease psoriasis [10]. Several research groups around the world are trying to get insight
into the cellular mechanisms that are at the basis of this switch in epidermal differentia-
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tion. Elucidation of these pathways will lead to a better understanding of the regulation of
epidermal growth and differentiation and potentially leads to new therapeutic targets in
skin diseases where abnormal differentiation is involved.
For scientists, the accessibility of reliable and controllable models in which epidermal phe-
notypes can be studied is indispensable. Much effort has been put into the development
of such models. After the introduction of the feeder cultures by Rheinwald and Green in
1975 [224] most of the experimental work has been performed using primary keratinocytes.
The development of media in which keratinocytes can be grown in the absence of serum
was a significant advance in controlling the experimental conditions of keratinocyte cul-
ture [77,439]. The present culture models of primary keratinocytes are very flexible and large
amounts of cells can be obtained for large scale screening experiments. However inheren-
tly these in vitro culture models differ considerably from the actual situation in skin, both
from a biological and a physical point of view. The fact that these keratinocyte cultures are
mainly monocultures means that the influence that other skin cells have in the epidermis
is not accounted for in these culture models. In addition the absence of a cornified layer
makes it very difficult predict potential irritancy and/or toxicity of compounds in vivo
because skin penetration may be very poor in intact human skin. And finally, due to the
lack of circulation in vitro, the clearance and half-life of compounds in culture models is
bound to be different in human skin.
The aim of the study described in this paper was to characterise a model in which the
switch from normal epidermal differentiation to regenerative maturation in intact human
skin could be induced and studied. Furthermore this model should be suitable for testing
new active pharmacological compounds or other agents that could potentially interfere
with this epidermal differentiation switch.
Here we have used two model systems that have been described previously [236,440,441] but
have remained poorly characterised with respect to stress-induced epidermal changes.
First we characterise an explant model in which skin biopsies are cultured for 24 hours,
and second, a skin grafting model using nude mice is described. Based upon the expres-
sion patterns and levels of a number of markers we conclude that regenerative maturation
can be studied in these models. In the explant model the regenerative phenotype is in-
duced by the explant procedure itself within 24 hours, whereas in the transplantation
model we can induce the abnormal epidermal phenotype by either irradiation of the
transplant with UV-B or by tape stripping. These models should, together with in vitro
models of cultured keratinocytes, provide us with an array of models each with its own
pros and cons from which the experimental information can be combined.
Materials and methods
Air-exposed skin explant model
Punch biopsies (4mm diameter) were taken from residual human skin after abdominop-
lasty. Informed consent was obtained from patients participating in this study. These
explants were washed in PBS, and placed with epidermis up in a Transwell insert system
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with tissue culture treated polycarbonate membranes (Corning Costar Corporation,
Badhoevedorp, the Netherlands). The inserts with the skin explants were put in 24-well
tissue culture plates in keratinocyte growth medium (KGM) supplemented with 5% foe-
tal calf serum (FCS) (Seralab, Nistelrode, the Netherlands). KGM was composed of
keratinocyte basal medium (KBM) ((Clonetics, San Diego, CA, USA); 0.15 mM calcium)
supplemented with ethanolamine (0.1 mM, Sigma, St. Louis, MO, USA), phosphoethanol-
amine (0.1 mM, Sigma), bovine pituitary extract (BPE) (0.4%, v/v, Clonetics), recombi-
nant mouse epidermal growth factor (EGF) (10 ng/ml, Sigma), insulin (5 µg/ml, Sigma),
hydrocortisone (0.5 g/ml, Collaborative Research Inc. Lexington, MA, USA), and penicil-
lin plus streptomycin (Life Technologies, USA). The stratum corneum of the explant was
air-exposed. The explants were incubated for 24 h at 37˚C under a 92% humidified
atmosphere containing 5% CO2 in air. Subsequently, they were further prepared for
immunohistochemical examination.
Mice
Female athymic nude BALB/C mice of 6 to 8 weeks were used as recipients for human skin
grafts. All mice were housed in filter-top cages, away from other animals, in specific bar-
rier-sustained conditions to decrease the incidence of infections. They were maintained on
autoclaved feed and acidified-chlorinated water, and bedding that was sterilised and chan-
ged weekly.
Grafting procedure
Informed consent was obtained from skin graft donors participating in this study. A
human skin sample of 0.6-mm thickness was taken with a keratotome from residual nor-
mal human skin after abdominoplasty. Samples were prepared for grafting by cutting into
circular pieces with 8-mm biopsy forceps. The mice were anaesthetised with ether and a
full thickness bed of 8 mm in diameter was prepared for the grafts. Each mouse received
two skin grafts on the upper-thoracic region, one on either side of the midline on the dor-
sal surface of the mouse. Grafts were fitted carefully into the graft bed, and the area was
bandaged with a sticking plaster and self-adhesive tape. On the 10th day after grafting, the
adhesive tape and plaster were removed carefully and the grafts were then inspected at
regular time intervals. After the stated periods of time, up to 72 days after transplantation,
the mice were sacrificed and the grafts were removed in total with a small strip of sur-
rounding mouse skin. Tissues were further prepared for immunohistochemical examina-
tion.
UV irradiation of human skin grafts
Human skin grafts on the back of the mice were irradiated with UV-B. Therefore, the mice
were anaesthetised by i.p. injection of 200 mg/kg ketamine (Nimatek®, Eurovet, Bladel, the
Netherlands). To be sure that only the human skin grafts would be irradiated, the mice
were wrapped in aluminium foil with an 8-mm gap. Ultraviolet light was generated using
a Fluo-Link (Vilber Lourmat) with a peak wavelength of 311 nm. One of the two grafts on
each mouse was irradiated with either 1.0 or 1.5 J/cm2 UV; the remaining graft was used
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as negative control. Body temperature was monitored and kept constant by the use of a
warming blanket and lamp. Mice were sacrificed either 2 h or 48 h after UV-B irradiation
and the skin grafts were removed and prepared for immunohistochemical examination.
Immunohistochemistry
Skin specimens were fixed for 4 h in buffered 3.8% formalin and processed for embedding
in paraffin. Care was taken to embed the specimens so that sections could be cut perpen-
dicular to the skin surface. Sections (6 µm) were mounted on 3-aminopropyltriethoxy-
silane (Sigma) coated slides and were subsequently deparaffinised and rehydrated. For
antigen retrieval from paraffin sections, the slides were pre-treated two times 5 min in 10
mM citrate buffer for LL025 (CK16), for MIB-1 (Ki-67) and for Mon150 (involucrin) a
pre-treatment of 10 min in 10 mM citrate buffer using a microwave oven (Miele, M720)
at 450 W was performed. Sections to be stained for CK10 were pre-treated with trypsin for
15 min. For immunohistochemical detection of SKALP, SLPI and NFκB no pre-treatment
was necessary. After pre-incubation with 20% normal swine, goat, or horse serum (Vector
Laboratories Inc., Burlingame, CA) the slides were incubated for 60 min with the prima-
ry antibodies and washed with PBS. Samples for the detection of SLPI, CK16, involucrin,
CK10, and Ki-67 were subsequently incubated with the appropriate biotinylated secon-
dary antibody for 30 min. To enhance the staining, the sections were incubated with
Avidin-Biotin-Complex (ABC) after which they were developed with metal enhanced
DAB or aminoethylcarbazole (AEC) (Sigma) as a chromogenic substrate. Samples for the
detection of SKALP were incubated with peroxidase-conjugated swine-anti-rabbit Ig or
(Vector Laboratories Inc.). Apoptotic cells were identified using TUNEL staining as
described before [357]. Immunohistochemical detection of phosphorylated p38 was perfor-
med using an enhancement kit for rabbit polyclonal antibodies (CSA kit, DAKO). If neces-
sary, the slides were counterstained with Mayer’s haematoxylin (Sigma) and mounted in
glycerol gelatine. Appropriate controls with pre-immune sera, blocking peptides or omis-
sion of the primary antibodies were performed.
Antisera
A polyclonal antiserum against recombinant SKALP was obtained as described previously
[309]. An antiserum against a synthetic peptide comprising amino acids 23 to 36 of SKALP
was prepared by coupling the peptide via a C-terminal cysteine residue to chicken ovalbu-
min, using the sulfo-SMCC procedure according to the manufacturer’s instructions
(Pierce, Rockford, IL, USA). This conjugate was used for immunisation of a rabbit accor-
ding to previously described protocols [238]. Control serum (pre-immune serum) was drawn
before the immunisation procedure. The antiserum against the synthetic peptide was
affinity purified using the synthetic peptide coupled to Sulfolink coupling gel according to
the manufacturer’s instructions (Pierce). The two antisera against recombinant SKALP
and against the synthetic peptide gave identical staining patterns in histological sections.
Antisera against SLPI were prepared, characterised, and used as described before [356,442]. In
this study we used a monoclonal serum (clone 31) against SLPI, which shows no cross-
reactivity with SKALP. Mon150, a monoclonal antibody against involucrin was obtained
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as previously described [263], and LL025, a monoclonal antibody recognising CK16 was
from Novocastra. For detection of Ki-67, the MIB-1 antibody of Immunotech was used,
and RKSE60 was used to detect CK10. Dually phosphorylated p38 was detected by using
a rabbit polyclonal antibody from New-England Biolabs. And finally the detection of
NFκB was performed with a rabbit polyclonal antibody from Santa-Cruz directed against
the p65 subunit of the NFκB transcription factor complex.
Results and discussion
Human skin models have proven their usefulness, since studies on humans are often con-
sidered ethically unacceptable, very time-consuming when performed on a large scale
basis, and difficult to interpret due to large inter-individual variability. Ideally, skin models
should approach the source tissue very closely and have a high predictive potential for the
in vivo situation. In the past several years three-dimensional systems have been developed
that are based on the recombination of cultured cells in order to form a reconstructed epi-
dermis which approaches the in vivo situation much more closely then in vitro monolay-
er cultures. Nowadays, growing differentiated keratinocyte cultures on cell-free or fibro-
blast-populated dermal substrates can create various types of skin systems. Examples of
substrates are dead de-epidermized dermis [443], inert filter substrates [234], and fibroblast-
populated collagen matrices [444]. Morphological studies have shown that these skin equiva-
lents form a multilayered epithelium and express markers of epidermal differentiation [445].
These three-dimensional skin equivalents are however not optimal for all studies, becau-
se they only consist of two cell types (keratinocytes and fibroblasts). Especially when stu-
dying inflammation or other immunological processes, other cell types such as melanocy-
tes, Langerhans cells, and Merkel cells, may play important key roles. So, despite the fact
that the use of these three-dimensional skin equivalent systems in vitro has resulted in a
considerable progress in the understanding of keratinocyte biology, other organotypic
systems and mouse models have additional potential advantages for scientific research.
The aim of the study described in this paper was to develop and characterise methods 
by which the switch from normal epidermal differentiation to regenerative maturation
could be induced and studied in intact skin. In this report we use two skin models that
have been described previously by other groups: an organotypic air-exposed skin explant
model [236,440] and a grafting mouse model [441]. These two models were analysed immuno-
histochemically and compared with each other with respect to their response in differen-
tiation and proliferation.
Air-exposed skin explant model
The first model that was characterised in this study is the air-exposed skin explant model.
In this model we use 4 mm punch biopsies of intact normal human skin that are maintai-
ned in tissue culture inserts in KGM supplemented with 5 % FCS for 24 hours. During this
period, the stratum corneum was air-exposed. We evaluated expression levels and patterns
of a number of genes that are regularly used as markers for epidermal proliferation (Ki-
Chapter 5Manipulation of epidermal differentiation in vivo
129
67), normal differentiation (CK10), and abnormal regenerative maturation (SKALP, SLPI,
CK16, involucrin). The markers for regenerative maturation are known to be strongly
induced (SKALP, CK16) or upregulated (SLPI, involucrin) in response to the disruption
of epidermal integrity like injured skin and during skin inflammation, as found in the skin
disease psoriasis.
Figure 1 shows immunohistochemical staining of the different markers in our explant
model. In explants cultured for 24 h, SKALP and SLPI (two proteinase inhibitors) were
strongly expressed in the granular layers. Some keratinocytes of the spinous layers also
tend to express SLPI. CK16 showed a minor increase in expression level (mainly in the
stratum granulosum), whereas involucrin was grossly upregulated in comparison to nor-
mal skin. Involucrin was present in spinous and granular layers of cultured explants. This
expression pattern was similar to that of submerged keratinocyte cultures, in which
expression of SKALP, SLPI, CK16, and involucrin can be induced/upregulated by the addi-
tion of 5% FCS. [77,356]. The 24 h-incubation period did not alter the expression levels of
CK10 and Ki-67. CK 10 was localised in the suprabasal layers and several basal keratino-
cytes showed expression of Ki-67, this is similar to their expression patterns in normal epi-
dermis. Based upon these expression patterns we hypothesise that regenerative maturation
can be induced through a 24 h-incubation of normal human skin explants in culture. In
principle this makes sense, as during this 24-h of incubation the keratinocytes in the mar-
gins of the explant react by inducing the process of wound healing, which is known to be
attended by the initiation of regenerative maturation.
This explant model could be useful to examine factors involved in regenerative matura-
tion or wound healing processes. In contrast to submerged culture models, tissue archi-
tecture is still similar to that of native skin, all epidermal strata are present with compara-
ble appearance. There are however also limitations of this explant model, for example the
lack of a vasculature and of migrating inflammatory cells. The ultimate manifestation of
inflammation can not be simulated in this system. Furthermore, the lifespan of explants
in culture covers a maximum of 24 h and therefore long-term studies are limited.
Skin grafting mouse model
Although laws and regulations are becoming more stringent regarding laboratory tests on
animals, animal models are still valuable tools in scientific research. We have used a model
of human skin grafted onto nude mice and investigated if we could switch the epidermal
differentiation pattern from normal to regenerative. For examination of the differentia-
tion pattern of the keratinocytes, immunohistochemical staining was performed using
antibodies directed against the cytokeratins CK10 and CK16 (specific keratinocyte diffe-
rentiation markers), SKALP and SLPI (proteinase inhibitors and antimicrobial proteins),
involucrin (precursor of the cornified envelope), and Ki-67 (proliferation marker).
Initially the expression pattern of the various marker genes was investigated at different
time-points during a period of 72 days after transplantation. As shown in figure 2, at day
15 (the first time-point) after transplantation the skin grafts show expression of the pro-
teinase inhibitors SKALP and SLPI, which is restricted to the keratinocytes in the granu-
lar layer. In addition the expression level of CK16 is very high in all suprabasal layers of
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the transplant, whereas involucrin is only highly expressed in upper spinous and granular
layers. Furthermore, the transplants show an elevated proliferation rate, since the number
of keratinocytes in the basal layer that stain positively for the Ki-67 antibody (MIB) is
increased. CK 10, a cytokeratin that is generally used as a marker for normal keratinocyte
differentiation, is expressed in all suprabasal layers, and its expression level remain
unchanged during the whole period of 72 days (not shown). Moreover we also observed a
thickening of the stratum corneum of the skin following transplantation (see figure 2).
Acanthosis of human skin grafts was found earlier by Bruengger et al. [446], who presumed
an adaptation to the changed mechanical stress. In summary, expression levels of proteins
that are absent or only slightly expressed in normal human epidermis but associated with
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Figure 1. Immunohistochemical analysis of differentiation and prolifera-
tion related gene expression in the air-exposed skin explant model.
Expression patterns of SKALP, SLPI, CK10, CK16, involucrin, and Ki-67
(MIB) in skin explants that were cultured in KGM supplemented with 5
% FCS (second column) were compared to those in normal skin (NS
(first column)). The culture period of 24 hours results in a slight increase
in the expression of genes associated with abnormal epidermal differentia-
tion e.g. SKALP, SLPI, CK16. The expression of involucrin is also marked-
ly increased whereas the proliferation rates in the basal layers are unaffec-
ted by the culturing period.
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Figure 2. Immunohistochemical analysis of differentiation and proliferation related gene expression in the skin
grafting model on nude mice. Expression patterns of SKALP, SLPI, CK16, involucrin, and Ki-67 (MIB) were
analysed at day 15 (column 2), 29 (column 3), 42 (column 4), 64 (column 5) and 72 (column 6) after the trans-
plantation of human skin and compared to normal skin (first column). In the last column the transition zone
between recipient mouse skin and transplanted human skin is shown. The expression of SKALP, SLPI, CK16,
and involucrin is increased in freshly transplanted skin until at least day 42. The apparent positive staining of
SKALP at day 0 is caused by counterstaining. At timepoints 15, 29 and 42 days after transplantation, a slight
increase in SKALP expression in the granular layer and the first layers of the spinous layer was found. Normal
skin stains positive for SLPI expression in the granular layer. At day 15, 29, and 42 SLPI is also expressed in the
upper layers of the stratum spinosum after which the expression returns to normal levels. CK16 expression is
absent in normal skin and found to be induced in the upper spinous layers at day 15, 29, and 42 after which
CK16 expression normalises. The use of a monoclonal antibody against CK16 results in rather high background
staining (especially found at day 42 and later). Involucrin is expressed in the stratum granulosom in normal
skin. In freshly transplanted mice (day 15 and 29) involucrin expression is found throughout the stratum spino-
sum as well. At day 64 the expression of involucrin returns to normal patterns. The proliferation rate of the
basal keratinocytes is slightly increased in transplanted human skin until at least day 29 (nuclei that stain posi-
tive for Ki-67 in the basal layers). After day 42 the number of proliferative basal cells normalise to initial levels.
The spinous layers of the skin transplants at the transition zone between mouse skin and human skin (last
column) remain positive for SKALP, SLPI, CK16 and involucrin. The proliferation rate of the basal keratinocytes
in this region is also increased compared to normal human skin (day 0) as witnessed by positive staining for Ki-
67 in the basal nuclei.
wound repair, hyperproliferation, and abnormal differentiation, are upregulated at day 15
after transplantation. In course of time, expression patterns of these markers that were ini-
tially upregulated, normalise to basal levels comparable to levels in normal human skin.
The transition zone between mouse skin and human skin transplant forms an exception.
These transplant margins remain positive until at least day 72 for SKALP, SLPI, CK16,
involucrin, and Ki-67 expression. So, except for the transplant margins, at day 72 after
transplantation, human skin transplants show an expression pattern of proliferation and
differentiation-specific genes that is essentially similar to normal differentiation.
Having established that already 30-40 days after transplantation the grafted human skin
mimics normal human skin, a method was sought to switch the epidermal differentiation
from normal to regenerative. It is known that regenerative differentiation is induced in
situations of epidermal stress. We therefore examined the effects of two stress-inducing
conditions, ultraviolet (UV)-B irradiation and tape stripping, on expression levels of the
investigated genes. Recently it was shown that UV-B irradiation of keratinocytes in vitro
and human skin in vivo leads to the activation of cellular stress response pathways, which
is exhibited by activation of p38, JNK, NFκB, AP-1, and to a lesser extent ERK. [130,133,339].
Examples of UV-B induced alterations in gene expression levels of human keratinocytes
are the upregulation of ICAM-1 [348], upregulation of CK 1/10 and 5/14 [349], and induction
of CK 16 [350]. Very recently, we found that SKALP, SLPI, CK16 and involucrin expression
was induced suprabasally after irradiating human skin with 2 MED of UV-B light. This
induction of gene expression was preceded by activation of cellular stress response path-
ways such as phosphorylation of c-jun and p38 MAP kinase (Pfundt et al. submitted).
Another stress-inducing condition that is known to cause increased SKALP and SLPI
expression in vivo is tape stripping. Through the repeated application and removal of
adhesive tape the stratum corneum is removed. This procedure can be used as a model for
standardised epidermal injury of the epidermis and epidermal osmotic stress [14,202,356]. We
were interested to know whether we could induce regenerative maturation by either UV-
B irradiation or tape stripping in human skin transplants. In figure 3, expression levels of
the earlier mentioned protein markers were analysed after either irradiation with 1.5
J/cm2 UV-B or tape stripping and compared with expression levels in untreated skin
transplants. Expression of SKALP, SLPI, CK16 and involucrin is induced, both 48 hours
after irradiation and 48 hours after tape tripping indicating the induction of abnormal
epidermal differentiation. The localisation pattern of this protein expression is however
different between UV-B irradiation and tape stripping. After irradiation, the upper spi-
nous layers and the granular layers of the epidermis stain negative for all the markers. A
band of positive cells can be found in the middle layers of the stratum spinosum. Based on
the morphology of the upper spinous and the granular layers and the presence of sunburn
cells in these locations we conclude that these cell layers are heavily damaged by the irra-
diation procedure and are/will become apoptotic (see figure 3). The presence of apopto-
tic cells in these cell layers is described below. The middle cell layers that have received
lower doses of UV-B radiation respond by altering their gene expression patterns. This in
contrast to the tape stripping procedure which is obviously less damaging. Forty-eight
hours after the stripping procedure expression of SKALP, SLPI, CK16 and involucrin can
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be found in the upper spinous and granular layers (see figure 3). Expression levels of CK10
remain constant, this was also found during 72 days after transplantation. Furthermore,
irradiation and tape stripping lead to an elevated proliferation rate, since massive num-
bers of keratinocytes in the basal layer stain positive with the Ki-67 antibody (MIB). This
indicated that epidermal hyperproliferation is induced both after UV-B irradiation and
tape stripping.
It is known that the effect of UV-B irradiation of human skin is dose-dependent. High
doses can lead to the formation of apoptotic (sunburn) cells [351,352], whereas lower doses of
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Figure 3. Immunohistochemical analysis of diffe-
rentiation-related gene expression in the grafting
mouse model 48 hours after UV-B irradiation
(second column (1.5 J/cm2)) and tape stripping
(third column) compared to untreated skin graft
(first column). The expression levels of SKALP,
SLPI, CK16, CK10, involucrin, and Ki-67 (MIB)
are shown. Irradiation of the skin grafts results in
induction of SKALP, SLPI, CK16 and involucrin
gene expression in the middle layers of the stra-
tum spinosum, and massive induction of cell pro-
liferation in the basal layer(s). After tape stripping
SKALP, SLPI, CK16 and involucrin expression is
also induced but in the upper layers on the stra-
tum spinosum and the stratum granulosum. In
addition tape stripping also results in high pro-
liferation rates in the basal layers(s). Expression of
cytokeratin 10 (CK10) remains unchanged.
UV-B allow cell survival and repair of genetic damage [354]. In the upper epidermal layers
of all irradiated transplants we observed hotspots of keratinocytes with apoptosis resem-
bling features (cell shrinkage and fragmentation). Therefore we performed TUNEL assays,
which show that these hotspots indeed contain apoptotic keratinocytes (figure 4). Based
on earlier studies (Pfundt et al., submitted) we examined the presence and/or activation
patterns of two proteins involved in stress-induced signal transduction pathways i.e. p38
and NFκB, following UV-B irradiation of the human skin transplants. As shown by immu-
nohistochemical staining (figure 4) both proteins are affected by the irradiation procedu-
re. In the keratinocytes of the grafted human skin NFκB is localised mainly cytoplasmic,
whereas 2 hours after UV-B irradiation NFκB is translocated from the cytoplasm to the
nucleus of the keratinocytes (see figure 4). Phosphorylated (hence activated) p38 is pre-
sent in untreated skin grafts in very small amounts (see figure 4). However after irradia-
tion the skin graft within 2 hours massive amounts of active p38 are present in the nuclei
of keratinocytes throughout the epidermis. This apparent recruitment of stress related
proteins to the nuclei of irradiated keratinocytes suggest involvement of these proteins in
nuclear processes like DNA repair programs or transcriptional activities. It should howe-
ver be noted that the dose of UV-B that was used in this experiment is considerably hig-
her than doses that are generally used in studies with normal human skin. In earlier per-
formed studies using healthy human volunteers we have found identical results, with
respect to protein expression patterns and stress-protein recruitment, using approximate-
ly a four-fold lower UV-B dose. We suspect that the enhanced thickening of the stratum
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Figure 4. Analysis of the cellular stress related proteins p38 (row 1)
and NFκB (row 2), 2 hours after UV-B irradiation (second column)
compared to untreated skin graft (first column). Phosphorylated
p38 is absent in untreated skin grafts, but in response to UV-B irra-
diation high levels of dually phosphorylated p38 were found
throughout the epidermis (row 1, column 2). The transcription fac-
tor NFκB is localised cytoplasmic in untreated skin grafts and
translocated to the nuclei within 2 hours after UV-B irradiation
(row 2, column 2). Forty-eight hours after UV-B irradiation the
presence of apoptotic cells was analysed using TUNEL staining. In
untreated skin grafts no TUNEL positive cells were detected (first
column, row 3) whereas after UV-B irradiation apoptotic keratino-
cytes could be detected in the upper layers of the stratum spinosum
and stratum granulosum (second column, row 3).
corneum in the skin grafts that was mentioned earlier could very well cause this differen-
ce. This hypothesis is confirmed by the observation that the activation of p38 and NFκB
was clustered on zones where the stratum corneum was obviously thinner (not shown).
In conclusion, the explant model and the transplantation model have great potential
value for studies aimed at the elucidation of the factors involved in the switch in epider-
mal differentiation. These models are attractive because different cell types and environ-
mental factors leading to regenerative differentiation may be studied in human tissue. In
the explant model, regenerative differentiation is induced within 24 h by the explant cul-
ture procedure itself, whereas in the skin grafting mouse model, UV-B irradiation and tape
stripping can induce this abnormal epidermal phenotype. Furthermore these models may
be suitable for testing new active pharmacological compounds or other agents that could
potentially interfere with this epidermal differentiation switch. However, investigators
should keep in mind that the grafted mouse model is still a ‘two-species-system’ and the
preparation time can run to several months. In contrast, the air-exposed skin explant sys-
tem is easy to handle, but long-term studies are restricted to 24 h due to the limited life-
span of the explants. Overall, although there is no model imitating the in vivo situation
completely, many aspects of normal and regenerative maturation are mirrored in the cur-
rently available models, including in vitro submerged keratinocyte cultures, three-dimen-
sional skin equivalent systems, organotypic explant model, and grafting mouse model.
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Abstract
Targeted and selective inhibition of keratinocyte gene expression in human epidermis
could be an efficient and safe pharmacological approach in a number of skin diseases. In
this study we investigated if topical application of antisense oligodeoxynucleotides
(ODNs) on intact human skin, can be used to inhibit expression of a gene in the differen-
tiated compartment of the epidermis. We applied a variety of 20-mer antisense and con-
trol ODNs designed to hybridise to different regions on the mRNA of the inducible epi-
dermal proteinase inhibitor SKALP/elafin that was used as a model target gene. When
nuclease-resistant fully phosphorothioate ODNs were applied to explant cultures of
human skin, they were found to be either ineffective at low doses or severely toxic at hig-
her doses which could be due to the extremely high degree of protein binding found with
this type of ODNs. When chimeric ODNs with a phosphodiester core and phosphorot-
hioate 5’ and 3’ ends were applied to intact skin no toxicity was noted. One of the tested
chimeric ODNs, that exhibit only minor protein binding, was found to inhibit SKALP
expression at the protein level in a dose-dependent manner. The observed inhibition on
SKALP expression levels was specific as evaluated by application of strict criteria.
Sequence-specificity was assessed by the addition of sense and scrambled ODNs that were
ineffective. Furthermore, the expression levels of three other differentiation-related genes
(involucrin, cytokeratin 16 and SLPI) were not affected, indicating that the inhibition was
gene-specific. Confocal laser scanning analysis of fluorescently labeled ODNs confirmed
that these molecules can easily penetrate the epidermis and localize in the cytoplasm of
differentiated keratinocytes. We conclude that topical application of antisense ODNs can
be used to modulate epidermal gene expression, and could potentially be useful to inhibit
expression of genes that are relevant in skin diseases.
Introduction
Antisense technology has gained increasing experimental and clinical interest as a tool to
modulate expression of a single gene, although considerable skepticism has been justly
expressed because of poorly controlled studies and non-sequence specific effects of
phosphorothioate oligodeoxynucleotides (ODN) [447,448]. The basis for antisense ODN-
based therapies is the formation of an antiparallel duplex by complementary base pairing
between the antisense ODN and the targeted mRNA. This results in the inhibition of
translation either by cleavage of the mRNA by RNaseH or through steric hindrance of the
ribosomal translation apparatus. The highly selective targeting of exact nucleic acid
sequences is a great advantage of this technique. The specific inhibition of gene expression
is preferred over the working mechanism of conventional drugs that are targeted at whole
pathways, complexes, or cell systems. The potential usefulness of antisense ODNs to inhi-
bit gene expression in vivo has been studied by several investigators and it is expected that
it will lead to new therapies for a number of human diseases. Nowadays these compounds
are already being investigated as therapeutic agents for the treatment of viral infections,
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cancers, and inflammatory diseases [449-451]. The most widely used, nuclease-resistant, ODNs
are the phosphorothioate (PS) ODNs, where one of the non-bridging oxygens in the
phosphodiester backbone is replaced with a sulfur. However, there are serious doubts
about the specificity of these compounds, because they were also found to exhibit effects
on cells that are not due to antisense mechanisms [448,452,453]. These non-antisense effects of
PS ODNs can be either sequence-dependent or sequence-independent. Examples of repor-
ted sequence-independent effects are SP1 induction [454], and binding of proteins such as
basic fibroblast growth factor, laminin, and fibronectin [455,456]. There are also reports of PS
ODN sequences that cause sequence-dependent non-antisense effects. For example, three
or more consecutive guanosine residues in a row that form G quartets resulting in the for-
mation of ODN aggregates and inhibition of phospholipase A2 enzyme activity [457]. In
addition, unmethylated CpG motifs promote B-cell activation and the production of
proinflammatory cytokines, including TNF-α, IFN-γ, IL-6, and IL-12 [458-460]. It has become
clear that the antisense technology requires careful experimental design and interpretation
of results, since it is complicated by frequent non-sequence dependent effects, and even
the control ODNs can exhibit sequence-dependent effects.
Because human skin is very accessible in contrast to most internal organs, diseases invol-
ving aberrant gene expression in the epidermis are likely candidates for treatment by
antisense ODNs. We therefore started to explore the uptake of ODNs and modulation of
gene expression in cultured keratinocytes. Although ODN are readily taken up by kerati-
nocytes [461], in our hands ODNs were not useful to study modulation of gene expression
in cultured keratinocytes, since the observed effects on two targeted genes could not be
ascribed to sequence specific antisense action (Wingens et al, submitted). Subsequent
experiments, however, revealed that the uptake and subcellular localisation of ODN was
different between cultured cells and intact skin. We therefore reasoned that the failure 
of finding a specific effect in vitro did not preclude the possibility that ODNs could be
effective in another experimental system. Therefore, we examined the application of anti-
sense ODNs in an air-exposed skin explant system that resembles the in vivo situation. The
gene targeted in this study is skin derived antileukoproteinase (SKALP), also known as
elafin [293], which we have extensively characterised at the cell biological and genetic 
level [246,408]. SKALP is, for various reasons, very suitable as a model gene to investigate anti-
sense action. Its expression can be induced in the upper layers of the epidermis by a 24-h
incubation in growth medium supplemented with 5% fetal calf serum. In addition,
SKALP expression levels can easily be followed on mRNA and protein level. An important
control, very often overlooked in antisense studies is gene-specificity of the applied ODN.
In the case of SKALP, specific inhibition can be proven by checking the expression levels
of the closely related gene coding for secretory leukocyte proteinase inhibitor (SLPI),
a homologous proteinase inhibitor with similar expression patterns and regulation
mechanisms, as was recently described [356,361]. Expression patterns of unrelated genes either
constitutively expressed such as involucrin, or inducible such as cytokeratin 16 (CK16),
and the effect of sense and scrambled ODNs were used as additional controls. Our results
show that if these strict criteria are applied, target specific inhibition of SKALP gene
expression can be demonstrated in this air-exposed skin culture model.
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Materials and methods
Air-exposed skin explant model
Punch biopsies (4mm diameter) were taken from residual human skin after abdomino-
plasty. Informed consent was obtained from patients participating in this study. These
explants were washed in PBS, and placed with epidermis up in a Transwell insert system
with tissue culture treated polycarbonate membranes (Corning Costar Corporation,
Badhoevedorp, the Netherlands). The inserts with the skin explants were put in 24-well
tissue culture plates in keratinocyte growth medium (KGM) supplemented with 5% fetal
calf serum (FCS) (Seralab, Nistelrode, the Netherlands). KGM was composed of keratino-
cyte basal medium (KBM) ((Clonetics, San Diego, CA, USA); 0.15 mM calcium) supple-
mented with ethanolamine (0.1 mM, Sigma, St. Louis, MO, USA), phosphoethanolamine
(0.1 mM, Sigma), bovine pituitary extract (BPE) (0.4 % v/v, Clonetics), recombinant
mouse epidermal growth factor (EGF) (10 ng/ml, Sigma), insulin (5 µg/ml, Sigma),
hydrocortisone (0.5 µg/ml, Collaborative Research Inc. Lexington, MA, USA), and peni-
cillin plus streptomycin (Life Technologies, USA). The stratum corneum of the explant
was air-exposed, and the ODNs were added locally on top of the skin explants. The
explants were incubated at 37˚C under a 92% humidified atmosphere containing 5% CO2
in air.
Oligodeoxynucleotides
HPLC-purified oligodeoxynucleotides (ODNs) were purchased from Eurogentec S.A.
(Seraing, Belgium) and resuspended in sterile water. Two chemically different ODNs were
used: the most often used phosphorothioate (PS) ODNs, and chimeric only partially
phosphorothioated (PSPO) ODNs. The chimeric ODNs have a phosphodiester core and
contain three phosphorothioated linkages at the 5’ and 3’ends. All ODNs were 20 nucle-
otides in length and were designed to optimize for sites with maximal melting temperatu-
re (Tm) and minimal self-complementarity. Furthermore, G-quartets and CpG-sequences
were avoided as much as possible, since these sequences are thought to cause unwanted
site-effects [448,460]. The ODNs were complementary to four different regions of the human
SKALP mRNA (figure 1) and the characteristics and sequences of the ODNs are listed in
Table 1. The concentration of the ODN was determined by their optical density at 260 nm.
From a stock solution of 500 µM, 1 µl (0.5 nmol) or 5 µl (2.5 nmol) was pipetted on top
of the skin explants and incubated for 24 h at 37˚C under a 92% humidified atmosphere
containing 5% CO2 in air. After ODN incubation, the protein expression levels and RNA
expression levels in the explants were studied by immunohistochemistry and Northern
blotting respectively. For the determination of ODN uptake and distribution in the skin
explants we used fluorescently labeled ODNs and a Biorad MRC-600 confocal laser-scan-
ning microscope (CLSM) with an argon laser. CLSM allows an optical section to be cut
through cells and even through whole explants and is therefore very suitable for the deter-
mination of the intracellular localisation of ODNs.
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Antisera
A polyclonal antiserum against recombinant SKALP was obtained as described previous-
ly [255]. An antiserum against a synthetic peptide comprising amino acids 23 to 36 of SKALP
was prepared by coupling the peptide via a C-terminal cystein residue to chicken oval-
bumin, using the sulfo-SMCC procedure according to the manufacturer’s instructions
(Pierce, Rockford, IL, USA). This conjugate was used for immunisation of a rabbit ac-
cording to previously described protocols [238]. Control serum (pre-immune serum) was
drawn before the immunisation procedure. The antiserum against the synthetic peptide
was affinity purified using the synthetic peptide coupled to Sulfolink coupling gel accor-
ding to the manufacturer’s instructions (Pierce). The two antisera against recombinant
SKALP and against the synthetic peptide gave identical staining patterns in histological
sections. Antisera against SLPI were prepared, characterised, and used as described 
before [356,462]. In this study we used a monoclonal serum (clone 31) against SLPI, which
shows no cross-reactivity with SKALP. Mon150, a monoclonal antibody against involucrin
was obtained as previously described [263], and Ks8.12, a monoclonal antibody recognising
CK13 and 16 was from Sigma.
Immunohistochemistry
Explants were fixed for 4 h in buffered 3.8% formalin and processed for embedding in
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Name ODN target site sequence (5'-3') backbone
PSASSK5 antisense coding region exon 2 GCACTTCTTGATTCCTGGGC PS
PSSESK5 sense coding region exon 2 GCCCAGGAATCAAGAAGTGC PS
PSSCSK5 scrambled coding region exon 2 GGGTTATGCCTTCCAGCCTT PS
PSPOASSK5 antisense coding region exon 2 GCACTTCTTGATTCCTGGGC PSPO
PSPOSESK5 sense coding region exon 2 GCCCAGGAATCAAGAAGTGC PSPO
PSPOSCSK5 scrambled coding region exon 2 GGGTTATGCCTTCCAGCCTT PSPO
PSPOASSK6 antisense translation start site AAGAAGCTGCTGGCCCTCAT PSPO
PSPOSESK6 sense translation start site ATGAGGGCCAGCAGCTTCTT PSPO
PSPOSCSK6 scrambled translation start site TACACGCGTATGCTAAGCCG PSPO
PSPOM1SK6 mismatched translation start site AAGAATCTGCTGGCCCTTAT PSPO
PSPOM2SK6 mismatched translation start site AAGAAGACATACGCCCTCAT PSPO
PSPOASSK7 antisense coding region exon 1 TGAGGAACACCACCACGATC PSPO
PSPOASSK8 antisense transglutaminase domain GTCTTGACCTTTAACAGGAA PSPO
POASSK5 antisense coding region exon 2 GCACTTCTTGATTCCTGGGC PO
POASSK6 antisense translation start site AAGAAGCTGCTGGCCCTCAT PO
All ODNs used are 20 nucleotides in length. Sense control ODNs are complementary to the antisense sequence;
scrambled ODNs have the same base composition as the antisense ODNs, though in random order. Underlined
nucleotides represent mismatches. PS=phosphorothioate, PO=phosphodiester, PSPO=chimeric phosphodiester
ODN with three phosphorothioate linkages at 5' and 3' ends.
Table 1 Characteristics of SKALP ODNs used in this study.
paraffin. Sections (6m) were mounted on 3-aminopropyltriethoxy-silane (Sigma) coated
slides. Sections were deparaffinised, rehydrated, and used for an indirect peroxidase tech-
nique. For antigen retrieval from paraffin sections, the slides were pretreated for 30 min
in 10 mM citrate buffer for Ks8.12, and for Mon150 a pretreatment of 10 min in 10 mM
citrate buffer using a microwave oven (Miele, M720) at 450 W was performed. After preïn-
cubation with 20% normal swine or rabbit serum (Vector Laboratories Inc., Burlingame,
CA) the slides were incubated with the antibodies and after washing with PBS they were
incubated with peroxidase-conjugated swine-anti-rabbit Ig or rabbit-anti-mouse Ig
(Vector Laboratories Inc.) for 30 min. A solution of aminoethyl carbazole (AEC) (Sigma)
in sodium-acetate buffer pH 4.9 containing 0.01% H2O2 was added for 15 min after
preincubation with sodium-acetate buffer pH 4.9. If necessary, the slides were counters-
tained with Mayer’s haematoxylin (Sigma) and mounted in glycerol gelatin. Appropriate
controls with pre-immune sera or omission of the primary antibodies were performed.
RNA-extraction and Northern blot analysis
Total RNA was extracted from explants using RNase-All (2.1 M Guanidine thiocyanate
(Research Organics Inc., Cleveland, USA), 8.5 mM N-lauroylsarcosine (Sigma), 12.5 mM
NaAc pH5.2, 0.35% v/v β-mercapto-ethanol (Merck, Darmstadt, Germany) and 50% v/v
Tris-saturated biophenol pH 8.0 (Biosolve, Amsterdam, the Netherlands). Skin explants
were added to a cold tube with RNase-All and homogenised with a blender. The homoge-
neous suspension was transferred to a vial and 0.1 volume of chloroform was added. After
vigorously mixing, the homogenates were centrifuged for 15 minutes (13000 rpm, 4C),
and the aqueous phase was brought to a new vial. Samples were mixed and kept on ice for
45 minutes after addition of one volume of isopropanol. After 15 minutes of centrifuga-
tion (13000 rpm, 4˚C), the RNA pellet was washed once with 70% ethanol and dried at
room temperature for 5 minutes. The RNA pellet was resuspended in 150 µl NSE (50 mM
NaAc/0.2% SDS/2 mM EDTA) and 562.5 µl 100% ethanol was added. For quantification,
62.5 µl of this RNA suspension was pelleted, resuspended in 625 l H2O and spectropho-
tometrically analyzed at 260 nm. Ten µg total RNA was denatured by glyoxal and DMSO,
loaded on a 1% agarose gel and electrophoretically separated in 10 mM sodium phospha-
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The mRNA encodes for three protein domains: the signal sequence, the transglutaminase domain, and the pro-
teinase inhibiting domain. The selected antisense ODNs of 20 nucleotides in length were complementary to one
region in each domain and another one covered the translation initiation codon (aug). Several segments with
frequent occurrence of cg or cccc sequences were avoided.
signal sequence transglutaminase domain proteinase inhibiting domain
5' 3'
     aug
ODN: cg cg cccc   cg ccccc  cg cg    cccc
6 7 8 5
te buffer, pH 7.0. The pH of the electrophoresis buffer was kept within acceptable limits
by constant circulation of the buffer. The gels were blotted by capillary transfer on positi-
vely charged nylon membranes (Boehringer, Mannheim, Germany) using 10 x SSC (1.5 M
NaCl, 0.15 M Sodium citrate). After RNA transfer, membranes were washed in 2 x SSC,
and RNA was cross-linked to the membrane using ultraviolet irradiation (312 nm, 0.2
J/cm2). Hybridisation was performed in phosphate buffer at 65˚C overnight using probes
that were labeled with [α-32P]-dTCP by random priming following standard procedures.
We used cDNA probes of the two inducible genes SKALP and SLPI, the last was kindly
donated by Dr R. Heinzel-Wieland (Grünenthal GmbH, Aachen, Germany). Furthermore,
cDNA probes of two constitutively expressed genes, involucrin and human acidic ribo-
phosphoprotein (hARP) [311], were used. The amount of 28S ribosomal RNA was deter-
mined to demonstrate equal loading of the gel. All autoradiography was done on X-Omat 
X-ray films (Kodak, Odijk, the Netherlands) at -80˚C with an intensifying screen.
Quantification of mRNA levels on northern blots was performed with a Biorad GS-363
Phosphor imaging system.
Radiolabeling of oligodeoxynucleotide probes
ODNs were labeled with 32P at the 5’ end by a T4 polynucleotide kinase labeling reaction.
Therefore, 20 pmol ODN was added to a buffer containing 50 mM Tris pH7.5, 10 mM
MgCl2, 5 mM DTT, and 50 µg/ml BSA. Then, 150 µCi [γ-32P]ATP (Amersham, UK) and
20 Units T4 polynucleotide kinase (New England Biolabs, UK) were added, mixed, and the
mixture was incubated for 60 minutes at 37˚C. The labeling reaction was stopped by
adding 1 µl of 0.5 M EDTA. The labeled ODN was separated from the unincorporated
labeled nucleotides by centrifugation through a spin column containing Sephadex G-50
(Pharmacia Biotech, UK).
Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were extracted from keratinocytes grown in KGM with 5%FCS for 2 h.
In brief, cells (3-6 x 106) were washed and allowed to swell in hypotonic buffer (10 mM
HEPES pH7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT) for 15 minutes on ice. The cell
suspension was transferred to a 7 ml dounce homogeniser (Kontes) and the cells were
lysed, in the presence of 0.2% Nonidet NP40, by 20 strokes with pestle B. The nuclei were
pelleted by centrifugation (30 sec, 13.000 rpm, 4˚C) and were thoroughly resuspended in
150 µl buffer B (20 mM HEPES pH7.9, 10 % glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 0.5 mM DTT, 1 mM PMSF). After centrifugation (5 min, 13.000 rpm, 4˚C),
the protein concentration of the nuclear protein extract was determined.
For the protein-ODN binding reaction, 105 cpm of 32P-labeled ODN, 1 µg of nonspecific
competitor DNA poly(dI-dC) (Pharmacia Biotech), and 10 µg nuclear protein extract
were added to a buffer containing 10 mM Tris pH7.6, 50 mM KCl, 1 mM EDTA, 5% gly-
cerol, and 1 mM DTT. This mixture was incubated for 30 minutes at room temperature.
Reaction mixture was run on a 4 % non-denaturing polyacrylamide gel at 10-15 Volts/cm
during 2 h. Gels were dried on a gel dryer (Savant model SGD2000) and autoradiograp-
hed at -80˚C using X-Omat X-ray films (Kodak) at -80˚C with an intensifying screen.
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Quantification of the protein-bound and free ODN levels was performed with a Biorad
GS-363 Phosphor imaging system.
Results
Phosphorothioate and chimeric ODNs are readily absorbed into 
intact air-exposed skin explants
We studied the uptake and distribution of phosphorothioate and chimeric ODNs in a skin
explant model. One nmol of FITC-labeled ODN was applied on the epidermal side of the
air-exposed explants. Figure 2A shows the CLSM view of the distribution of chimeric
PSPO ODNs in the explants after a 24 h incubation period. The PSPO ODNs were easily
absorbed, and were located in the cytoplasm of the keratinocytes in the upper layers of the
epidermis. In the dermis, cells with positive nuclear staining were found. Furthermore,
most of the basal cells appeared to be completely negative. The stratum corneum was stai-
ned very strongly. To exclude the possibility that staining of the cells was caused by resi-
dual free fluorescein in the ODN preparations we used pure fluorescein as a control, a
compound known not to diffuse freely into viable cells. As shown in figure 2B free fluo-
rescein behaves totally different and does not accumulate in the living cell layers. Only the
stratum corneum is strongly positive. Incubation of the explants with FITC-labeled PS
ODNs showed identical results as found with the chimeric ODNs (not shown).
Phosphorothioate ODNs cause toxic non-sequence-specific effects in skin explants
In normal human skin the proteinase inhibitor SKALP is not expressed, and the proteinase
inhibitor/antimicrobial protein SLPI is weakly expressed in the stratum granulosum [246,356].
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Figure 2. Uptake of FITC-labeled PS ODNs in air-exposed
skin explants. Skin explants were incubated with 1 nmol
FITC-labeled antisense SKALP PS ODNs (A) or free fluores-
cein (B) for 24 h at 37˚C. ODN uptake was visualised by con-
focal laser scanning microscopy. Scale bar: 100µm.
Immunohistochemical staining of skin explants which were incubated for 24 h in KGM
with 5% FCS under air exposure showed an induction of SKALP in the upper epidermal
layers, and an upregulation of SLPI expression which was now also present in the stratum
spinosum. Expression levels of involucrin and CK 16, two differentiation-related markers,
were also increased compared to normal skin (not shown). As normal PO ODNs are
known to be broken down very rapidly by exo- and endo-nucleases, we examined the
modified nuclease-resistant PS ODNs for their ability to inhibit the induced SKALP
expression. To this end PS ODNs  were applied topically onto the epidermis of the skin
explants and incubated for 24 h. We studied the effects of antisense PS ODNs, targeted at
the coding region (exon 2) of the SKALP mRNA, and the corresponding control sense and
scrambled PS ODNs. Figure 3 shows the H&E-staining and the immunostaining for
SKALP and involucrin of the PS ODN-treated explants. Application of 2.5 nmol of all
types of PS ODNs caused signs of severe cellular toxicity. Necrosis-like features such as cell
shrinkage and loss of attachment between cells were observed in the upper layers of the
epidermis throughout the whole explant as seen with H&E-staining. The effect was dose
dependent as 0.5 nmol of PS ODNs caused mild cellular damage. After the addition of 2.5
nmol antisense or sense PS ODNs, SKALP and involucrin expression levels were slightly
decreased in comparison to the expression levels in untreated explants. When scrambled
PS ODNs were used, similar effects were seen indicating that the effect was non-specific.
For comparison, we stained the explants for CK 16, a differentiation-related marker, and
for SLPI, a SKALP-related protein. The expression levels of these genes were also slightly
diminished by the antisense, sense, and scrambled PS ODNs (not shown). When 0.5 nmol
of ODNs was applied the expression of all the aforementioned genes was still slightly
decreased by all types of PS ODNs. No sequence-specific effects were seen.
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Figure 3. Immunohistochemical staining
of SKALP and involucrin expression in
explants incubated with PS ODNs targe-
ted at the coding region (exon 2) of the
SKALP mRNA. Skin explants were incu-
bated with 2.5 nmol antisense or sense
SKALP PS ODNs for 24 h at 37˚C. H&E-
staining reveals morphological abnormali-
ties in the epidermis. Scale bar: 100 µm.
A chimeric antisense SKALP ODN induces sequence-specific  inhibition of SKALP expression
in skin explants
Because all the PS ODNs tested caused toxic effects, we designed chimeric ODNs with a
phosphodiester core and three phosphorothioate linkages at each end (PSPO) to compro-
mise between toxicity and nuclease sensitivity. We studied the effects of four different
antisense PSPO ODNs targeted at specific sites on the SKALP mRNA (see Table 1 and
Figure 1). H&E-staining did not reveal any deviation from the normal skin morphology,
even at the highest dose (2.5 nmol). We performed immunohistochemical stainings for
SKALP, SLPI, involucrin, and CK 16 to examine a gene-specific effect of the applied
ODNs. Only one of the four tested antisense SKALP PSPO ODNs (PSPOASSK5) induced
a decrease of SKALP expression in the upper layers of the epidermis. None of the control
ODNs (sense or scrambled) showed an effect on SKALP expression, indicating that the
effect was sequence-specific. In Figure 4, SKALP and involucrin expression levels are
shown after application of 2.5 nmol PSPOASSK5 ODN, targeted at the coding region in
exon 2 of the SKALP mRNA, or sense control ODN. SKALP expression in the antisense
treated explants was decreased in comparison to the sense and scrambled ODN treated
explants, whereas the involucrin expression is unaltered. This was found in five indepen-
dent experiments with explants cultured in duplicate. Additional control proteins that
were studied (SLPI and CK16) were not affected by ODN treatment (not shown).
Furthermore, the inhibition of SKALP induction by PSPOASSK5 was concentration-
dependent, since the application of 0.5 nmol showed a weaker SKALP inhibition.
To investigate whether inhibition of SKALP expression by the chimeric ODN was due to
(RNase H mediated) breakdown of mRNA or interference at the level of translation, RNA
was extracted from the explants and analyzed by Northern blotting. RNA levels of SKALP,
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Figure 4. Immunohistochemical staining
of SKALP and involucrin expression in
explants incubated with PSPO ODNs tar-
geted at the coding region (exon 2) of the
SKALP mRNA. Skin explants were incu-
bated with 2.5 nmol antisense or sense
SKALP PSPO ODNs for 24 h at 37˚C.
SKALP expression in the antisense treated
explant is decreased in comparison to the
sense treated explant. Expression of invol-
ucrin is unaltered. H&E-staining shows
normal skin morphology. Scale bar: 100
µm.
SLPI, and hARP were determined by phospho-imager quantification of the bands on the
northern blot (Figure 5). No major changes of relative mRNA levels were found between
the explants.
Chimeric ODNs exhibit minor non-specific protein binding compared to fully phosphorot-
hioate ODNs 
In order to find an explanation for the observed differences in activity/toxicity profile of
PS and PSPO ODNs, we determined the protein binding properties of PS, PSPO, and nor-
mal phosphodiester (PO) ODNs. The ODNs were radioactively labeled and incubated
with a nuclear protein extract from cultured keratinocytes. Figure 6 shows an electropho-
retic mobility shift assay which indicates a strong protein binding of the PS ODN in com-
parison to PSPO and PO ODNs, 53% ± 2% of the labeled PS ODNs is bound to nuclear
proteins versus 3% ± 4% for PSPO or PO ODNs (mean of 6 measurements (± sem)).
Discussion
In contrast to most internal organs, the skin is readily accessible and is therefore, in theo-
ry, very suitable for application of antisense ODNs. In addition, topical application of
pharmacological compounds usually circumvents the unwanted effects on internal tissues
often seen with systemic therapies. In this study, we provide proof of concept that appli-
cation of antisense ODNs on intact human skin can cause sequence-specific inhibition of
gene expression in keratinocytes. This finding could potentially open up new therapeutic
possibilities in skin diseases that would benefit from inhibition of a specific gene expres-
sed in the epidermal compartment. Our study underlines several points that are relevant
for the antisense ODN approach. Similar to what others have found [463-465], not every ODN,
although targeted to an apparently suitable region of the mRNA, will induce the desired
effect. Out of 4 ODNs tested, one showed clear-cut inhibition, one caused a marginal,
insignificant inhibition, and the others were ineffective. Another important finding is that
chimeric PSPO ODNs represent a substantial improvement compared to fully phospho-
rothioate ODNs, with respect to toxicity. Our finding, using electrophoretic mobility shift
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Figure 5. mRNA levels of SKALP, SLPI, and cytokeratin 16 in explants treated
with antisense (lane 1) or sense (lane 2) SKALP PSPO ODNs. A probe for hARP
was used to correct for differences in sample loading. Quantification of the
SKALP and SLPI mRNA signal relative to the hARP signal, indicated no major
differences in antisense treated explants in comparison to sense treated explants.
assays to demonstrate protein binding, strongly suggest (although not prove) that this
property of PS ODNs contributes to these unwanted side-effects. Finally, we think that our
study addresses an important aspect that is often overlooked, i.e. to use controls both for
sequence specificity and gene-specificity. To demonstrate sequence-specificity, usually
sense, scrambled or mismatch control ODNs are examined that should not display the
effect seen with the antisense ODN. In our case this was only found for one PSPO ODN.
A second requirement of such an antisense ODN would be that it does not affect the
expression of a (preferably related) gene that does not contain the exact target sequence of
the gene inhibited by the antisense ODN. In this study we examined the expression of
hARP (a household gene), involucrin and CK16 (differentiation related genes), and SLPI
(a proteinase inhibitor closely related to SKALP). SLPI in particular is very suitable con-
trol gene, because it is homologous to SKALP, it has similar expression patterns, and it is
regulated by the same factors (e.g. induction by serum). Based on the fact that only the
PSPOASSK5 inhibits SKALP expression, and that none of the other genes are affected we
conclude that this is a true antisense effect.
What can be learnt from this study and what are the potential applications in the treat-
ment of human skin diseases? A surprising finding was the poor predictive power of the
in vitro study that was performed prior to these studies. Using cultured keratinocytes, we
found a rapid uptake of FITC-labeled ODNs in the cytoplasm or in the nucleus of the
cells, depending which mode of delivery was used [461]. In subsequent studies, however, we
failed to find a sequence-specific effect of SKALP antisense ODNs both on the mRNA and
protein level (Wingens et al, submitted). It has to be noted that others, using similar
culture systems to target, did find sequence specific effects in keratinocytes [466-468]. Our
results indicate that the skin explant culture used in this study can be used to test ODNs
directed against genes expressed in the differentiated compartment of the epidermis. We
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Figure 6. Protein binding characteristics of PS, PSPO, and PO
ODNs. Electrophoretic mobility shift assay was performed with
nuclear protein extract from keratinocytes grown for 2 h with
5%FCS and radioactive labeled ODNs. Protein-ODN complexes (p)
migrate slow and are visible as a smear; free ODNs (f) migrate fast
and are detected at the bottom of the gel. About 53% (± 2%) of
the PS ODNs is bound to the protein extract, whereas only 3% (±
4%) of the PO or PSPO ODNs show protein binding (mean of 6
measurements (± sem)).
did not use penetration enhancers but simply applied the ODNs in an aqueous solution
on top of the skin. The CLSM studies with FITC-labeled ODNs revealed a cell-type speci-
fic uptake. In the keratinocytes the absorbed ODNs were primarily located in the cyto-
plasm in a diffuse pattern, whereas some dermal cells show nuclear uptake. Furthermore,
the serrated edge of fluorescing keratinocytes suggests that the basal keratinocytes are
unable to absorb ODNs. Whether this is a general phenomenon for all ODNs remains to
be investigated. Application of penetration enhancers (lotions, creams, ointments, liposo-
me formulations) might affect the cellular distribution as well. ODNs are thought to be
taken up by receptor-mediated endocytoses after binding to cell surface proteins [469,470]. The
heterogeneity in ODN uptake between dermal cells, basal, and supra-basal keratinocytes
could be the result of differences in receptor abundance or type on the cell surface. This
pattern of ODN uptake that we observed here indicates that the antisense approach is very
suitable for mRNAs expressed in the suprabasal layer as is the case for our model gene
SKALP. When this approach would be applied to skin diseases, logical targets would be
genes that are expressed in this compartment. The antisense approach could be applied to
polygenic diseases, such as psoriasis, or to monogenic diseases that are caused by domi-
nant-negative mutations. A problem in psoriasis would be the lack of suitable target genes
that are known to significantly contribute to the disease. Possible candidate genes would
include TGF-α, TNF-α, IL-8, and interferon-γ because these cytokines are produced by
keratinocytes and are known to be involved in features of psoriatic skin, such as hyper-
proliferation, cellular infiltration, increased cytokine production, and expression of HLA
class II [10,471,472]. Examples of monogenic skin diseases that would be amenable to an antis-
ense approach are congenital bullous ichthyosiform erythrodermas, like the Brocq and
Siemens types that are based on dominant negative mutations in the cytokeratin 1,10 and
2e genes. In theory, ODNs targeted against the mutated allele that harbors a mismatch
compared to the wild type allele, could specifically knockout the expression of the domi-
nant negative protein. However, the applications would be severely limited by the choice
of the targeted region on the mRNA, which is dictated by the location of the mutation. We
would therefore surmise that antisense approaches would be most useful for polygenic
diseases, provided that adequate molecular targets can be defined. In case that uptake of
epicutaneously applied ODNs can be further manipulated to target the germinate (basal)
cells, the application of antisense approaches would be further extended to include neo-
plasia and viral infection. The explant culture model presented here, or models using
transplanted human skin on immunodeficient mice would provide excellent systems to
further investigate the application of this approach.
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SKALP as a paradigm for disturbed epidermal differentiation; function and regulation.
In a number of studies that are described in chapters 3, 4 and 5 of this thesis we have used
the induction and regulation of the proteinase inhibitor and anti-microbial protein
SKALP as a marker for the keratinocyte phenotype of regenerative differentiation also
referred to as regenerative maturation. Although we are aware of the fact that one should
be very careful to simplify the complex characteristics of an epidermal phenotype into the
expression of one gene, there are a number of reasons why we chose this approach. Several
studies by our own and other departments have shown that the expression of SKALP is
very tightly associated with the onset and maintenance of abnormal epidermal differen-
tiation in the context of hyperproliferation [277,310,473], the so-called regenerative maturation
phenotype. Because of this very tight association we assume that elucidation of mecha-
nisms and/or factors that are involved in the regulation of SKALP gene expression should
be informative on the regulation of at least part of the total phenotype. In addition from
an experimental point of view it is very practical and fast to initially analyse the expres-
sion profile of one gene product instead of analysing multiple parameters. However it
remains essential that also other characteristics of the regenerative maturation phenotype
are analysed and confirm the results found for SKALP gene expression before firm con-
clusions concerning the total phenotype can be made. These characteristics include the de
novo expression of CK17, CK6 and CK16, the upregulation of suprabasal proteins like
involucrin and transglutaminase-I, and the induction of epidermal hyperproliferation.
However before starting the studies that focussed on the regulation of SKALP expression
we first wanted to analyse the SKALP protein further with respect to its tissue distribution,
sub-cellular localisation, expression profile and possible physiological function. Studies in
which this was analysed are described in the second chapter of this thesis.
Function of SKALP
In chapter 2.1 we present a descriptive and a functional study of the proteinase inhibitor
SKALP. We have shown that SKALP is constitutively expressed in epithelia that are con-
stantly subjected to environmental stresses and inflammatory stimuli. We have shown that
SKALP can protect monolayers of keratinocytes against PMN and elastase mediated cell-
damage and detachment. A study by Zaidi et al confirms our findings and shows that
SKALP expression in vivo can indeed prevent elastase mediated tissue damage [366]. Several
studies have shown that in vivo SKALP is cross-linked into the cornified envelope [258,474],
where it could possibly still act as a functional proteinase inhibitor, providing cell protec-
tion. In addition to its function as a protective proteinase inhibitor it was recently shown
that SKALP is also capable of inhibiting bacterial growth and thus can act as an anti-
microbial protein [355]. Several studies have shown that the epidermis can act as a source 
of several proteins with antimicrobial [356,361,362,475,476], antiviral [477,478] and/or anti-inflam-
matory [365,479] properties. These findings suggest that when epidermal homeostasis is
threatened or disturbed, the keratinocytes can also act as a source of protective proteins
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that are secreted extracellularly or incorporated in the stratum corneum. With respect to
the protective properties of SKALP we have hypothesised on a possible causal relation
between disturbed SKALP expression levels and the excessive PMN infiltration and PMN
mediated tissue destruction in pustular forms of psoriasis. This hypothesis has emerged
from the fact that in the skin of patients with pustular psoriasis, SKALP protein levels 
are significantly decreased when compared to the skin of patients with plaque type pso-
riasis [261,300]. In chapter 2.2 we describe that these low levels of SKALP in the skin of pustu-
lar psoriasis patients are not caused by mutations in the SKALP gene itself. Recently a
study by Reid et al describes that in alveolar cells the expression of the SKALP gene is
subjected to regulation by human neutrophil elastase (HNE) [480]. At HNE concentrations
ranging from 10-9 M to 10-12 M SKALP promoter activity is enhanced and the transcrip-
tion of the endogenous gene is upregulated. In contrast to this induction of gene expres-
sion at the transcriptional level, the level of secreted protein is decreased. Reid et al sug-
gests that SKALP could perhaps have an intracellular function as well and is therefore not
secreted in all cases. It remains obscure which mechanisms are involved in this expression
regulation and it can not be ruled out that in this study by Reid et al the induction of
SKALP expression by human HNE is mediated through non-specific cell damage rather
than being an HNE specific effect. It is unclear whether HNE modulates the expression of
SKALP in keratinocytes as well and how this could affect the SKALP expression levels in
the skin of patients with pustular psoriasis, a pathological skin condition with relatively
high concentrations of HNE. Comparison of skin from plaque psoriasis patients and skin
from pustular psoriasis patients showed that at the RNA level there is little or no differen-
ce in SKALP expression levels [261], which is not analogous to the findings of Reid et al.
However if high extracellular concentrations of HNE could prevent SKALP from being
secreted from the cells, this could contribute to the low levels of SKALP that are found in
pustular psoriasis lesions.
Regenerative maturation and cytokines/growth factors
In response to stimulants of different origin, e.g. barrier disruption (wounding/tape strip-
ping), UV-light or inflammatory mediators, epidermal cells are known to produce a large
variety of cytokines, such as interleukins, TNF-α, several colony-stimulating factors and
growth factors. In fact growth factors and cytokines cause the major changes in gene
expression and keratinocyte behaviour in various cutaneous diseases. In some cases, such
as in wound healing, these changes are highly beneficial; in others, such as psoriasis, they
are pathological. Furthermore keratinocytes express receptors for many polypeptide
factors, respond to autocrine stimulation and also respond to signals produced by the
immune system. The importance of signalling between keratinocytes and lymphocytes is
apparent in the cutaneous skin disorders that involve both these types of cells, such as pso-
riasis and forms of eczema. In response to epidermal injury the keratinocytes become acti-
vated, follow the regenerative maturation pathway and start to produce and respond to a
large number of growth factors and cytokines. A recent study by Wei et al describes the
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induction of regenerative differentiation in an explant culture by both IL-1 and IFN-γ [236].
Using IL-1β antibodies and IL-1 receptor antagonist (IL1ra) they showed that this induc-
tion could be blocked and that the induction of the regenerative maturation phenotype by
IFN-γ is (partially) mediated through endogenous IL-1 [236]. This onset of regenerative
maturation was characterised by the induction of suprabasal expression of CK16, CK17,
CK5 and integrin-β1. In our in vitro culture model system we have tested a large number
of cytokines and growth factors for their ability to induce regenerative maturation char-
acterised by SKALP expression including IFN-γ but not IL-1β. In our model TNF-α is the
most potent inducer of regenerative maturation and IFN-γ and TGF-α are moderate indu-
cers. It is possible that in our in vitro model the induction of SKALP expression by IFN-γ
is also mediated through endogenous IL-1β production. Experiments with antagonists or
blocking antibodies would be very interesting to study this possibility. It would also be
useful to test combinations of cytokines and growth factors for potential synergistic effects
on their influence on the differentiation of cultured keratinocytes, since in many in vivo
situations the keratinocytes are subjected to a broad array of cytokines.
Regenerative maturation and p38 MAPK
In chapter 3.1 we have further shown that the TNF-α mediated induction of SKALP
expression depends on p38 activity, since the p38 inhibitors SB202190 and 203580 block
TNF-α and FCS induced SKALP expression. It is known from a large number of studies
that p38 is a major downstream effector in TNF-α signalling [481-484]. Recently a number of
studies have shown p38 involvement in IFN-γ signalling at the level of STAT1 phosphory-
lation as well [485-487]. The transcription factor STAT1 has been implicated in regulation of
CK17 gene expression in activated keratinocytes [91,200]. Since CK17 gene expression is a
well-known marker for the regenerative differentiation of keratinocytes [12,200] these data
could strengthen our hypothesis that p38 is involved in the transition from normal to
abnormal epidermal phenotypes. In that respect it is however surprising to know that
recently it was described that cultured keratinocytes derived from non lesional skin from
psoriasis patients show a reduced STAT1 activation in response to IFN-γ compared with
keratinocytes derived from normal human skin [488]. The relevance of p38 mediated STAT1
activation in abnormal epidermal gene expression remains therefore unclear. Preliminary
results suggest that the expression levels of a number of genes involved in IFN-γ signalling
are differentially expressed between normal and uninvolved psoriatic keratinocytes (van
Ruissen et al, personal communication). It is therefore highly recommended that addi-
tional studies are performed in which differential gene expression in different keratinocy-
te populations is analysed. With modern techniques, like for instance the use of cDNA/-
oligonucleotide based microarrays and SAGE analysis, it is possible to compare the
expression of a broad range of genes between different keratinocyte populations. With
such an experimental approach and using these techniques it should be possible to iden-
tify more relevant genes that are involved in the regulation of keratinocyte differentiation
phenotypes.
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Regenerative maturation and extracellular matrix
As mentioned in the introduction, changes in the extracellular matrix can induce and
maintain the differentiation of epithelial cells. Loss of integrin mediated contact with 
the basement membrane is an important step in the initiation of keratinocyte differen-
tiation [83,85]. When the keratinocytes undergo terminal differentiation, intracellular trans-
port of newly synthesised integrins is inhibited and mature receptors are lost from the cell
surface [86]. In activated keratinocytes, that follow the regenerative maturation pathway in
the context of hyperproliferation, abnormal integrin expression is found. In normal skin,
integrin expression is largely confined to the basal layer whereas during e.g. wound healing
and in psoriatic skin lesions suprabasal integrin expression is found [303]. There are several
indications that this ectopic expression of epithelial integrins is involved in maintaining
epidermal hyperproliferation in several abnormal skin conditions [489,490]. Integrin signal-
ling is thought to be mediated through a recently identified associated kinase called
Integrin-Linked Kinase (ILK) [491-493]. Integrin-linked kinase has been implicated in the
expression regulation of proteins that are involved in cell cycle progression and in the acti-
vation of the transcription factor AP-1 [494-495]. Overexpression of ILK in cells results in
anchorage independent cell cycle progression and stimulates the formation of functional
AP-1 complexes in the nucleus. A recent paper by Xie et al describes the expression of ILK
in basal keratinocytes and the downregulation of ILK in the suprabasal compartment of
mouse epidermis [496]. One could speculate on the effect of abnormal integrin expression
on the expression/activity levels of ILK and its downstream targets in pathological skin
conditions. It would be very interesting to investigate the activity levels of ILK in several
skin conditions and analyse its role in epidermal hyperproliferation. Moreover there have
been a number of papers that have shown integrin-mediated activation of members of the
MAP kinase family including p38 [120,497]. The relation between the ectopic expression of
integrins on keratinocytes during abnormal epidermal differentiation and the activation
of members of the MAP kinase family could shed more light on the regulation of this epi-
dermal phenotype.
p38 MAPK, promoting life or death?
In chapter 3.3 we describe the induction/enhancement of massive cell death by inhibiting
p38 activity directly after UV-B irradiation of cultured keratinocytes. These data suggest a
protective/anti-apoptotic role for p38 after UV-B irradiation. The activation of p38 MAP
kinase is common after UV-B irradiation, but its role in UV induced apoptosis, or apop-
tosis in general, is controversial. There have been several reports that suggest a protective
role for p38 MAP kinase in the apoptosis pathway [332,437,498]. However a paper by Nemoto et
al demonstrates that inhibition of p38 by SB202190 by itself is sufficient to induce cell
death, with typical apoptotic features like internucleosomal DNA fragmentation [499].
Moreover SB202190 was able to remarkably increase apoptosis induced by Fas ligation or
UV irradiation. Overexpression of p38β reduced the apoptotic effects of SB202190, Fas or
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UV treatment suggesting protective properties. Overexpression of p38α showed a some-
what opposite effect and slightly increases apoptosis in all cases [499], suggesting an anti-
apoptotic effect of p38β and proapoptotic effects of p38α. These distinct effects for these
two different p38 members are confirmed in a study by Wang et al in cardiac muscle cells
[500]. Moreover a recent report by Hsu et al suggests the possibility that apoptosis induction
may be enhanced by p38α activation through increased expression of FasL [501]. There are
numerous reports that link p38 activity causally to the onset of apoptosis and in which
p38 inhibition by either SB202190 or SB203580 prevent the cells from undergoing pro-
grammed cell death [502,503]. A study by Shimizu et al, using HaCaT cells, describes a similar
situation in keratinocytes after UV-B irradiation [141]. In that study inhibition of p38 by
SB203580 suppressed UV-B induced caspase activation and apoptosis. However the UV-B
dose that is used in this study is extremely high (2500 J/m2 ) and the physiological rele-
vance of these observations is therefore uncertain. Since the pyridinyl imidazoles
SB203580 and SB202190 inhibit both α- and β-isoforms of p38 [137,504], the total effect of
p38 inhibition on apoptosis seems to depend on the expression repertoire of the p38 iso-
forms in a certain cell. There are five different isoforms of p38 MAP kinase, i.e. p38α,
p38β, p38β2, p38γ and p38δ, and a different tissue distribution is found among the diffe-
rent p38 isoforms [505]. For example p38α and p38β are highly expressed in the brain
whereas p38γ is predominantly expressed in skeletal muscle. The expression profile of the
p38 isoforms in the different cell-types in the skin however is not known. It would be inte-
resting to analyse the expression levels of the different p38 isoforms in skin and compare
different types of keratinocytes including HACAT cells, SCC-lines and differentiated
human keratinocytes (both normally and regeneratively differentiated KC). In addition in
this respect it would be informative to analyse the expression and activity/activation levels
of different p38 MAP kinase isoforms in the skin of patients with cutaneous lupus
erythematosis, since the skin of these patients shows enhanced cell-death after UV-B irra-
diation [506-508].
Transcription regulation of SKALP
Although we have invested a lot of time and effort in the analysis of SKALP transcription
regulation, it still remains obscure what factors and mechanisms are at the basis of gene
activation and the onset of transcription. One thing that we unfortunately must conclude
is that the culture model system that we have used, is not suited for transfection studies
with SKALP promoter constructs. Apart from the fact that reporter constructs are hard to
study in keratinocytes due to low transfection efficiencies, the promoter constructs that we
have used were constitutively active in contrast to the endogenous SKALP gene promoter.
However since it is known that MAPK can regulate gene expression at different levels: very
early expression response through mRNA stabilisation, early responses through nucleoso-
mal reorganisations and ‘late’ responses through transcription factor activation. It could
very well be possible that p38 mediated SKALP gene expression is not regulated at the level
of transcription factor activation but through changes in chromatin accessibility or stabi-
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lisation of the SKALP messenger. Additional studies should shed more light on these
questions
Regenerative maturation as an epidermal stress response
Considering all the data presented in this thesis reflected against the literature we specu-
late that regenerative maturation is a physiological epidermal adaptation program, which
is induced upon cellular stress in the epidermis that could potentially threaten epithelial
integrity. At least part of this program is regulated through MAP kinase mediated gene
expression. Skin diseases like psoriasis, where the phenotype of regenerative maturation
does not seem to have a physiological function but in fact is pathological, could therefore
be considered as an aberrant ongoing stress response. One could expect that compounds
that can interfere with this stress response at the level of MAPK activation, like SB202190,
potentially represent a new generation of anti-psoriatic pharmacological compounds.
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The main subject that was analysed in the studies presented in this thesis is the induction
and regulation of the abnormal epidermal differentiation pathway known as ‘regenerative
maturation’. In chapter 1 the differentiation and proliferation characteristics of normal
and disturbed human epidermis are introduced. Chapter 1 furthermore comprises an
introduction into the regulatory routes and factors that are known to be active in kerati-
nocytes and that may affect the differentiation and/or proliferative characteristics of the
epidermal cells. In addition an overview of models that are available to study epidermal
growth and differentiation is given. Chapter 1 ends with the description of the proteinase
inhibitor SKALP both at the protein and gene level, and we provide a justification for the
use of SKALP expression as a marker for the regenerative maturation phenotype.
In chapter 2.1 we present the human tissue distribution of SKALP and show that it is con-
stitutively expressed in a number of stratified squamous epithelia. In these epithelia the
presence of inflammatory cells seems physiological and therefore these tissues are conti-
nuously subjected to inflammatory stimuli suggesting a possible role for SKALP tempe-
ring proteolytic cell damage. In addition we showed high expression levels of SKALP in
psoriatic skin by means of in situ hybridisation. In foetal epidermis SKALP is expressed
from week 28 onwards, and is downregulated in neonatal skin within three months sug-
gesting a possible role for SKALP in the early maturation of the epidermis. At the subcel-
lular level, using immuno-electron microscopy, we showed the presence of SKALP in
secretory vesicles including lammelar granules. In culture models for epidermal keratino-
cytes we found that the expression of endogenous SKALP protects the cells against cell
detachment caused by purified elastase or activated PMN. These findings suggested a role
for SKALP in the protection of tissues against protease mediated cell damage during e.g.
inflammatory responses. In view of the possible role of SKALP in regulating inflammation
mediated proteinase activity we have speculated in the past on the causal relation between
low SKALP expression and pustular psoriasis, a subform of psoriasis [261,300]. In chapter 2.2
we describe a study in which we analysed the SKALP gene and the upstream region from
a large number of patients with either plaque psoriasis or pustular psoriasis and healthy
subjects for the presence of polymorphisms possibly affecting SKALP expression levels. In
the first exon of the SKALP gene at position +43 (relative to A1T2G3) a polymorphism was
detected, resulting in a substitution of a threonine for an alanine in the signal peptide. In
the promoter region of the SKALP gene a dinucleotide repeat polymorphism was detec-
ted. However both polymorphisms are not associated with pustular psoriasis or psoriasis
in general. Based on these results we conclude that the decrease in SKALP activity in
pustular forms of psoriasis is not caused by SKALP gene mutations.
Chapter 3 comprises three separate studies sharing overlap with respect to the experi-
mental focus and procedures. All studies analyse the involvement of the stress response
pathway (MAPK kinases) in the induction of ‘abnormal’ gene expression in skin. Chapter
3.1 describes a study in which we analysed the ability of a large number of inflammatory
cytokines and growth factors to induce abnormal epidermal differentiation in vitro.
Confluent keratinocyte cultures were grown for 48 hours in a basal medium that induces
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normal differentiation. To this basal medium different concentrations of a cytokine or
growth factor was added. We analysed the cells for SKALP expression at the protein level
using an ELISA and at the RNA level using northern blot analysis. Of all the cytokines and
growth factors that were tested, only TNF-α was found to be a very potent inducer of
SKALP expression and TGF-α and INF-γ only induce moderate levels of SKALP expres-
sion, whereas others did not significantly induce SKALP expression. The fact that SKALP
expression is induced by pro-inflammatory cytokines (TNF-α) and other environmental
stimuli in vivo prompted us to analyse the activity levels of members of the stress respon-
se pathways regulated through the mitogen activated protein kinase cascade (MAPK).
Members of the MAPK family are activated upon phosphorylation and therefore their
phosphorylation status is indicative for their activation level. We used phosphorylation
specific antibodies against a number of MAP kinase family members and found that their
phosphorylation levels remained nearly constant during both normal (induced by growth
factor depletion) and abnormal differentiation (induced by either TNF-α or FCS).
However using a specific inhibitor against the MAPK family member p38 we could show
that p38 activity is crucial for the induction of SKALP expression in vitro. In chapter 3.2
an in vivo model is presented for the induction of regenerative differentiation by UV-B
irradiation of normal skin of healthy volunteers. Through immunohistochemical analysis
we found that a dose of 2 minimal erythema doses (2MED) of UV-B irradiation results in
epidermal hyperproliferation and abnormal epidermal differentiation characterised by the
induction of SKALP/CK16/SLPI/Involucrin (over)expression. Using both normal and
phosphospecific antibodies we observed that (over)expression of these genes was prece-
ded by activation of cellular stress response pathways such as phosphorylation of mem-
bers of the MAPK family and translocation of NFκB to the nuclei of the keratinocytes. In
concordance with the results found in vivo we found that UV-B irradiation of normal cul-
tured keratinocytes also results in a quick and massive activation of members of the
MAPK cascade. However this does not result in abnormal differentiation in vitro. More
strikingly inhibition of p38 activity in keratinocytes that were irradiated with UV-B light
resulted in massive cell-death. Based on these results we speculate that p38 could play a
dual role in the cutaneous response to ultraviolet irradiation. Chapter 3.3 describes a
study which is similar to the study described in chapter 3.1 in which the expression levels
of the extracellular matrix protein tenascin-C were investigated in keratinocyte cultures
that were stimulated with a large number of different cytokines and growth factors. It was
previously shown by Latijnhouwers et al that epidermal keratinocytes could upregulate
the expression of tenascin-C under conditions of external stress such as skin injury [377]. In
contrast to SKALP stimulation, TNF-α is only a moderate inducer of tenascin-C, just like
INF-γ. Interleukin 4 proved to be a very potent inducer of tenascin-C in keratinocytes.
Keratinocytes derived from skin tumours did not respond to IL-4 and IFN-γ, whereas
TNF-α resulted, like in normal keratinocytes, in tenascin-C overexpression. These data
suggested that there are distinct regulatory mechanisms for tenascin-C expression in nor-
mal keratinocytes and tumour derived keratinocytes. In addition, the exposure of normal
keratinocytes to sphingomyelinase, a phospholipase generating ceramide as a second mes-
senger, also resulted in high expression of tenascin-C. Inhibitors against members of the
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MAPK cascade were used to investigate the potential role of the MAPK cascade in tenas-
cin-C expression regulation. SB203580 or SB202190 (p38 inhibitors) and PD98059 (a
MEKK inhibitor directly affecting ERK phosphorylation) had little or no effect on tenas-
cin-C induction by TNF-α. We speculate that tenascin-C expression induced after cellular
stress either through the activation of SAPK/JNK or through the JAK/STAT pathway. This
chapter shows that distinct stress response signalling pathways are utilised by keratino-
cytes that lead to the expression of SKALP and tenascin-C.
In chapter 4 a molecular study is presented focussing on the regulation of SKALP gene
expression through regulatory sequences and transcription factors. Using two different
techniques we have elucidated the transcription start site of the SKALP gene. This start of
transcription is situated at a different location than was expected by us and several other
groups based upon promoter consensus sequences. Furthermore we describe the con-
struction of a set of promoter/reporter-gene constructs that were subsequently used in
transient transfection assays in different cell types. These experiments revealed that a
region of approximately 1000 basepairs upstream of the translation startsite of the SKALP
gene could confer keratinocyte specific gene expression since this promoter regions shows
no activity in human skin fibroblasts, glioblastoma cells or A431 cells. Deletion analysis
showed that upon removal of the region between 440 and 290 bases upstream of the trans-
lation startsite results in a loss of promoter activity of about 75%. Deletion up to 130 bases
upstream of the ATG only leaves 10% of the initial promoter activity. Unfortunately we
found a discrepancy between these promoter constructs and the endogenous SKALP gene.
The promoter constructs are active under all culturing conditions, even under conditions
where the endogenous SKALP gene is silent. The promoter region between 440 and 130
basepairs upstream of the translation startsite harbours a great number of transcription
factor consensus binding sequences that are known to respond to cellular stress e.g. AP-1,
NF-IL6 and NFκB. Transfection experiments in which promoter/reporter constructs were
used that contained mutated consensus sequences remain inconclusive. However potent
inducers of endogenous SKALP gene expression like e.g. FCS and TNF-α lead to the trans-
location of NFκB to the nuclei of keratinocytes. These results lead to the hypothesis that
cellular stress response pathways in which NFκB and p38 play a major role regulate SKALP
expression found during regenerative epidermal conditions. We furthermore speculate
that, in view of the discrepancy between the endogenous SKALP gene and the promo-
ter/reporter-constructs, also other processes than transcription factor mediated gene
expression could play a role in this response such as chromatin accessibility or mRNA sta-
bility.
Chapter 5 is composed of two studies that describe the development and use of in vivo
models for studies focussing on the induction and manipulation of epidermal stress
responses. In chapter 5.1, the development of two models is described. The first model
uses 4-mm punch biopsies that are subsequently cultured for 24 hours in an air exposed
skin explant model. The second model is a grafting model in which normal human skin is
transplanted on athymic ‘nude’ mice. After a healing period of 40 days the human skin
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transplants resemble normal human skin and regenerative differentiation is induced
through UV-B irradiation. Based upon immunohistochemical analysis of the epidermal
expression levels of a large number of proteins in both models, we conclude that in both
models regenerative differentiation can be induced and studied. With the development of
these models two new tools for epidermal research are at our disposal. In chapter 5.2 one
of these models, the air exposed skin explant model, is used in a study in which the mani-
pulation of epidermal gene expression using single stranded anti-sense oligodeoxynucle-
otides (ODN) is investigated. A variety of 20-mer antisense and control ODN designed to
hybridise to different region of the inducible SKALP messenger RNA were tested on their
ability to inhibit SKALP expression after topical application. When fully phosphorothio-
ated ODN were applied they were found to be either ineffective at low doses or highly
cytotoxic at high doses. With the electrophoretic mobility shift assay (EMSA) we found
that these phosphorotioated ODN bind huge amounts of protein that could contribute to
the cytotoxic effect of these ODN. Partially phosphorotioated ODN, consisting of a core
of normal phosphodiëster bonds and posphorotioated 5’- and 3’-ends were shown to have
much lower protein binding capacities and did not have any cytotoxic effect after topical
application. One of the tested chimeric ODN was found to inhibit SKALP expression in a
dose dependent manner. By using a number of control oligodeoxynucleotides and by ana-
lysing the expression levels of a number of other epidermal proteins we can conclude that
the inhibition of SKALP by the chimeric ODN is specific. Confocal laser scanning micro-
scopy showed that 20-mer oligonucleotides can easily penetrate the skin and be localised
in the differentiated compartment of human epidermis. We speculate that the use of antis-
ense ODN could prove to be a useful addition to the therapeutic arsenal for the treatment
of skin diseases where ectopic epidermal gene expression needs to be downregulated.
Finally in chapter 6 some general conclusions are drawn based on analysis of the results
that are described in this thesis and the recent literature. Different concluding remarks are
made with respect to the function of SKALP and its use as a marker for regenerative epi-
dermal differentiation, the regulation of SKALP and the disturbed epidermal phenotype
and the involvement of the cellular stress response in epidermal differentiation switches.
Finally some suggestions for future work are made.
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Het onderzoek en de studies die in dit proefschrift beschreven staan waren met name
gericht op de inductie en regulatie van de abnormale epidermale differentiatieroute die
bekend staat als ‘regeneratieve maturatie’. Hoofdstuk 1 is de algemene inleiding van dit
boekje en beschrijft de differentiatie en proliferatie karakteristieken van normale en ver-
stoorde humane epidermis. Verder wordt in hoofdstuk 1 een introductie gegeven in de
regulatoire routes en factoren waarvan bekend is dat deze in keratinocyten functioneel
aanwezig zijn en de differentiatie en/of proliferatie van keratinocyten kunnen beïnvloe-
den. Verder wordt er nog een overzicht gegeven van de modellen die beschikbaar zijn voor
bestudering van epidermale groei en differentiatie. Hoofdstuk 1 eindigt met de beschrij-
ving van de protëinase remmer SKALP op zowel het gen als het eiwitniveau, en de argu-
mentatie voor het gebruik van SKALP als marker voor regeneratieve maturatie.
In hoofdstuk 2.1 laten we de humane weefselverdeling van SKALP zien en tonen we dat
een aantal gelaagde verhoornde epithelia positief is voor SKALP. In deze epithelia is de
aanwezigheid van ontstekingscellen fysiologisch waardoor deze weefsels constant blootge-
steld worden aan ontstekingsstimuli. Het leek ons mogelijk dat SKALP een rol speelt in het
reguleren van de inflammatoire respons in deze weefsels en dat SKALP de celschade die
veroorzaakt kan worden door proteasen afkomstig van inflammatoire cellen beperkt.
Met behulp van in situ hybridisatie laten we verder zien dat SKALP expressieniveaus in
psoriatische huid erg hoog zijn. In foetale epidermis wordt SKALP tot expressie gebracht
vanaf week 28. Deze wordt echter in neonatale huid weer binnen drie maanden gedown-
reguleerd waardoor een potentiële rol voor SKALP in de vroege uitrijping van de huid
wordt gesuggereerd. Op subcellulair niveau, gebruikmakend van immuno-electronen-
microscopie, laten we zien dat SKALP in de cel zich in secretieblaasjes bevindt, onder
andere in de zogenaamde ‘lamellair bodies’ blaasjes. In celkweekmodellen laten we zien dat
endogeen geproduceerd SKALP bescherming biedt tegen celschade veroorzaakt door
gezuiverd elastase of geactiveerde PMN. Deze experimentele gegevens leiden tot de veron-
derstelling dat SKALP een rol speelt in de bescherming van weefsels tegen celschade die
veroorzaakt zou kunnen worden door proteinasen gedurende inflammatoire processen.
Gezien deze potentiële rol van SKALP hebben we in het verleden gespeculeerd over een
oorzakelijk verband tussen lage expressieniveaus van SKALP en pustuleuze vormen van
psoriasis [261,300]. In hoofdstuk 2.2 beschrijven we een studie waarin bij een grote groep
gezonde vrijwilligers en patiënten, met of plaque psoriasis of pustuleuze psoriasis, geke-
ken wordt naar de aanwezigheid van mogelijke polymorfismen in het SKALP gen en de
promoterregio die een lage SKALP expressie tot gevolg zouden kunnen hebben. In het
eerste exon van het SKALP gen werd op positie +43 (ten opzichte van A1T2G3) een poly-
morfisme gevonden dat, in het signaalpeptide, resulteert in de substitutie van een threo-
nine in een alanine. In de promoter regio van het SKALP gen werd een dinucleotide repeat
polymorfisme gevonden. Geen van beide polymorfismen is echter geassocieerd met pustu-
leuze psoriasis of psoriasis in het algemeen. Deze resultaten leiden tot de conclusie dat de
zeer lage SKALP niveaus die gevonden worden bij pustuleuze vormen van psoriasis niet
worden veroorzaakt door SKALP genmutaties.
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Hoofdstuk 3 omvat drie afzonderlijke studies waarvan de vraagstelling en experimentele
benadering parallel lopen. De drie studies analyseren de rol van cellulaire stress signaal
transductie paden (MAP-kinasen) in de inductie van abnormale genexpressie in de huid.
In hoofdstuk 3.1 wordt een studie beschreven waarin een groot aantal inflammatoire cyto-
kinen en groeifactoren worden getest op hun vermogen om abnormale epidermale gen-
expressie te induceren met SKALP als uitlezing. Confluente keratinocyt kweken werden 48
uur doorgekweekt in een medium dat normale differentiatie induceert. Aan dit medium
werden verschillende concentraties groeifactor of cytokine toegevoegd. Na deze incubatie
werden de cellen geanalyseerd op SKALP expressie op eiwitniveau met een ELISA en op
RNA niveau met behulp van northern blot analyse. Van alle cytokines en groeifactoren die
getest werden bleek enkel TNF-α een sterke SKALP inductie te veroorzaken. Toevoeging
van IFN-γ of TGF-α resulteerde in een matige SKALP inductie. Het feit dat SKALP expres-
sie geïnduceerd wordt door pro-inflammatoire cytokines en andere beschadigende omge-
vingsfactoren, zoals waterverlies en verwonding, leidde tot de vraag of leden van de stress
response familie (de MAP-kinasen MAPK) betrokken zouden kunnen zijn bij de inductie
van regeneratieve differentiatie. Leden van deze familie worden geactiveerd door fosfory-
latie en daarom kan onderzoek naar de staat van fosforylering iets zeggen over de activi-
teit van deze eiwitten. We hebben fosfospecifieke antilichamen gebruikt om met behulp
van western blot analyse de fosforyleringsstaat van een aantal leden van de MAPK familie
te volgen gedurende de inductie van SKALP expressie in vitro door zowel FCS als TNF-α.
Zowel bij de inductie van normale als van regeneratieve maturatie blijven de fosforyle-
rings niveaus van de MAPK leden nagenoeg gelijk. Met behulp van een specifieke p38
remmer hebben we echter aangetoond dat p38 activiteit cruciaal is voor de inductie van
SKALP expressie in vitro. In hoofdstuk 3.2 wordt een in vivo model beschreven voor de
inductie van regeneratieve maturatie door het bestralen van huid van gezonde vrijwilligers
met UV-B licht. Met behulp van immunohistochemische technieken tonen we dat een
dosis van twee minimale erytheem dosis (MED) resulteert in epidermale hyperprolifera-
tie en abnormale epidermale differentiatie, gekarakteriseerd door de inductie van
SKALP/CK16/SLPI/involucrine (over)expressie. Door gebruik te maken van zowel con-
ventionele als fosfospecifieke antilichamen bleek dat de (over)expressie van deze genen
voorafgegaan werd door activering van cellulaire stress response paden zoals fosforylatie
van MAPK leden en translocatie van NFκB naar de celkernen van de keratinocyten. Ook
in vitro resulteerde bestraling van gekweekte keratinocyten in een snelle activatie van
MAPK familieleden. In tegenstelling tot de in vivo situatie resulteert deze bestraling
gevolgd door activatie van MAPK niet in abnormale keratinocyt differentiatie. Tot onze
verbazing resulteerde remming van p38 activiteit na UV-B bestraling in massale celsterfte
onder de bestraalde keratinocyten. Deze resultaten leidden tot onze speculatie dat p38
mogelijk een dubbele rol speelt in de epidermale respons na UV-B bestraling. In hoofd-
stuk 3.3 wordt een studie beschreven die overlap heeft met de studie die wordt beschreven
in hoofdstuk 3.1 en waarin de expressie niveaus van het extracellulaire matrix eiwit tenas-
cine-C worden geanalyseerd in keratinocytkweken die zijn gestimuleerd met verschillende
cytokines en groeifactoren. In tegenstelling tot SKALP inductie blijkt TNF-α een matige
inducer van tenascine-C expressie, net als IFN-γ. Interleukine-4 (IL-4) bleek een zeer
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potente inducer van tenascine-C expressie te zijn. Keratinocyten die afgeleid zijn van
huidtumoren reageren echter niet op IL-4 of IFN-γ maar wel op TNF-α. Deze data sugge-
reren dat de regulatie van tenascine-C expressie bij normale keratinocyten en tumor afge-
leide keratinocyten differentieel wordt gereguleerd. Verder wordt aangetoond dat bloot-
stelling van keratinocyten aan sphingomyelinase (SMase), een phospholipase die ceramide
als tweede boodschapper vrijmaakt, ook resulteert in een sterke inductie van tenascine-C
expressie. Remmers tegen leden van de MAPK familie werden gebruikt om de mogelijke
betrokkenheid van deze eiwitten in de expressieregulatie van tenascine-C te bestuderen.
SB203580 of SB202190 (p38 remmers) en PD98059 (een MEKK remmer die direct invloed
heeft op ERK1/2 activiteitenniveaus) waren niet of nauwelijks van invloed op de tenasci-
ne-C inductie door TNF-α. We speculeren over het feit dat tenascine-C expressie door
keratinocyten wordt geïnduceerd door cellulaire stress door de activatie van JNK/SAPK of
door de JAK/STAT signaalroute. Uit deze resultaten concluderen we dat SKALP en tenas-
cine-C afzonderlijk gereguleerd worden.
In hoofdstuk 4 wordt een moleculair biologische studie gericht op de opheldering van de
regulatie van SKALP genexpressie door regulatoire sequenties en/of transcriptiefactoren
beschreven. Met behulp van twee verschillende technieken hebben we de plaats waar de
transcriptie van het SKALP gen start opgehelderd. Deze transcriptiestartplaats ligt op een
andere plaats in de promoterregio van het SKALP gen dan door ons en anderen werd ver-
wacht op basis van promoter consensus sequenties. Verder beschrijven we de constructie
van een set promoter/reportergen plasmiden die vervolgens in transiënte transfectie-
experimenten werd gebruikt. Er bleek een discrepantie te bestaan tussen de regulatie van
endogene SKALP promoteractiviteit en de activiteit van de SKALP promoter/reporter
constructen. Terwijl het endogene SKALP gen enkel tot expressie wordt gebracht onder
kweekomstandigheden die abnormale keratinocyt differentiatie induceren, zijn de pro-
moterconstructen onder alle kweekcondities actief. Desalniettemin bleek dat een gebied
van 1000 basenparen 5’ van de translatiestartplaats voldoende informatie bevat voor kera-
tinocyt specifieke genexpressie. Bij deletieanalyse bleek dat verwijdering van het gebied
tussen -440 en -290 basenparen 5’ van de translatiestartplaats resulteert in een verlies van
75 % promoteractiviteit. Bij verdere deletie tot 130 basen 5’ van de ATG blijft slechts 10 %
van de oorspronkelijke (1000 basenparen construct) promoteractiviteit over. Deze regio 
(-130 t/m -440) bevat een groot aantal potentiële transcriptiefactor bindingsplaatsen zoals
voor AP-1, NF-IL6 en NFκB (gebaseerd op consensus sequenties). Voorlopige analyse van
constructen die gemuteerde consensussequenties bevatten verschafte geen helderheid.
Inductie van endogene SKALP expressie door TNF-α of FCS leidde echter wel tot een
translocatie van de transcriptiefactor NFκB naar de kernen van de gestimuleerde kerati-
nocyten. Deze data bij elkaar leidden tot de hypothese dat cellulaire stress responspaden,
waarin NFκB en p38 een voorname rol spelen, SKALP expressie reguleren. Gezien de dis-
crepantie tussen endogene SKALP promoteractiviteit en de activiteit van getransfecteerde
promoter constructen verwachten we verder dat ook andere processen dan enkel trans-
criptie factor gemedieerde genexpressie een rol in deze expressie zouden kunnen spelen,
zoals chromatine toegankelijkheid en mRNA stabiliteit.
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Hoofdstuk 5 bestaat uit twee studies die de ontwikkeling en het gebruik van in vivo en ex
vivo modellen voor onderzoek naar epidermale groei en differentiatie beschrijven. In
hoofdstuk 5.1 wordt de ontwikkeling van de modellen beschreven. Bij het eerste model
wordt gebruik gemaakt van 4 mm punchbiopten. Deze huidbiopten worden 24 uur
gekweekt in een model waarbij de huid wordt blootgesteld aan de lucht, een zogenaamd
air-exposed huidexplant model. Het tweede model is een transplantatiemodel waarbij
normale humane huid wordt getransplanteerd op imuundeficiënte (naakte) muizen. Na
een genezingsperiode van zo’n 40 dagen zijn de huidtransplantaten genormaliseerd en
wordt regeneratieve maturatie geïnduceerd door middel van UV-B bestraling.
Immunohistochemische analyse van een groot aantal eiwitten toonde aan dat in beide
modellen regeneratieve differentiatie geïnduceerd wordt. Met de ontwikkeling van deze
twee modellen staan twee extra hulpmiddelen voor onderzoek naar de regulatie van epi-
dermale groei en differentiatie tot onze beschikking. In hoofdstuk 5.2 wordt een studie
beschreven waarin het explant model wordt gebruikt in een onderzoek naar de mogelijk-
heid van het gebruik van enkelstrengs antisense oligideoxynucleotiden (ODN) bij de
manipulatie van epidermale genexpressie. Met een aantal verschillende antisense en con-
trole ODN met een lengte van 20 nucleotiden, en ontworpen om te hybridiseren met ver-
schillende regio’s van de induceerbare messenger RNA van het SKALP gen, werd getest of
SKALP genexpressie kon worden geremd na topicale ODN applicatie. In deze experimen-
ten werden chemisch gemodificeerde ODN (met i.p.v. fosfodiester, fosforothioate verbin-
dingen) en gedeeltelijk gemodificeerde ODN (met aan de 5’/3’-uiteinden basen waartus-
sen fosforothioate verbindingen en middenin de reguliere fosfodiester verbindingen)
gebruikt. Deze chemisch gemodificeerde verbindingen zijn nodig om snelle afbraak door
endogene nucleasen te voorkomen en de halfwaardetijd van de ODN te verhogen. Deze
volledig chemisch gemodificeerde ODN bleken in lage doses ineffectief en in hoge doses
erg cytotoxisch. Met zogeheten ‘electrophoretic mobility shift assays’ (EMSA of bandshift)
werd vastgesteld dat deze volledig gemodificeerde ODN grote hoeveelheden eiwitten bin-
den wat mogelijk bijdraagt aan het cytotoxisch effect. Gedeeltelijk chemisch gemodifi-
ceerde ODN bleken veel lagere eiwitbindingscapaciteiten te hebben en waren ook niet
cytotoxisch na topicale applicatie. Een van de geteste gedeeltelijk gemodificeerde ODN
bleek dosisafhankelijk SKALP inductie te remmen. Door een groot aantal controle-
experimenten waarin controle ODN werden gebruikt en waarin gekeken werd naar de
expressieniveaus van een aantal andere epidermale eiwitten, konden we concluderen dat
de door de ODN geremde SKALP expressie een specifiek effect was. Confocale laser scan-
ning microscopie toonde aan dat ODN met een grootte van 20 nucleotiden gemakkelijk
de huid kunnen penetreren en terecht kunnen komen in het gedifferentieerde comparti-
ment van de opperhuid. Wij speculeren in hoofdstuk 5.2 dan ook dat het gebruik van
antisense ODN een potentieel nieuwe experimentele techniek zou kunnen zijn voor ziek-
ten waarin expressie van een relevant target gen geremd kan worden.
Tenslotte worden in hoofdstuk 6 de resultaten die in dit proefschrift beschreven staan in
het licht van de tot nu toe bekende literatuur gehouden en wordt gekeken naar de doelen
die in de inleiding zijn vermeld. Een aantal conclusies worden getrokken met betrekking
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tot de functie van SKALP en het gebruik van SKALP als een marker gen/eiwit voor rege-
neratieve maturatie. Verder wordt er gespeculeerd over de regulatie van het verstoorde epi-
dermale fenotype ‘regeneratieve maturatie’ en de betrokkenheid van cellulaire stress
responsepaden bij veranderingen in epidermale differentiatieroutes. Tenslotte wordt er
een aantal aanbevelingen en suggesties gedaan voor toekomstig onderzoek naar regulatie
van epidermale groei en differentiatie.
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